NZ715151B2 - Modulators of growth hormone receptor - Google Patents

Abstract

The present embodiments provide methods, modified antisense oligonucleotide compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using modified antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).

Description

WO 02971 MODULATORS OF GROWTH HORMONE RECEPTOR Field The present embodiments provide methods, compounds, and compositions for treating, preventing, or rating a e associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).

Seguence Listing The present ation is being filed along with a Sequence Listing in onic format. The Sequence Listing is provided as a file entitled BIOL0226WOSEQ_ST25.txt, created on June 30, 2014, which is 1028 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

Background Growth hormone is produced in the pituitary and secreted into the bloodstream where it binds to growth hormone receptor (GHR) on many cell types, g production of insulin-like growth -1 (IGF- 1). IGF-l is ed mainly in the liver, but also in adipose tissue and the kidney, and secreted into the bloodstream. Several disorders, such as acromegaly and gigantism, are associated with elevated growth hormone levels and/or elevated lGF-I levels in plasma and/or tissues.

Excessive production of growth hormone can lead to diseases such as acromegaly or gigantism.

Acromegaly and gigantism are associated with excess growth hormone, often caused by a pituitary tumor, and affects 40-50 per million people worldwide with about 15,000 patients in each of the US and Europe and an annual incidence of about 4-5 per million people. Acromegaly and gigantism are initially characterized by abnormal growth of the hands and feet and bony s in the facial features. Many of the growth related outcomes are mediated by elevated levels of serum IGF-l.

Sumflx ments provided herein relate to methods, compounds, and compositions for treating, preventing, or rating a disease associated with excess growth hormone. l embodiments provided herein are drawn to antisense compounds or oligonucleotides targeted to growth hormone or (GHR). Several embodiments are directed to treatment, prevention, or amelioration of acromegaly with antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).

WO 02971 ed Description It is to be understood that both the foregoing general description and the following detailed ption are exemplary and explanatory only and are not restrictive of the invention, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including” as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as nt” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

The n headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or ns of nts, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

Unless ise indicated, the following terms have the following meanings: “2’-O-methoxyethyl” (also 2’-MOE and 2’-O(CH2)g-OCH3) refers to an O-methoxy-ethyl modification at the 2’ position of a furanose ring. A 2’-O-methoxyethyl modified sugar is a modified sugar. “2’-MOE nucleoside” (also 2’-O-methoxyethyl nucleoside) means a nucleoside comprising a 2’- MOE modified sugar . “2’-substituted nucleoside” means a nucleoside comprising a substituent at the 2’-position of the furanosyl ring other than H or OH. In certain embodiments, 2’ substituted nucleosides include nucleosides with bicyclic sugar modifications. “3’ target site” refers to the nucleotide of a target nucleic acid which is complementary to the t nucleotide of a particular antisense compound. “5’ target site” refers to the nucleotide of a target nucleic acid which is complementary to the 5’-most nucleotide of a particular antisense nd. “5-methylcytosine” means a cytosine modified with a methyl group attached to the 5 position. A 5- methylcytosine is a modified nucleobase. ” means within ::10% of a value. For example, if it is stated, “the compounds affected at least about 70% inhibition of GHR”, it is d that GHR levels are inhibited within a range of 60% and 80%.

"Administration” or "administering” refers to routes of ucing an antisense compound provided herein to a subject to perform its intended function. An example of a route of administration that can be used includes, but is not limited to parenteral administration, such as subcutaneous, intravenous, or intramuscular injection or infusion.

“Amelioration” refers to a lessening of at least one indicator, sign, or symptom of an associated disease, disorder, or condition. In certain embodiments, amelioration includes a delay or slowing in the progression of one or more indicators of a condition or disease. The ty of tors may be determined by subjective or objective measures, which are known to those skilled in the art.

“Animal” refers to a human or man animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not d to, monkeys and chimpanzees.

“Antisense activity” means any detectable or measurable ty attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid. ense compound” means an oligomeric compound that is is capable of undergoing hybridization to a target nucleic acid through hydrogen g. Examples of antisense compounds include single-stranded and double-stranded compounds, such as, antisense oligonucleotides, , shRNAs, ssRNAs, and occupancy-based compounds.

“Antisense inhibition” means reduction of target nucleic acid levels in the presence of an antisense compound complementary to a target nucleic acid compared to target nucleic acid levels in the e of the antisense nd.

“Antisense mechanisms” are all those mechanisms ing hybridization of a compound with target nucleic acid, wherein the outcome or effect of the hybridization is either target degradation or target occupancy with concomitant ng of the cellular machinery involving, for example, transcription or splicing.

“Antisense ucleotide” means a single-stranded oligonucleotide having a nucleobase sequence that permits hybridization to a ponding region or segment of a target nucleic acid.

“Base complementarity” refers to the capacity for the precise base pairing of nucleobases of an antisense oligonucleotide with corresponding nucleobases in a target nucleic acid (i.e., hybridization), and is mediated by Watson—Crick, Hoogsteen or reversed Hoogsteen hydrogen binding between corresponding nucleobases.

“Bicyclic sugar moiety” means a modified sugar moiety comprising a 4 to 7 membered ring (including but not d to a furanosyl) comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, ing in a bicyclic structure. In certain embodiments, the 4 to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7 membered ring is a furanosyl. In certain such embodiments, the bridge connects the 2’-carbon and the 4’-carbon of the furanosyl.

“Bicyclic nucleic acid“ or “ BNA” or “BNA nucleosides” means nucleic acid rs having a bridge connecting two carbon atoms n the 4’ and 2’position of the nucleoside sugar unit, thereby forming a bicyclic sugar. Examples of such bicyclic sugar include, but are not limited to A) (x—L— Methyleneoxy (4’-CH2-O-2’) LNA , (B) B-D-Methyleneoxy (4’-CH2-O-2’) LNA , (C) Ethyleneoxy (4’- (CH2)2-O-2’) LNA LNA and (E) Oxyamino (4’-CH2-N(R)-O-2’) LNA, , (D) Aminooxy (4’-CH2-O-N(R)-2’) as depicted below.

(A) (B) As used herein, LNA compounds include, but are not d to, compounds having at least one bridge between the 4’ and the 2’ position of the sugar n each of the s independently comprises 1 or from 2 to 4 linked groups independently selected from -[C(R1)(R2)]n-, -C(R1)=C(R2)-, -C(R1)=N- and -N(R1)-; wherein: X is , 1)-, -C(=O)-, -C(=S)-, -O-, -Si(R1)2-, -S(=O)x- O, l, or 2; n is l, 2, 3, or 4; each R1 and R2 is, ndently, H, a protecting group, hydroxyl, C1-C12 alkyl, substituted C1- C12 alkyl, C2-C12 alkenyl, substituted C2-C9 l, C2-C12 alkynyl, substituted C2-C1; alkynyl, C5-C20 aryl, tuted C5-C20 aryl, a heterocycle radical, a substituted heterocycle radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, OJ 1, NJ1J2, SJ 1, N3, COOJ 1, acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O)2-J1), or sulfoxyl (S(=O)-J1); and each J1 and J2 is, independently, H, C1-C12 alkyl, substituted C1-C9 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C9 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a tuted heterocycle radical, C1—C12 aminoalkyl, substituted C1—C12 aminoalkyl or a protecting group.

Examples of 4’- 2’ bridging groups encompassed within the definition of LNA include, but are not limited to one of formulae: -[C(R1)(R2)]n-, -[C(R1)(R2)]n-O-, -C(R1R2)-N(R1)-O- or —C(R1R2)-O-N(R1)-.

Furthermore, other ng groups encompassed with the definition of LNA are -2', 4'—(CH2)2-2', 4'- (CH2)3-2', 4'-CH2-O-2', 2)2-O-2', 4'-CH2-O-N(R1)-2' and 4'-CH2-N(R1)-O-2'- bridges, wherein each R1 and R2 is, independently, H, a protecting group or C1-C12 alkyl.

Also ed within the definition of LNA according to the invention are LNAs in which the 2'- hydroxyl group of the ribosyl sugar ring is connected to the 4' carbon atom of the sugar ring, thereby forming a methyleneoxy (4’-CH2-O-2’) bridge to form the bicyclic sugar moiety. The bridge can also be a methylene (-CH2-) group connecting the 2' oxygen atom and the 4' carbon atom, for which the term methyleneoxy (4’- CHz-O-Z’) LNA is used. Furthermore; in the case of the bicylic sugar moiety having an ethylene bridging group in this position, the term ethyleneoxy (4’-CH2CH2-O-2’) LNA is used. (X -L- methyleneoxy (4’-CH2- 0-2’), an isomer of methyleneoxy (4’-CH2-O-2’) LNA is also encompassed within the definition of LNA, as used herein.

“Cap structure” or “terminal cap moiety” means chemical modifications, which have been incorporated at either terminus of an antisense compound. “cEt” or “constrained ethyl” means a bicyclic sugar moiety comprising a bridge connecting the 4’- carbon and the 2’-carbon, wherein the bridge has the formula: 4’-CH(CH3)-O-2’.

“Constrained ethyl nucleoside” (also cEt nucleoside) means a nucleoside comprising a ic sugar moiety comprising a 4’-CH(CH3)-O-2’ bridge. cally distinct region” refers to a region of an antisense compound that is in some way chemically different than another region of the same antisense compound. For example, a region having 2’- O-methoxyethyl nucleotides is chemically distinct from a region having nucleotides without 2’-O- methoxyethyl modifications.

“Chimeric antisense compounds” means antisense compounds that have at least 2 chemically distinct regions, each position having a plurality of subunits.

“Complementarity” means the capacity for pairing n nucleobases of a first nucleic acid and a second nucleic acid.

"Comprise, comprises” and "comprising" will be tood to imply the inclusion of a stated step or t or group of steps or elements but not the exclusion of any other step or t or group of steps or elements.

“Contiguous nucleobases” means nucleobases immediately adjacent to each other.

“Dcoxyribonucleotide” means a nucleotide having a hydrogen at the 2’ position of the sugar portion of the nucleotide. Deoxyribonucleotides may be modified with any of a y of tuents.

“Designing” or “Designed to” refer to the process of designing an oligomeric compound that cally hybridizes with a selected nucleic acid molecule. tive amount” means the amount of active pharmaceutical agent sufficient to effectuate a desired physiological outcome in an dual in need of the agent. The effective amount may vary among individuals depending on the health and physical condition of the individual to be treated, the taxonomic group of the duals to be treated, the formulation of the composition, assessment of the individual’s medical ion, and other relevant factors.

“Efficacy” means the ability to e a desired effect. ssion” includes all the functions by which a gene’s coded information is ted into structures present and operating in a cell. Such structures include, but are not limited to the products of transcription and translation.

“Fully complementary” or “100% complementary” means each nucleobase of a first nucleic acid has a complementary nucleobase in a second nucleic acid. In certain embodiments, a first nucleic acid is an antisense compound and a target nucleic acid is a second nucleic acid.

“Gapmer” means a chimeric antisense compound in which an internal region having a plurality of nucleosides that support RNase H cleavage is positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions. The internal region may be referred to as the “gap” and the external s may be referred to as the “wings.” “Growth e Receptor (GHR)” means any c acid or protein of GHR. “GHR nucleic acid” means any nucleic acid encoding GHR. For example, in certain embodiments, a GHR nucleic acid includes a DNA sequence encoding GHR, an RNA sequence transcribed from DNA encoding GHR (including genomic DNA comprising introns and exons), including a non-protein encoding (i. e. non-coding) RNA sequence, and an mRNA sequence ng GHR. “GHR mRNA” means an mRNA encoding a GHR protein.

“GHR specific inhibitor” refers to any agent capable of specifically inhibiting GHR RNA and/or GHR protein expression or activity at the molecular level. For example, GHR specific inhibitors include nucleic acids (including antisense compounds), peptides, antibodies, small molecules, and other agents capable of inhibiting the expression of GHR RNA and/or GHR protein.

“Hybridization” means the annealing of complementary nucleic acid molecules. In n embodiments, complementary nucleic acid molecules include, but are not limited to, an antisense compound and a c acid target. In certain embodiments, complementary nucleic acid molecules include, but are not d to, an antisense ucleotide and a nucleic acid .

“Identifying an animal having, or at risk for having, a disease, disorder and/or condition” means identifying an animal having been diagnosed with the disease, disorder and/or ion or identifying an animal predisposed to develop the disease, disorder and/or condition. Such identification may be lished by any method ing evaluating an individual’s medical y and standard clinical tests or assessments.

“Immediately adjacent” means there are no intervening elements between the immediately adjacent elements.

“Individual” means a human or non—human animal selected for treatment or therapy.

"Inhibiting the expression or activity” refers to a reduction, blockade of the sion or activity and does not necessarily indicate a total elimination of expression or activity. “lntemucleoside e” refers to the chemical bond between nucleosides.

“Lengthened” antisense oligonucleotides are those that have one or more additional nucleosides relative to an antisense oligonucleotide disclosed herein.

“Linked deoxynucleoside” means a c acid base (A, G, C, T, U) substituted by deoxyribose linked by a phosphate ester to form a nucleotide.

“Linked nucleosides” means adjacent nucleosides linked together by an internucleoside linkage.

“Mismatch” or omplementary nucleobase” refers to the case When a nucleobase of a first nucleic acid is not capable of pairing with the ponding nucleobase of a second or target nucleic acid.

“Modified internucleoside linkage” refers to a substitution or any change fiom a naturally occurring internucleoside bond (i.e. a phosphodiester internucleoside bond).

“Modified nucleobase” means any nucleobase other than adenine, cytosine, guanine, thymidine, or . An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).

“Modified side” means a nucleoside having, independently, a modified sugar moiety and/or modified nucleobase.

“Modified nucleotide” means a nucleotide having, independently, a modified sugar moiety, modified internucleoside linkage, or modified nucleobase.

“Modified oligonucleotide” means an ucleotide comprising at least one modified internucleoside linkage, a modified sugar, and/or a modified nucleobase.

“Modified sugar” means substitution and/or any change from a l sugar moiety.

“Modulating” refers to changing or adjusting a feature in a cell, tissue, organ or organism. For example, ting GHR mRNA can mean to increase or se the level of GHR mRNA and/or GHR protein in a cell, , organ or organism. A “modulator” effects the change in the cell, tissue, organ or organism. For example, a GHR antisense compound can be a modulator that decreases the amount of GHR mRNA and/or GHR protein in a cell, tissue, organ or organism.

“Monomer” refers to a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally ng or modified.

“Motif” means the pattern of unmodified and modified nucleosides in an antisense compound.

“Natural sugar moiety” means a sugar moiety found in DNA (2’-H) or RNA (2’-OH).

“Naturally occurring intemucleoside linkage” means a 3' to 5' phosphodiester e.

“Non-complementary nucleobase” refers to a pair of nucleobases that do not form en bonds with one another or otherwise support hybridization.

“Nucleic acid” refers to molecules ed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, and double-stranded nucleic acids.

“Nucleobase” means a heterocyclic moiety e of pairing with a base of r nucleic acid.

“Nucleobase complementarity” refers to a nucleobase that is capable of base pairing with r nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase refers to a nucleobase of an antisense compound that is e of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a base at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair.

“Nucleobase sequence” means the order of contiguous nucleobases independent of any sugar, linkage, and/or nucleobase modification.

“Nucleoside” means a nucleobase linked to a sugar. oside mimetic” es those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo or tricyclo sugar mimetics, e.g., non fiiranose sugar units. tide mimetic includes those ures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for example peptide nucleic acids or morpholinos (morpholinos linked by C(=O)-O- or other non-phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside c but is intended to indicate replacement of the sugar unit (furanose ring) only. The tetrahydropyranyl rings provided herein are illustrative of an example of a sugar ate wherein the furanose sugar group has been replaced with a tetrahydropyranyl ring system. ”Mimetic” refers to groups that are substituted for a sugar, a nucleobase, and/ or intemucleoside linkage. Generally, a c is used in place of the sugar or sugar-intemucleoside linkage combination, and the nucleobase is maintained for hybridization to a selected .

“Nucleotide” means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.

“Oligomeric nd” means a polymer of linked monomeric subunits which is capable of hybridizing to at least a region of a nucleic acid molecule.

“Oligonucleoside” means an oligonucleotide in which the cleoside linkages do not contain a phosphorus atom.

“Oligonucleotide” means a r of linked nucleosides each of which can be modified or unmodified, independent one from another.

“Parenteral administration” means administration through injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g. intrathecal or intracerebroventricular stration.

“Pharmaceutical composition” means a mixture of substances suitable for stering to an individual. For example, a pharmaceutical composition may comprise one or more active pharmaceutical agents and a sterile aqueous solution.

“Pharmaceutically acceptable salts” means physiologically and pharmaceutically acceptable salts of antisense compounds, i.e., salts that retain the d ical activity of the parent oligonucleotide and do not impart undesired toxicological effects thereto.

“Phosphorothioate linkage” means a linkage between nucleosides where the phosphodiester bond is modified by replacing one of the idging oxygen atoms with a sulfur atom. A phosphorothioate linkage is a d intemucleoside linkage.

“Portion” means a defined number of contiguous (i.e., linked) nucleobases of a nucleic acid. In certain ments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In certain embodiments, a n is a defined number of contiguous nucleobases of an antisense compound “Prevent” refers to delaying or forestalling the onset, development or progression of a disease, disorder, or condition for a period of time from minutes to indefinitely. t also means reducing the risk of developing a disease, disorder, or condition.

“Prophylactically effective amount” refers to an amount of a pharmaceutical agent that provides a prophylactic or preventative benefit to an animal.

“Region” is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic.

“Ribonucleotide” means a nucleotide having a y at the 2’ position of the sugar portion of the nucleotide. Ribonucleotides may be modified with any of a variety of tuents.

“Segments” are defined as smaller or sub-portions of regions within a target nucleic acid.

“Side effects” means physiological disease and/or conditions attributable to a treatment other than the desired s. In n embodiments, side effects include injection site reactions, liver function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system alities, myopathies, and malaise. For example, increased aminotransferase levels in serum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver toxicity or liver function abnormality.

“Sites,” as used herein, are defined as unique nucleobase positions within a target nucleic acid.

"Slows progression” means decrease in the development of the said disease.

“Specifically hybridizable” refers to an antisense compound having a sufficient degree of complementarity between an antisense oligonucleotide and a target nucleic acid to induce a d effect, while exhibiting minimal or no s on non-target nucleic acids under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays and therapeutic treatments.

“Stringent hybridization conditions” or “stringent conditions” refer to conditions under which an oligomeric compound will hybridize to its target ce, but to a minimal number of other sequences.

“Subject” means a human or non-human animal selected for treatment or therapy.

“Target” refers to a protein, the modulation of which is desired. t gene” refers to a gene encoding a target.

“Targeting” means the process of design and selection of an antisense compound that will specifically hybridize to a target c acid and induce a d . t nucleic acid,” “target RN ,” “target RNA transcript” and “nucleic acid target” all mean a c acid capable of being targeted by antisense compounds.

“Target region” means a portion of a target nucleic acid to which one or more antisense compounds is targeted.

“Target segment” means the sequence of nucleotides of a target nucleic acid to Which an antisense compound is targeted. “5’ target site” refers to the 5’-most nucleotide of a target segment. “3’ target site” refers to the 3 ’-most tide of a target segment.

“Therapeutically effective amount” means an amount of a pharmaceutical agent that provides a therapeutic benefit to an individual.

“Treat” refers to administering a pharmaceutical composition to an animal in order to effect an alteration or improvement of a disease, disorder, or condition in the animal. In certain embodiments, one or more pharmaceutical itions can be administered to the animal. ified" bases mean the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).

“Unmodified nucleotide” means a nucleotide composed of naturally occuring nucleobases, sugar moieties, and internucleoside linkages. In certain embodiments, an unmodified nucleotide is an RNA nucleotide (i.e. B-D-ribonucleosides) or a DNA nucleotide (i.e. B-D-deoxyribonucleoside).

Certain Embodiments Certain embodiments provide methods, nds and compositions for inhibiting growth e receptor (GHR) expression.

Certain embodiments provide antisense compounds targeted to a GHR nucleic acid. In certain embodiments, the GHR nucleic acid has the sequence set forth in GENBANK Accession No. NM_000163.4 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NT_006576.16 truncated from tides 42411001 to 42714000 (incorporated herein as SEQ ID NO: 2), GENBANK Accession No X06562] (incorporated herein as SEQ ID NO: 3), GENBANK Accession No. DR006395.1 porated herein as SEQ ID NO: 4), GENBANK Accession No. DB052048.1 (incorporated herein as SEQ ID NO: 5), GENBANK Accession No. AF230800.1 (incorporated herein as SEQ ID NO: 6), the complement of GENBANK Accession No. AA398260.1 porated herein as SEQ ID NO: 7), K ion No.

BC136496.1 porated herein as SEQ ID NO: 8), GENBANK Accession No. NM_001242399.2 (incorporated herein as SEQ ID NO: 9), GENBANK Accession No. NM_001242400.2 (incorporated herein as SEQ ID NO: 10), GENBANK Accession No. NM_001242401.3 (incorporated herein as SEQ ID NO: 11), GENBANK Accession No. NM_001242402.2 (incorporated herein as SEQ ID NO: 12), GENBANK Accession No. NM_001242403.2 (incorporated herein as SEQ ID NO: 13), GENBANK Accession No.

NM_001242404.2 porated herein as SEQ ID NO: 14), GENBANK Accession No. 242405.2 (incorporated herein as SEQ ID NO: 15), GENBANK Accession No. NM_001242406.2 (incorporated herein as SEQ ID NO: 16), GENBANK Accession No. NM_001242460.1 (incorporated herein as SEQ ID NO: 17), GENBANK ion NM_001242461.1 (incorporated herein as SEQ ID NO: 18), or GENBANK Accession No. NM_001242462.1 (incorporated herein as SEQ ID NO: 19).

Certain embodiments provide a compound comprising a modified ucleotide consisting of 10 to linked nucleosides and having a nucleobase sequence sing at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 20—2295.

Certain ments provide a compound comprising a modified oligonucleotide consisting of 10 to linked nucleosides mentary Within nucleotides 30-51, 63-82, 103-118, 9, 164-197, 206-259, 361-388, 554-585, 625-700, 736-776, 862-887, 923-973, 978-996, 1127-1142, 1170-1195, 1317-1347, 1360- 1383, 1418-1449, 1492-1507, 1524-1548, 1597-1634, 1641-1660, 1683-1698, 1744-1768, 860, 1949- 2002, 2072—2092, 2095—2110, 2306—2321, 2665—2683, 2685—2719, 2739—2770, 2859—2880, 2941—2960, 2963— 2978, 3037—3052, 3205—3252, 3306—3332, 3371—3386, 3518—3542, 3975—3990, 087, 4418—4446, 4528— 4546, 246, 585, 8395—8410, 9153—9168, 9554—9569, 9931—9946, 10549—10564, 11020—11035, 11793-11808, 12214-12229, 12474-12489, 12905-12920, 13400-13415, 13717-13732, 14149-14164, 14540- 14555, 15264-15279, 15849-15864, 16545, 17377-17392, 17581-17596, 17943-17958, 18353-18368, 18636-18651, 19256-19271, 19814-19829, 20365-20380, 20979-20994, 21566-21581, 22150-22165, 22803- 22818, 29049-29064, 29569, 30245-30260, 30550-30565, 30915-30930, 31468-31483, 32366-32381, 32897-32912, 33187-33202, 33780-33795, 34407-34422, 34861, 35669-35684, 36312-36327, 36812- 36827, 37504-37519, 38856, 40250-40265, 40706-40721, 40922-40937, 41424-41439, 41999-42014, 42481-42496, 42700-42715, 43291-43306, 43500-43515, 43947-43962, 44448-44463, 45162-45177, 46010- 46025, 46476-46491, 47447-47462, 47752-47767, 48001-48016, 48423-48438, 50210, 50470-50485, 51104-51119, 51756-51771, 52015-52030, 52230-52245, 52588-52603, 53532-53547, or 54645-54660 of SEQ ID NO: 1, wherein said modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.

Certain embodiments provide a compound comprising a modified oligonucleotide ting of 10 to linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion ofnucleobases 30-51, 63-82, 103-118, 143-159, 164-197, 206-259, 361-388, 554-585, 625-700, 6, 862-887, 923-973, 978-996, 1127-1142, 1170-1195, 347, 1360-1383, 1418-1449, 1492-1507, 1524-1548, 1597-1634, 1641-1660, 1683-1698, 1744-1768, 1827-1860, 1949-2002, 2072-2092, 2095-2110, 321, 2665-2683, 2685-2719, 2739-2770, 2859-2880, 2941-2960, 978, 3037-3052, 3205-3252, 3306-3332, 3371-3386, 3518-3542, 3975-3990, 4041-4087, 4418-4446, 4528-4546, 246, 7570-7585, 8395-8410, 9153-9168, 9554-9569, 9931-9946, 10549- 10564, 11020-11035, 11793-11808, 17714-17779, 17474-17489, 17905-17970, 13400-13415, 13717-13732, 14149-14164, 14540-14555, 15264-15279, 15864, 16545, 17377-17392, 17581-17596, 17943- 17958, 18353-18368, 18636-18651, 19256-19271, 19814-19829, 20365-20380, 20979-20994, 21566-21581, 22150-22165, 22803-22818, 29049-29064, 29554-29569, 30245-30260, 30550-30565, 30915-30930, 31468- 31483, 32366-32381, 32897-32912, 33187-33202, 33780-33795, 34407-34422, 34861, 35669-35684, 36312-36327, 36812-36827, 37504-37519, 38856, 40250-40265, 40706-40721, 40922-40937, 41424- 41439, 41999-42014, 42481-42496, 42700-42715, 43291-43306, 43500-43515, 43947-43962, 44448-44463, 45177, 46010-46025, 46476-46491, 47447-47462, 47767, 48001-48016, 48423-48438, 50195- 50210, 50470-50485, 51104-51119, 51756-51771, 52015-52030, 52230-52245, 52588-52603, 53532-53547, or 54645-54660 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is mentary to SEQ ID NO: 1.

Certain embodiments provide a compound comprising a modified oligonucleotide consisting of 10 to linked sides complementary Within nucleotides 2571-2586, 2867-3059, 3097-3116, 3341-3695, 4024-4039, 4446-4894, 5392-5817, 6128-6265, 6499-6890, 7231-7246, 8395-8410, 9153-9168, 9554-9569, 9931-9946, 10549-10564, 10660-10679, 11020-11035, 11793-12229, 12469-12920, 13351-13415, 13717- 13732, 14149-14164, 14361-14555, 14965-15279, 15849-16001, 16272, 16447-16545, 17130-17149, 17377-17669, 17927-17958, 18353-18368, 18636-18773, 19661-19918, 20288-20470, 20979-20994, 21215- 21606, 21820-21837, 22150-22165, 22518-22536, 22803-22818, 26494-26522, 29049-29069, 29323-29489, 30550-30565, 30915-31191, 31483, 32363-32382, 32827-33202, 33635-33795, 34138-34157, 34407- 34422, 34845-34864, 35466-35485, 35669-35684, 36073-36047, 36766-36377, 36791-36877, 37037-37130, 37276-37295, 37504-37675, 38094-38118, 38841-38856, 39716-40538, 40706-40937, 41164-41183, 41342- 41439, 42164, 42700-42760, 43173-43537, 43765-46025, 46532, 48423-48438, 50072-50210, 50485, 50719-51234, 51747-51797, 52015-52143, 52230-52245, 52573-52652, 53466-54660, 54886- 54901, 63751-64662, 64882-65099, 65363-65378, 65600-65615, 65988-66183, 66566-66581, 66978-67080, 67251-67270, 67662-67929, 68727-68742, 69242, 69565-69620, 69889-70145, 70352-70584, 70925- 71071, 71314-71329, 71617-71769, 72107-72241, 72584-72670, 73061-73076, 73350-73369, 73723, 74107-74131, 74317-74557, 74947-75009, 75192-75207, 75979-76066, 76410-77095, 77292-77307, 77638- 77869, 78326, 79006-79021, 79478-79505, 80277-80292, 80575-80939, 81207-81222, 81524-81543, 81761-81776, 82233-82248, 82738-83198, 83330-83416, 83884-84063, 84381-85964, 86220-86392, 86554- 86655, 86901-86920, 87181-87262, 88063-88082, 88308, 88605-88967, 89160-89175, 89940-90255, 90473-90528, 91073-91088, 91273-91292, 91647-91662, 91930-92126, 92356-92371, 93190-93443, 93762- 94111, 94374-94389, 94581-94653, 94839-94858, 95292-95583, 95829-95844, 96137-96503, 96793-97013, 97539-97554, 97800-97889, 98132-98151, 98624-98672, 98810-99115, 99258-99273, 99478-99503, 99791- 3O 99858, 100281-100300, 100406-100421, 100742-100828, 101080-101103, 101242-101320, -101906, 102549-102568, -103625, 104067-104086, -104858, 105255-105274, 106147-106364, 106632—106647, 106964—107735, —108788, —109505, 109849—109864, 110403—110442, 110701—110974, 111203—111322, 112030—112049, 112499-112514, 112842-112861, 113028-113056, 113646-113665, 113896-113911, 114446-114465, 115087-115106, 119269-119284, 119659-119703, 120376-120497, 120738-120845, -121228, -122013, 122180-122199, 122588-122770, 123031-123050, 123152-123167, 123671-124055, 124413-124608, 125178-125197, 125533-125616, 126357-126434, 126736-126751, 126998-127236, 127454-127682, 128467-128482, 128813-129111, 129976-130013, 130308-130323, 131036-131056, 131286-131305, -131691, 132171-132517, 133168-133241, 133522-133877, 13408643410L 134240-134259, 134441-134617, 135015-135030, 135431-135519, 135818-135874, 136111-136130, 136282-136595, 136996-137152, 137372-137387, 137750-137765, 138048-138067, 138782-139840, 140343-140358, 140593-140701, 141116-141131, -141719, 142113-142342, -143048, 143185-143486, 143836-144109, 144558-144650, 144990-145078, 145428-145525, 145937-145952, 146235-146386, 147028-147043, 147259-147284, 147671-147686, 148059-148154, 148564-148579, 148904-149084, 149491-149506, 149787-149877, 150236-150251, 150588-151139, 151373-151659, 152201-152388, 152549-152771, 153001-153026, 153349-153364, 153831-154112, 154171-154186, -154521, 154724-154828, 155283-155304, 155591-155616, 155889-155992, 156233-156612, 156847-156907, 157198-157223, 157330-157349, 157552-157567, 157927-158029, 158542-15863L 159216-159267, 159539-159793, 160352-160429, 160812-160827, 161248-161267, 161461-161607, 161821-161969, 162064-162083, 162132-162147, 162531-162770, 163019-163557, 164839-165059, 165419-165575, 165856-165875, 166241-166450, 166837-166852, 167107-167122, 168004-168019, 168760-168823, 169062-169092, 169134-169153, 169601-169711, 170081-170291, 170407-170426, -170814, 171021-171036, 171207-171226, 171431-171568, 171926-171945, -172462, 172733-172956, 173045-173756, -174885, -177830, 178895-180539, -187644, 187857-189904, 190109-194159, 194425-195723, 2O 196536-196873, -197961, 198145-198170, 198307-19838L 198715-199007, 199506-199563, 1998 1 6-19983 8, -200635, 201258-20186L 202079-202094, 2023 82-202717, 203098-203934, 204181-204740, -205915, 206412-206764, 207510-207532, 209999-210014, 210189-210296, 210502-210583, 210920-211418, 211836-212223, 212606-212816, 213025-213044, 213425-213440, 213825-213933, 214479-214498, 214622-214647, 214884-21495L 215446-215508, 215932-215951, 216192—217595, 218132—218248, 218526—21 8541, 218734—21219037, 219342—219633, 219886—220705, 221044—221059, 221483—221607, 221947221962, 222569—222584, 222914—222998, 223436—223451, 223948-224122, -224430, 224717224769, 225133-225148, 225436-225761, 226785-226898, 227025-227040, 227218-227251, 227485-227500, 227914-228837, 229174-229189, 229423-229438, 229615-229640, 230042-230057, 230313-230595, 231218-231345, 231817-232037, -232408, 232823-232848, 232884-232899, -233225, 23 3623-233646, 234447-234466, 234876-234918, 235258-235328, 235770-235785, 236071-236213, 23 6684-237 1 96, 237585-237698, 237949-237557, 244873-244897, 245319-245334, 245701-245780, 246152-246523, -247031, 247203-247240, 247431-247450, 247644-247659, 248223-248363, -248762, 249494-249509, 250001-250020, 250693-250708, 251214-251233, 251601-251637, -252060, 252665-252680, 25283 8-252863, 253140-253166, 253594-253819, -254083, -254345, -254660, 254905-254920, 255397-255422, 255618-255633, 255992-256704, 257018-257092, 257317-257332, 257818-259305, 259500-259515, 261294-261656, 262021-262036, 262453-262779, 263338-266518, 266861-267131, 267375-268051, 268366-269447, 270038-271850, 271950-271969, 272631-274145, 274205-275747, 275808-276636, 276932-277064, 277391-278380, 278932-279063, 279303-281001, -281610, 282229-283668, 290035-290474, 290924-292550, 292860-294408, 295475-297012, 297587-298115, 298161-298418, 298489-298738, 299082-299187, 299276-299669, 299723-299749, 299788-300504, or 300835-301295 of SEQ ID NO: 2, wherein said modified oligonucleotide is at least 90% complementary to SEQ ID NO: 2.

Certain embodiments provide a compound comprising a modified ucleotide consisting of 10 to 30 linked nucleosides having a nucleobase sequence comprising a n of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 2571-2586, 2867-3059, 3097- 3116, 3341-3695, 4024-4039, 4446-4894, 5392-5817, 6128-6265, 6499-6890, 7231-7246, 8395-8410, 9153- 9168, 9554-9569, 9931-9946, 10549-10564, 10660-10679, 11020-11035, 11793-12229, 12469-12920, 13415, 13717-13732, 14149-14164, 14361-14555, 14965-15279, 15849-16001, 16272, 16447- 16545, 17130-17149, 17377-17669, 17927-17958, 18353-18368, 18636-18773, 19661-19918, 20288-20470, 90979-70994, 71715-71606, 71870-71837, 77150-77165, 77518-77536, 77803-77818, 76494-76577, 79049- 29069, 29323-29489, 30550-30565, 30915-31191, 31468-31483, 32363-32382, 32827-33202, 33635-33795, 34138-34157, 34407-34422, 34845-34864, 35466-35485, 35669-35684, 36023-36042, 36266-36327, 36721- 36827, 37032-37130, 37276-37295, 37504-37675, 38094-38118, 38856, 39716-40538, 40937, 41164-41183, 41342-41439, 42141-42164, 42700-42760, 43173-43537, 43765-46025, 46532, 48423- 48438, 50072-50210, 50485, 50719-51234, 51747-51797, 52015-52143, 52230-52245, 52573-52652, 53466-54660, 54886-54901, 64662, 64882-65099, 65363-65378, 65600-65615, 65988-66183, 66566- 66581, 66978-67080, 67251-67270, 67662-67929, 68742, 69203-69242, 69565-69620, 69889-70145, 70352-70584, 70925-71071, 71329, 71617-71769, 72107-72241, 72584-72670, 73061-73076, 73350- 73369, 73689-73723, 74131, 74317-74557, 74947-75009, 75192-75207, 75979-76066, 76410-77095, 77292-77307, 77638-77869, 78326, 79006-79021, 79478-79505, 80277-80292, 80939, 81207- 81222, 81524-81543, 81776, 82233-82248, 82738-83198, 83330-83416, 83884-84063, 84381-85964, 86392, 86554-86655, 86901-86920, 87181-87262, 88063-88082, 88293-88308, 88967, 89160- 89175, 89940-90255, 90528, 91088, 91273-91292, 91647-91662, 91930-92126, 92356-92371, 3O 93190-93443, 93762-94111, 94374-94389, 94653, 94839-94858, 95292-95583, 95829-95844, 96137- 96503, 96793-97013, 97539-97554, 97800-97889, 98132-98151, 98624-98672, 98810-99115, 99258-99273, 99478—99503, 99791—99858, 100281—100300, 100406—100421, 100742—100828, 101080-101103, 101242— 101320, 101788—101906, 102549—102568, 103566—103625, 104067—104086, 104277—104858, 105255— , 106147-106364, 106632-106647, 106964-107735 n 108514-108788, 109336-109505, 109849- 109864, 110403-110442, 110701-110974, 111203-111322 112030-112049, 112499-112514, 112842- 112861, 113028-113056, 113646-113665, 113896-113911, 114446-114465, 115087-115106, 119269- , -119703, 120376-120497, 120738-120845, 121209-121228, 121823-122013, 122180- 122199, 122588-122770, 123031—123050, 123152-123167, 123671-124055, 124413-124608, 125178- 125197, 125533-125616, -126434, 126736-126751, 126998-127236, 127454-127682, 128467- 128482, 128813-129111, 129976-130013, 130308-130323, 131036-131056, 131286-131305, 131676- 131691, 132171-132517, 133168-133241, 133522-133877, 134086-134101, 134240-134259, 134441- 134617, -135030, 135431—135519, 135818-135874, 136111-136130, 136282-136595, 136996- 137152, 137372-137387, 137750-137765, 138048-138067, 138782-139840, 140343-140358, 140593- 140701, 141116-141131, —141719, 142113-142342, -143048, 143185-143486, 143836- , 144558-144650, 144990-145078, 145428-145525, 145937-145952, 146235-146386, 147028- 147043, 147259-147284, -147686, 148059-148154, 148564-148579, 148904-149084, 149491- 149506, 149787-149877, 150236-150251, 150588-151139, 151373-151659, 152201-152388, 152549- 152771, 153001-153026, 153349-153364, 153831-154112, -154186, 154502-154521, 154724- 154828, 155283-155304, 155591-155616, 155889-155992, 156233-156612, 156847-156907, 157198- 157223, 157330-157349, 157552-157567, 157927-158029, 158542-158631, 159216-159267, 159539- , 160352-160429, 160812-160827, -161267, 161461-161607, 161821-161969, 162064- 162083, 162132-162147, 162531-162770, 163019-163557, 164839-165059, 165419-165575, 165856- , 166241-166450, 166837-166852, 167107-167122, 168004-168019, 168760-168823, 169062- 169092, 169134-169153, 16960116971L 170081-170291, 170407-170426, 170703-170814, 171021- 171036, 171207-171226, -171568, 171926-171945, 172447-172462, 172733-172956, 173045- 173756, 174122-174885, 175014-177830, -180539, 181514-187644, 187857-189904, 190109- 194159, 194425-195723, 196536-196873, 197326-197961, 198145-198170, 198307-198381, 198715- 199007, -199563, 199816-199838, 200249-200635, 201258-201861, 202079-202094, 202382- 202717, 203098-203934, 204181-204740, 205549-205915, 206412-206764, 207510-207532, 209999- 210014, 210189—210296, 210502—210583, 210920—211418, 211836—212223, 212606—212816, 213025— 213044, 213425—213440, 213825—213933, 214479—214498, 214622—214647, —214951, 215446— 215508, 215932-215951, 216192-217595, 218132-218248, 218526-218541, 218734-21219037, 219342- , 219886-220705, 221044-221059, 221483-221607, 221947-221962, 222569-222584, 222914- 222998, 223436-223451, 223 948-224122, -224430, 224717-224769, 225133-225148, 225436- 225761, 226785-226898, 227025-227040, -227251, 227485-227500, 227914-228837, 229174- 229189, 229423-22943 8, 229615-229640, 230042-230057, 230313-230595, -231345, 231817- 232037, 232088-232408, 232823-232848, 232884-232899, -233225, -233646, 234447- 234466, 234876-234918, 235258-235328, 235770-235785, 236071-236213, 236684-237196, 237585- 237698, 237949-237557, 244873-244897, -245334, 245701-245780, 246152-246523, 246936- 247031, 247203-247240, -247450, 247644-247659, 248223-248363, 248694-248762, 249494- 249509, 250001-250020, 250693-250708, 251214-251233, 251601-251637, 251950-252060, - , 252838-252863, -253166, 253594-253819, 254036-254083, -254345, 254641- , -254920, 255397-255422, 255618-255633, 255992-256704, -257092, 257317- 257332, 257818-259305, 259500-259515, 261294-261656, 262021-262036, 262453-262779, 263338- 266518, 266861-267131, 267375-268051, -269447, 270038-271850, 271950-271969, 272631- 274145, 274205-275747, 275808-276636, 276932-277064, 277391-278380, 278932-279063, 279303- 281001, 281587-281610, -283668, 290035-290474, 290924-292550, 292860-294408, 295475- 297012, 297587-298115, 298161-298418, 298489-298738, 299082-299187, 299276-299669, 299723- 299749, 299788-300504, or -301295 of SEQ ID NO: 2, wherein the nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID NO: 2. In certain aspects, the compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides complementary within nucleotides 155594-155613, 72107-72126, 153921-153940, 159252-159267, 213425-213440, 153004-153019, 155597- 155612, 248233-248248 of SEQ ID NO: 2.

Certain embodiments provide a compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 20-2295.

Certain embodiments provide a compound comprising a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 20-2295.

In certain embodiments, an antisense nd or oligonucleotide ed to a growth hormone receptor nucleic acid is complementary within the ing nucleotide regions of SEQ ID NO: 1: 30—5 1, 63— 82, 8, 143-159, 164-197, 206-259, 361-388, 554-585, 625-700, 736-776, 862-887, 923-973, 978-996, 1127-1142, 1170-1195, 1317-1347, 1360-1383, 1418-1449, 1492-1507, 1524-1548, 1597-1634, 1641-1660, 1683-1698, 1744-1768, 860, 002, 2072-2092, 2095-2110, 2306-2321, 2665-2683, 2685-2719, 2739-2770, 2859-2880, 960, 2963-2978, 3037-3052, 3205-3252, 3306-3332, 3371-3386, 3518-3542, 3975-3990, 4041-4087, 4418-4446, 4528-4546, 7231-7246, 7570-7585, 8395-8410, 9153-9168, 9554-9569, 9931-9946, 10549-10564, 11020-11035, 11793-11808, 12214-12229, 12474-12489, 12905-12920, 13400- 13415,13717-13732,14149-14164,14540-14555,15264-15279,15849-15864, 16530-16545, 17377-17392, 17581-17596, 17943-17958, 18353-18368, 18636-18651, 19256-19271, 19814-19829, 20365-20380, 20979- 20994, 21566-21581, 22150-22165, 22803-22818, 29049-29064, 29554-29569, 30245-30260, 30550-30565, 30915-30930, 31468-31483, 32366-32381, 32897-32912, 33187-33202, 33780-33795, 34407-34422, 34846- 34861, 35669-35684, 36312-36327, 36812-36827, 37504-37519, 38841-38856, 40250-40265, 40721, 40922-40937, 41424-41439, 41999-42014, 42481-42496, 42700-42715, 43291-43306, 43500-43515, 43947- 43962, 44448-44463, 45162-45177, 46010-46025, 46491, 47447-47462, 47752-47767, 48001-48016, 48438, 50210, 50470-50485, 51104-51119, 51756-51771, 52015-52030, 52245, 52588- 52603, 53532-53547, or 54645-54660.

In certain embodiments, an nse compound or ucleotide ed to a growth hormone receptor nucleic acid target the following nucleotide regions of SEQ ID NO: 1: 30-51, 63-82, 103-118, 143- 159, 164-197, 206-259, 361-388, 554-585, 625-700, 736-776, 7, 923-973, 978-996, 1127-1142, 1170- 1195,1317-1347,1360-1383,1418-1449,1492-1507,1524-1548,1597-1634,1641-1660,1683-1698,1744- 1768, 1827-1860, 1949-2002, 2072-2092, 2095-2110, 2306-2321, 2665-2683, 2685-2719, 2739-2770, 2859- 2880, 2941-2960, 2963-2978, 052, 3205-3252, 3306-3332, 3371-3386, 3518-3542, 3975-3990, 4041- 4087, 446, 4528-4546, 7231-7246, 7570-7585, 8395-8410, 168, 9554-9569, 9931-9946, 10549- 10564, 11020-11035, 11793-11808, 12214-12229, 12474-12489, 12905-12920, 13400-13415, 13717-13732, 14149-14164, 14540-14555, 15264-15279, 15849-15864,16530-16545, 17377-17392, 17581-17596, 17943- 17958, 18353-18368, 18636-18651, 19256-19271, 19814-19829, 20365-20380, 20994, 21581, 22150-22165, 22803-22818, 29049-29064, 29554-29569, 30245-30260, 30550-30565, 30915-30930, 31468- 31483, 32366-32381, 32897-32912, 33187-33202, 33780-33795, 34407-34422, 34846-34861, 35669-35684, 36312-36327, 36827, 37504-37519, 38841-38856, 40250-40265, 40706-40721, 40922-40937, 41424- 41439, 41999-42014, 42481-42496, 42715, 43291-43306, 43500-43515, 43947-43962, 44448-44463, 45162-45177, 46010-46025, 46476-46491, 47447-47462, 47767, 48001-48016, 48423-48438, 50195- 50210, 50470-50485, 51104-51119, 51756-51771, 52015-52030, 52230-52245, 52588-52603, 53532-53547, or 54645-54660.

In certain embodiments, antisense compounds or oligonucleotides target a region of a growth hormone receptor nucleic acid. In certain embodiments, such compounds or oligonucleotides targeted to a region of a GHR nucleic acid have a contiguous nucleobase portion that is complementary to an equal length nucleobase portion of the region. For example, the portion can be at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobases portion mentary to an equal length portion of a region recited herein. In certain embodiments, such compounds or oligonucleotide target the following nucleotide regions of SEQ ID NO: 1: 30—51, 63—82, 103—118, 143—159, 164—197, 9, 361—388, 554—585, 625—700, 736—776, 862—887, 923-973, 978-996, 142, 1170-1195, 1317-1347, 383, 1418-1449, 1492-1507, 1524-1548, 1597- 1634, 1641-1660, 1683-1698, 1744-1768, 1827-1860, 1949-2002, 2072-2092, 2095-2110, 2306-2321, 2665- 2683, 2685-2719, 2739-2770, 2859-2880, 2941-2960, 2963-2978, 052, 3205-3252, 3306-3332, 3371- 3386, 3518-3542, 3975-3990, 4041-4087, 4418-4446, 4528-4546, 7231-7246, 7570-7585, 8395-8410, 9153- 9168, 9554-9569, 9931-9946, 10549-10564, 11020-11035, 11793-11808, 12214-12229, 12474-12489, 12905-12920, 13415, 13717-13732, 14149-14164,14540-14555, 15264-15279, 15849-15864, 16530- 16545,17377-17392,17581-17596,17943-17958,18353-18368,18636-18651, 19256-19271,19814-19829, 20365-20380, 20979-20994, 21566-21581, 22150-22165, 22803-22818, 29049-29064, 29554-29569, 30245- 30260, 30550-30565, 30930, 31468-31483, 32366-32381, 32897-32912, 33187-33202, 33780-33795, 34407-34422, 34846-34861, 35669-35684, 36312-36327, 36812-36827, 37504-37519, 38841-38856, 40250- 40265, 40706-40721, 40937, 41424-41439, 41999-42014, 42481-42496, 42700-42715, 43291-43306, 43500-43515, 43962, 44448-44463, 45162-45177, 46010-46025, 46491, 47447-47462, 47752- 47767, 48001-48016, 48423-48438, 50195-50210, 50485, 51104-51119, 51756-51771, 52015-52030, 52230-52245, 52588-52603, 53532-53547, or 54645-54660.

In certain ments, an antisense compound or ucleotide ed to a growth hormone receptor nucleic acid is complementary Within the ing nucleotide regions of SEQ ID NO: 2: 2571- 2586, 2867-3059, 3097-3116, 3341-3695, 4024-4039, 4446-4894, 5392-5817, 6128-6265, 6499-6890, 7231- 7246, 8395-8410, 9153-9168, 9554-9569, 9931-9946, 10549-10564, 10679, 11020-11035, 11793- 12229,12469-12920,]3351-13415,13717-13732,14149-14164,]4361-14555,14965-15279,]5849-16001, 16253-16272,16447-16545,]7130-17149,17377-17669,17927-17958,18353-18368,18636-18773,19661- 19918, 20288-20470, 20979-20994, 21215-21606, 21820-21837, 22150-22165, 22518-22536, 22818, 26494-26522, 29049-29069, 29323-29489, 30550-30565, 30915-31191, 31468-31483, 32382, 32827- 33202, 33635-33795, 34138-34157, 34422, 34845-34864, 35466-35485, 35669-35684, 36023-36042, 36266-36327, 36721-36827, 37032-37130, 37276-37295, 37504-37675, 38094-38118, 38841-38856, 39716- 40538, 40706-40937, 41183, 41342-41439, 42141-42164, 42700-42760, 43173-43537, 43765-46025, 46476-46532, 48423-48438, 50072-50210, 50470-50485, 50719-51234, 51747-51797, 52015-52143, 52230- 52245, 52573-52652, 53466-54660, 54886-54901, 63751-64662, 64882-65099, 65363-65378, 65600-65615, 65988-66183, 66566-66581, 66978-67080, 67270, 67662-67929, 68742, 69203-69242, 69565- 69620, 70145, 70352-70584, 70925-71071, 71314-71329, 71617-71769, 72107-72241, 72584-72670, 73061-73076, 73350-73369, 73689-73723, 74107-74131, 74317-74557, 74947-75009, 75192-75207, 75979- 76066, 76410-77095, 77292-77307, 77638-77869, 78122-78326, 79006-79021, 79478-79505, 80277-80292, 80575-80939, 81207-81222, 81524-81543, 81761-81776, 82233-82248, 82738-83198, 83330-83416, 83884- 84063, 84381-85964, 86220-86392, 86554-86655, 86901-86920, 87181-87262, 88063-88082, 88293-88308, 88605—88967, 89160—89175, 89940—90255, 90473—90528, 91073—91088, 91273—91292, 91647—91662, 91930— 92126, 92371, 93190—93443, 93762—94111, 94374—94389, 94581—94653, 94839—94858, 95583, 95829-95844, 96137-96503, 97013, 97539-97554, 97800-97889, 98132-98151, 98624-98672, 98810- 99115, 99258-99273, 99478-99503, 99791-99858, 100281-100300, 100406-100421, 100742-100828, 101080-101103, 101242-101320, 101788-101906, 102549-102568, 103566-103625, 104067-104086, 104277-104858, 105255-105274, 106147-106364, 106632-106647, 106964-107735, 108514-108788, 109336-109505, 109849-109864, 110403-110442, 110701-110974, 111203-111322, 112030-112049, 112499-112514,112842-112861,113028-113056,113646-113665,113896-113911,114446-114465, 115087-115106, 119269-119284, 119659-119703, 120376-120497, 120738-120845, 121209-121228, 121823-122013, -122199,122588-122770,123031-123050,123152-123167,123671-124055, 124413-124608, 125178-125197, 125533-125616, 126357-126434, 126736-126751, 126998-127236, 127454-127682, -128482, 128813-129111, 129976-130013, 130308-130323, 131036-131056, 131286-131305,131676-131691,132171-132517,133168-133241,133522-133877,134086-134101, 134240-134259,134441-134617,135015-135030,135431-135519,135818-135874,136111-136130, 136282-136595, 136996-137152, 137372-137387, 137750-137765, 138048-138067, 138782-139840, 140343-140358,140593-140701,141116-141131,141591-141719,142113-142342,143021-143048, 143185-143486, -144109, 144558-144650, 144990-145078, 145428-145525, 145937-145952, 146235-146386, 147028-147043, 147259-147284, 147671-147686, 148059-148154, 148564-148579, 148904-149084, 149491-149506, 149787-149877, 150236-150251, 150588-151139, 151373-151659, 152201-152388,152549-152771,153001-153026,153349-153364,153831-154112,154171-154186, 154502-154521, 154724-154828,155283-155304,155591-155616,155889-155992,156233-156612, 156847-156907, 157198-157223, 157330-157349, 157552-157567, 157927-158029, 158542-158631, 159216-159267, 159539-159793, 160352-160429, 160812-160827, 161248-161267, 161461-161607, 161821-161969, 162064-162083, 162132-162147, 162531-162770, 163019-163557, -165059, 165419-165575, 165856-165875, 166241-166450, 166837-166852, 167107-167122, 168004-168019, 168760-168823, 169062-169092, 169134-169153, 169601-169711, 170081-170291, 170407-170426, 170703-170814, 171021-171036,171207-171226,171431-171568,171926-171945,172447-172462, -172956, 173045-173756, 174122-174885, 175014-177830, 178895-180539, 181514-187644, 187857-189904, 190109-194159, 194425-195723, 196536-196873, 197326-197961, 198145-198170, 198307-198381, 198715-199007, 199506-199563, 199816-199838, 200249-200635, 201258-201861, 2O 202079-202094, 202382-202717, 203098-203934, -204740, 205549-205915, 206412-206764, 207510-207532, -210014, 210189-210296, 210502-210583, 210920-211418, -212223, 212606-212816, 213025-213044, 213425-213440, 213825-213933, 214479-214498, 214622-214647, 214884-214951, -215508, 215932-215951, 216192-217595, 218132-218248, 218526-218541, 218734-21219037, 219342-219633, 219886-220705, -221059, 221483-221607, 221947-221962, 222569—222584, 222914—222998, 223436—223451, 223948—224122, —224430, 224717—224769, 225133—225148, 225436—225761, 226785—226898, 227025—227040, 227218—227251, 227485—227500, 227914-228837, 229174-229189, 229423-229438, 229615-229640, -230057, 230313-230595, 231218-231345, 231817-232037, 232088-232408, 232823-232848, 232884-232899, 233210-233225, 233623-233646, 234447-234466, 234876-234918, 235258-235328, 235770-235785, 236071-236213, 236684-237196, 237585-237698, 237949-237557, 244873-244897, 245319-245334, 245701-245780, 246152-246523, 246936-247031, 247203-247240, 247431-247450, 247644-247659, 248223-248363, 248694-248762, 249494-249509, 250001-250020, 250693-250708, 251214-251233, 251601-251637, 251950-252060, 252665-252680, 252838-252863, 253140-253166, 253594-253819, -254083, -254345, 254641-254660, 254905-254920, 255397-255422, 255618-255633, -256704, -257092, 257317-257332, -259305, 259500-259515, 261294-261656, 262021-262036, 262453-262779, -266518, 266861-267131, 267375-268051, 268366-269447, 270038-271850, 271950-271969, 272631-274145, 274205-275747, 275808-276636, 276932-277064, 277391-278380, 278932-279063, 279303-281001, 281587-281610, 282229-283668, 290035-290474, 290924-292550, -294408, 295475-297012, 297587-298115, 298161-298418, 298489-298738, 299082-299187, 299276-299669, 299723-299749, 299788-300504, or -301295.

In certain embodiments, an antisense compound or oligonucleotide ed to a growth hormone receptor nucleic acid target the following nucleotide regions of SEQ ID NO: 2: : 2571-25 86, 2867-3059, 3097-3116, 3341-3695, 4024-4039, 4446-4894, 5392-5817, 6128-6265, 890, 7231-7246, 8395-8410, 9153-9168, 9554-9569, 9931-9946, 10549-10564, 10660-10679, 11020-11035, 11793-12229, 12469-12920, 13351-13415,13717-13732,]4149-14164,14361-14555,14965-15279,15849-16001,16253-16272,16447- 16545, 17130-17149, 17377-17669, 17927-17958, 18353-18368, 18636-18773, 19661-19918, 20288-20470, 20979-20994, 21215-21606, 21837, 22150-22165, 22518-22536, 22803-22818, 26494-26522, 29049- 29069, 29323-29489, 30550-30565, 30915-31191, 31468-31483, 32363-32382, 33202, 33635-33795, 34138-34157, 34407-34422, 34845-34864, 35466-35485, 35669-35684, 36023-36042, 36266-36327, 36721- 36827, 37032-37130, 37295, 37504-37675, 38094-38118, 38841-38856, 39716-40538, 40706-40937, 41164-41183, 41439, 42141-42164, 42700-42760, 43537, 43765-46025, 46476-46532, 48423- 48438, 50072-50210, 50470-50485, 50719-51234, 51747-51797, 52015-52143, 52230-52245, 52573-52652, 53466-54660, 54886-54901, 63751-64662, 64882-65099, 65363-65378, 65600-65615, 66183, 66566- 66581, 66978-67080, 67251-67270, 67662-67929, 68727-68742, 69203-69242, 69565-69620, 69889-70145, 2O 70352-70584, 70925-71071, 71314-71329, 71617-71769, 72241, 72670, 73061-73076, 73350- 73369, 73689-73723, 74107-74131, 74317-74557, 74947-75009, 75192-75207, 75979-76066, 76410-77095, 77292-77307, 77638-77869, 78122-78326, 79006-79021, 79478-79505, 80292, 80575-80939, 81207- 81222, 81543, 81761-81776, 82233-82248, 82738-83198, 83416, 83884-84063, 84381-85964, 86220-86392, 86554-86655, 86901-86920, 87181-87262, 88063-88082, 88293-88308, 88605-88967, 89160- 89175, 89940—90255, 90528, 91073—91088, 91273—91292, 91647—91662, 91930—92126, 92356—92371, 93190—93443, 93762—94111, 94374—94389, 94581—94653, 94858, 95292—95583, 95829—95844, 96137— 96503, 96793-97013, 97539-97554, 97800-97889, 98132-98151, 98624-98672, 98810-99115, 99258-99273, 99478-99503, 99791-99858, 100281-100300, 100406-100421, 100742-100828, 101080-101103, - 101320, 101788-101906, 102549-102568, 103566-103625, 104067-104086, 104277-104858, 105255- 105274, 106147-106364, 106632-106647, -107735, 108514-108788, 109336-109505, - 109864, 110403-110442, 110701-110974, 111203-111322, 112030-112049, 112499-112514, 112842- 112861,ll3028-113056,113646-113665,113896-113911,114446-114465,115087-115106,119269- 119284, 119659-119703, 120376-120497, 120738-120845, 121209-121228, 121823-122013, 122180- 122199, 122588-122770, 123031-123050,123152-123167,123671-124055,124413-124608,125178- 125197, 125533-125616, 126357-126434, 126736-126751, 126998-127236, 127454-127682, 128467- 128482,128813-129111, 129976-130013,130308-130323,131036-131056,131286-131305,131676- 131691,132171-132517,133168-133241,133522-133877,134086-134101,134240-134259,134441- 134617,135015-135030,135431-135519,135818-135874,136111-136130,136282-136595,136996- 137152, 137372-137387, 137750-137765, 138048-138067, -139840, -140358, 140593- 140701,]41116-141131,141591-141719,142113-142342,143021-143048,143185-143486,143836- 144109, 144558-144650, 144990-145078, 145428-145525, 145937-145952, 146235-146386, 147028- 147043, 147259-147284, 147671-147686, 148059-148154, 148564-148579, 148904-149084, 149491- 149506, 149787-149877, 150236-150251, 150588-151139, 151373-151659, 152201-152388, - 152771,153001-153026,153349-153364,153831-154112,154171-154186,154502-154521,154724- ,155283-155304, 155591-155616,155889-155992,156233-156612,156847-156907,157198- 157223, 157330-157349, 157552-157567, -158029, 158542-158631, 159216-159267, 159539- 159793,160352-160429, 160812-160827,161248-161267,161461-161607,161821-161969,162064- 162083,162132-162147, 162531-162770,163019-163557,164839-165059,165419-165575,165856- 165875, 166241-166450, 166837-166852, 167107-167122, 168004-168019, 168760-168823, 169062- 169092,169134-169153, 169601-169711,170081-170291,170407-170426,170703-170814,171021- 171036,171207-171226, 171431-171568,171926-171945,172447-172462,172733-172956,173045- 173756, 174122-174885, -177830, 178895-180539, 181514-187644, 187857-189904, 190109- ,194425-195723, 196536-196873,197326-197961,198145-198170,198307-198381,198715- , 199506-199563, 199816-199838, 200249-200635, 201258-201861, 202079-202094, 202382- 2O 202717, 203098-203934, 204181-204740, 205549-205915, 206412-206764, 207510-207532, 209999- 210014, 210189-210296, 210502-210583, 210920-211418, 211836-212223, 212606-212816, 213025- 213044, 213425-213440, 213825-213933, 214479-214498, 214622-214647, -214951, 215446- 215508, -215951, -217595, 218132-218248, 218526-218541, 218734-21219037, 219342- 219633, 219886-220705, 221044-221059, 221483-221607, 221947-221962, 222569-222584, 222914- 222998, 223436—223451, 223948—224122, 224409—224430, 224717—224769, 225133—225148, 225436— 225761, 226785—226898, 227025—227040, 227218—227251, 227485—227500, 227914—228837, 229174— 229189, 229423-229438, 229615-229640, 230042-230057, 230313-230595, 231218-231345, 231817- 232037, 232088-232408, 232823-232848, 232884-232899, 233210-233225, -233646, 234447- 234466, 234876-234918, 235258-235328, 235770-235785, 236071-236213, 236684-237196, 237585- 237698, 237949-237557, 244873-244897, -245334, 245701-245780, 246152-246523, 246936- 247031, 247203-247240, 247431-247450, -247659, 248223-248363, -248762, 249494- 249509, 250001-250020, 250693-250708, 251214-251233, 251601-251637, 251950-252060, 252665- 252680, 252838-252863, 253140-253166, 253594-253819, 254036-254083, 254246-254345, 254641- 254660, 254905-254920, 255397-255422, 255618-255633, -256704, -257092, 257317- , 257818-259305, 259500-259515, 261294-261656, 262021-262036, 262453-262779, 263338- 266518, 266861-267131, 267375-268051, 268366-269447, 270038-271850, 271950-271969, 272631- 274145, 274205-275747, 275808-276636, 276932-277064, 277391-278380, 278932-279063, 279303- 281001, 281587-281610, 282229-283668, -290474, 290924-292550, 292860-294408, 295475- 297012, 297587-298115, 298161-298418, 298489-298738, 299082-299187, 299276-299669, 299723- 299749, 299788-300504, or 300835-301295.

In certain embodiments, antisense compounds or oligonucleotides target a region of a growth hormone receptor nucleic acid. In certain embodiments, such compounds or oligonucleotides targeted to a region of a GHR nucleic acid have a contiguous nucleobase n that is complementary to an equal length nucleobase portion of the . For example, the n can be at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobases portion complementary to an equal length portion of a region recited herein. In certain embodiments, such compounds or oligonucleotide target the following nucleotide s of SEQ ID NO: 2: 2571-2586, 2867-3059, 3097-3116, 3341-3695, 4024-4039, 4446-4894, 5392-5817, 6128-6265, 6499- 6890, 7231-7246, 410, 9153-9168, 9554-9569, 9931-9946, 10549-10564, 10679, 11020-11035, 11793-12229,12469-12920,13351-13415,13717-13732,14149-14164,14361-14555,14965-15279,15849- 16001,16253-16272,16447-16545,17130-17149,17377-17669,17927-17958, 18353-18368,18636-18773, 19661-19918, 20288-20470, 20979-20994, 21215-21606, 21820-21837, 22150-22165, 22518-22536, 22803- 22818, 26494-26522, 29049-29069, 29323-29489, 30550-30565, 30915-31191, 31468-31483, 32363-32382, 32827-33202, 33795, 34157, 34407-34422, 34845-34864, 35466-35485, 35669-35684, 36023- 36042, 36266-36327, 36827, 37032-37130, 37276-37295, 37504-37675, 38094-38118, 38856, 39716-40538, 40706-40937, 41164-41183, 41342-41439, 42141-42164, 42700-42760, 43173-43537, 43765- 46025, 46476-46532, 48423-48438, 50072-50210, 50470-50485, 50719-51234, 51747-51797, 52015-52143, 52230-52245, 52573-52652, 53466-54660, 54886-54901, 63751-64662, 64882-65099, 65363-65378, 65600- 65615, 65988-66183, 66566-66581, 67080, 67251-67270, 67662-67929, 68727-68742, 69203-69242, 69565-69620, 69889-70145, 70352-70584, 70925-71071, 71314-71329, 71617-71769, 72107-72241, 72584- 72670, 73061—73076, 73350—73369, 73689—73723, 74107—74131, 74317—74557, 74947—75009, 75192—75207, 75979—76066, 76410—77095, 77292—77307, 77638—77869, 78122—78326, 79006—79021, 79478—79505, 80277— 80292, 80575-80939, 81207-81222, 81524-81543, 81776, 82233-82248, 82738-83198, 83416, 83884-84063, 84381-85964, 86220-86392, 86554-86655, 86920, 87181-87262, 88082, 88293- 88308, 88605-88967, 89160-89175, 89940-90255, 90528, 91073-91088, 91273-91292, 91647-91662, 91930-92126, 92356-92371, 93190-93443, 94111, 94374-94389, 94581-94653, 94839-94858, 95292- 95583, 95844, 96137-96503, 96793-97013, 97539-97554, 97800-97889, 98132-98151, 98624-98672, 98810-99115, 99258-99273, 99478-99503, 99791-99858, 100281-100300, 100406-100421, 100742-100828, 101080-101103, 101242-101320, 101788-101906, 102549-102568, 103566-103625, -104086, 104277-104858, 105255-105274, 106147-106364, 106632-106647, 106964-107735, 108514-108788, 109336-109505, 109849-109864, 110403-110442, 110701-110974, 111203-111322, 112030-112049, 112499-112514,112842-112861,113028-113056,113646-113665,113896-113911,114446-114465, 115087-115106, 119269-119284, 119659-119703, 120376-120497, 120738-120845, 121209-121228, 121823-122013, -122199,122588-122770,123031-123050,123152-123167,123671-124055, 124413-124608, -125197, 125533-125616, -126434, 126736-126751, 126998-127236, 127454-127682, -128482, 128813-129111, 129976-130013, 130308-130323, 131036-131056, 131286-131305,131676-131691,132171-132517,133168-133241,133522-133877,134086-134101, 134240-134259,134441-134617,135015-135030,135431-135519,135818-135874,136111-136130, 136282-136595, -137152, 137372-137387, -137765, 138048-138067, 138782-139840, 140343-140358,140593-140701,141116-141131,141591-141719,142113-142342,143021-143048, 143185-143486, 143836-144109, 144558-144650, 144990-145078, -145525, 145937-145952, 146235-146386, 147028-147043, 147259-147284, 147671-147686, 148059-148154, 148564-148579, 148904-149084, 149491-149506, 149787-149877, 150236-150251, 150588-151139, -151659, -152388,152549-152771,153001-153026,153349-153364,153831-154112,154171-154186, 154502-154521, 154724-154828,155283-155304,155591-155616,155889-155992,156233-156612, 156847-156907, 157198-157223, 157330-157349, 157552-157567, 157927-158029, 158542-158631, 159216-159267, 159539-159793, 160352-160429, 160812-160827, 161248-161267, 161461-161607, 161821-161969, -162083, 162132-162147, 162531-162770, 163019-163557, -165059, 165419-165575, 165856-165875, 166241-166450, 166837-166852, 167107-167122, 168004-168019, 168760-168823, 169062-169092, 169134-169153, 169601-169711, 170081-170291, 170407-170426, 170703-170814, 171021-171036,171207-171226,171431-171568,171926-171945,172447-172462, 172733-172956, 173045-173756, 174122-174885, 175014-177830, 178895-180539, 181514-187644, -189904, 190109-194159, 194425-195723, 196536-196873, -197961, 198145-198170, 198307-198381, 198715-199007, 199506-199563, 199816-199838, 200249-200635, 201258-201861, 202079-202094, 202382-202717, 203098-203934, -204740, 205549-205915, 206412-206764, 207510—207532, 209999—210014, 210189—210296, 210502—210583, 210920—211418, 211836—212223, 212606—212816,213025—213044, 213425—213440, 213825—213933, 214479—214498, 214622—214647, 214884-214951, 215446-215508, 215932-215951, 216192-217595, 218132-218248, 218526-218541, 218734-21219037, 219342-219633, -220705, 221044-221059, 221483-221607, 221947-221962, 222569-222584, 222914-222998, 223436-223451, 223948-224122, 224409-224430, 224717-224769, 225133-225148, 225436-225761, 226785-226898, 227025-227040, 227218-227251, 227485-227500, 227914-228837, 229174-229189, 229423-229438, 229615-229640, 230042-230057, 230313-230595, 231218-231345, 231817-232037, 232088-232408, 232823-232848, 232884-232899, 233210-233225, 233623-233646, 234447-234466, 234876-234918, 235258-235328, 235770-235785, 236071-236213, 236684-237196, 237585-237698, -237557, 244873-244897, -245334, 245701-245780, 246152-246523, 246936-247031, 247203-247240, 247431-247450, 247644-247659, 248223-248363, 248694-248762, 249494-249509, 250001-250020, 250693-250708, 251214-251233, 251601-251637, 251950-252060, 252665-252680, 252838-252863, 253140-253166, 253594-253819, 254036-254083, 254246-254345, 254641-254660, 254905-254920, 255397-255422, 255618-255633, 255992-256704, 257018-257092, 257317-257332, 257818-259305, 259500-259515, 261294-261656, 262021-262036, 262453-262779, 263338-266518, 266861-267131, 267375-268051, 268366-269447, 270038-271850, 271950-271969, 272631-274145, 274205-275747, -276636, 276932-277064, 277391-278380, 278932-279063, 279303-281001, 281587-281610, 282229-283668, -290474, 290924-292550, 292860-294408, 295475-297012, 297587-298115, 298161-298418, 298489-298738, 299082-299187, 799776-799669, -799749, 799788-300504, or 300835-301295.

In certain embodiments, antisense compounds or oligonucleotides target intron 1 of a growth hormone or nucleic acid. In certain aspects, antisense nds or oligonucleotides target within nucleotides 3058-144965 (intron 1) of a growth hormone receptor nucleic acid having the nucleobase sequence of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 01 to 42714000).

In certain embodiments, antisense compounds or oligonucleotides target intron 2 of a growth hormone receptor nucleic acid. In certain aspects, antisense compounds or oligonucleotides target within nucleotides 145047-208139 (intron 2) of a growth hormone receptor nucleic acid having the nucleobase ce of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 ted from nucleotides 42411001 to 42714000).

In certain ments, nse nds or oligonucleotides target intron 3 of a growth hormone receptor nucleic acid. In certain aspects, nse compounds or oligonucleotides target within nucleotides 208206-267991 (intron 3) of a growth e receptor nucleic acid having the nucleobase sequence of SEQ ID NO: 2 (GENBANK ion No. NT_006576.16 ted from nucleotides 42411001 to 42714000).

In certain embodiments, antisense compounds or oligonucleotides target intron 4 of a growth hormone receptor nucleic acid. In certain aspects, antisense compounds or oligonucleotides target within nucleotides 268122-274018 (intron 4) of a growth hormone receptor nucleic acid having the nucleobase sequence of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 42714000).

In certain embodiments, antisense compounds or oligonucleotides target intron 5 of a growth hormone receptor nucleic acid. In certain aspects, antisense compounds or ucleotides target within nucleotides 274192-278925 (intron 5) of a growth hormone or nucleic acid having the nucleobase sequence of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 00).

In certain embodiments, antisense compounds or oligonucleotides target intron 6 of a growth hormone receptor nucleic acid. In certain aspects, antisense compounds or ucleotides target within nucleotides 279105-290308 (intron 6) of a growth hormone receptor nucleic acid having the nucleobase sequence of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 42714000).

In certain embodiments, antisense compounds or oligonucleotides target intron 7 of a grth hormone or nucleic acid. In certain s, antisense compounds or oligonucleotides target within nucleotides 290475-292530 (intron 7) of a growth e receptor nucleic acid having the nucleobase sequence of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 42714000).

In certain ments, antisense compounds or oligonucleotides target intron 8 of a grth hormone receptor nucleic acid. In certain aspects, antisense compounds or ucleotides target within nucleotides 292622-297153 (intron 8) of a growth hormone receptor nucleic acid having the nucleobase ce of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 42714000).

In certain embodiments, antisense compounds or oligonucleotides target intron 9 of a grth hormone receptor nucleic acid. In certain aspects, antisense compounds or oligonucleotides target within 2O nucleotides 297224-297554 (intron 9) of a growth hormone receptor nucleic acid having the base sequence of SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 ted from nucleotides 42411001 to 42714000).

In certain ments, any of the foregoing compounds or oligonucleotides ses at least one modified sugar. In certain aspects, at least one modified sugar comprises a 2’-O-methoxyethyl group. In n aspects, at least one modified sugar is a bicyclic sugar, such as a 4’-CH(CH3)-O-2’ group, a 4’-CH2- O-2’ group, or a 4’-(CH2)2—O-2’group. In certain aspects, the modified ucleotide comprises at least one modified intemucleoside linkage, such as a phosphorothioate intemucleoside linkage.

In certain ments, any of the foregoing compounds or oligonucleotides comprises at least one d nucleobase, such as 5-methylcytosine.

In certain embodiments, any of the foregoing compounds or oligonucleotides comprises: a gap segment consisting of linked deoxynucleosides; a 5’ wing segment consisting of linked nucleosides; and a 3’ wing segment consisting of linked nucleosides; wherein the gap segment is oned n the 5’ wing segment and the 3’ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

Certain embodiments provide a compound comprising a modified oligonucleotide consisting of 10 to linked sides having a nucleobase sequence comprising the sequence recited in SEQ ID NO: 918, 479, 703, 1800, 1904, 2122, 2127, or 2194.

In certain aspects, the modified oligonucleotide has a nucleobase sequence comprising the ce recited in SEQ ID NOS: 918, 479 or 703, wherein the modified oligonucleotide comprises a gap t consisting of ten linked deoxynucleosides; a 5’ wing segment consisting of five linked nucleosides; and a 3’ wing segment consisting of five linked nucleosides; n the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing t comprises a 2’-O-methoxyethyl sugar; n each internucleoside linkage is a phosphorothioate linkage and wherein each cytosine is a 5-methylcytosine.

In certain aspects, the modified oligonucleotide has a base sequence comprising the sequence recited in SEQ ID NOs: 1800, 1904, 2122, 2127, or 2194, wherein the d oligonucleotide ses: a gap segment consisting often linked deoxynucleosides; a 5’ wing segment consisting of 3 linked nucleosides; and a 3’ wing segment consisting of 3 linked nucleosides; wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a ethoxyethyl sugar or a constrained ethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage.

Certain embodiments e a compound comprising a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 703. In certain aspects, the modified oligonucleotide comprises at least one modified sugar. In n aspects, the at least one modified sugar comprises a 2’-O-methoxyethyl group. In certain aspects, the at least one modified sugar is a bicyclic sugar, such as a 4’-CH(CH3)-O-2’ group, a 4’-CH2-O-2’ group, or a 4’-(CH2)2-O- 2’group. In certain aspects, the modified oligonucleotide ses at least one modified internucleoside linkage, such as a phosphorothioate internucleoside linkage. In certain aspects, the modified oligonucleotide comprises at least one d nucleobase, such as a 5-methylcytosine. In certain aspects, the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5’ wing segment consisting of linked sides; and a 3’ wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment and n each nucleoside of each wing segment ses a modified sugar.

Certain embodiments e a compound sing a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence consisting of the sequence d in SEQ ID NO: 703, wherein the modified oligonucleotide ses: a gap segment ting often linked deoxynucleosides; a 5’ wing segment consisting of five linked nucleosides; and a 3’ wing segment consisting of five linked nucleosides; wherein the gap segment is oned n the 5’ wing segment and the 3’ wing segment; wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

In any of the foregoing embodiments, the compound or oligonucleotide can be at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% complementary to a nucleic acid encoding growth hormone receptor.

In any of the foregoing embodiments, the nucleic acid encoding growth hormone receptor can comprise the nucleotide sequence of any one of SEQ ID NOs: l—l9.

In any of the foregoing embodiments, the compound or oligonucleotide can be single-stranded.

Certain embodiments provide a composition comprising the nd of any of the aforementioned embodiments or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent. In certain aspects, the composition has a viscosity less than about 40 centipoise (cP), less than about 30 centipose (cP), less than about 20 centipose (cP), less than about 15 centipose (cP), or less than about 10 centipose (cP). In certain aspects, the composition having any of the aforementioned viscosities comprises a compound provided herein at a concentration of about 100 mg/mL, about 125 mg/mL, about 150 mg/mL, about 175 mg/mL, about 200 mg/mL, about 225 mg/mL, about 250 mg/mL, about 275 mg/mL, or about 300 mg/mL. In certain s, the composition having any of the aforementioned viscosities and/or compound concentrations has a temperature of room ature or about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, or about 30°C.

Certain embodiments provide a method of treating a disease associated with excess growth hormone in a human comprising administering to the human a eutically effective amount of the compound or composition of any of the aforementioned ments, thereby treating the disease associated with excess growth e. In certain aspects, the disease associated with excess growth hormone is acromegaly. In certain aspects, the treatment reduces IGF-l levels.

Certain embodiments provide a method of preventing a disease associated with excess growth hormone in a human comprising administering to the human a therapeutically effective amount of a compound or composition of any of the aforementioned embodiments, thereby preventing the disease associated with excess growth hormone. In certain embodiments, the disease associated with excess growth hormone is acromegaly.

Certain embodiments provide a method of reducing growth hormone receptor (GHR) levels in a human comprising administering to the human a therapeutically ive amount of the compound or composition of any of the aforementioned ments, thereby ng GHR levels in the human. In certain aspects, the human has a disease associated with excess growth hormone. In certain aspects, the disease associated with excess growth e is acromegaly.

In certain aspects, the ing methods comprise co-administering the compound or composition and a second agent. In certain s, the compound or composition and the second agent are stered concomitantly.

Antisense compounds eric compounds include, but are not limited to, oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide cs, antisense compounds, antisense oligonucleotides, and siRNAs. An oligomeric compound may be “antisense” to a target nucleic acid, meaning that is is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.

In certain embodiments, an antisense compound has a nucleobase sequence that, when written in the ’ to 3’ direction, comprises the e complement of the target segment of a target nucleic acid to which it is targeted. In n such embodiments, an antisense ucleotide has a nucleobase sequence that, when written in the 5’ to 3’ direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

In certain embodiments, an antisense compound is 10 to 30 subunits in length. In certain ments, an antisense compound is 12 to 30 subunits in length. In certain embodiments, an antisense compound is 12 to 22 subunits in length. In certain embodiments, an antisense nd is 14 to 30 subunits in length. In certain embodiments, an nse nd is 14 to 20 subunits in length. In certain embodiments, an antisense compoun is 15 to 30 subunits in length. In certain embodiments, an antisense compound is 15 to 20 subunits in length. In certain embodiments, an antisense compound is 16 to 30 subunits in length. In n embodiments, an antisense compound is 16 to 20 subunits in length. In certain embodiments, an nse compound is 17 to 30 subunits in length. In certain embodiments, an antisense compound is 17 to 20 subunits in length. In certain embodiments, an antisense compound is 18 to 30 subunits in length. In certain embodiments, an antisense compound is 18 to 21 ts in length. In certain embodiments, an antisense compound is 18 to 20 subunits in length. In certain embodiments, an antisense nd is 20 to 30 subunits in length. In other words, such antisense compounds are from 12 to 30 linked subunits, 14 to 30 linked subunits, 14 to 20 subunits, 15 to 30 subunits, 15 to 20 subunits, 16 to 30 subunits, 16 to 20 subunits, 17 to 30 ts, 17 to 20 subunits, 18 to 30 subunits, 18 to 20 subunits, 18 to 21 subunits, to 30 subunits, or 12 to 22 linked subunits, respectively. In certain embodiments, an antisense compound is 14 subunits in length. In certain embodiments, an antisense compound is 16 subunits in length. In certain embodiments, an antisense nd is 17 subunits in length. In certain embodiments, an antisense compound is 18 subunits in length. In certain embodiments, an antisense compound is 19 subunits in length.

In certain embodiments, an antisense compound is 20 subunits in . In other embodiments, the antisense compound is 8 to 80, 12 to 50, 13 to 30,13 to 50,14 to 30, 14 to 50, 15 to 30,15 to 50,16 to 30, 16 to 50,17 to 30, 17 to 50, 18 to 22,18 to 24, 18 to 30, 18 to 50,19 to 22,19 to 30, 19 to 50, or 20 to 30 linked subunits. 2O In certain such embodiments, the antisense compounds are 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,30, 31, 32, 33, 34, 35, 36, 37, 38, 39,40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,53, 54,55, 56,57, 58,59, 60,61, 62, 63, 64, 65, 66, 67, 68, 69, 70,71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked subunits in length, or a range defined by any two of the above values. In some embodiments the nse compound is an antisense ucleotide, and the linked subunits are nucleotides.

In certain embodiments antisense oligonucleotides may be shortened or truncated. For example, a single subunit may be deleted from the 5’ end (5’ truncation), or atively from the 3’ end (3’ truncation).

A shortened or truncated antisense compound targeted to a GHR nucleic acid may have two subunits deleted from the 5’ end, or alternatively may have two subunits deleted from the 3’ end, of the antisense nd.

Alternatively, the deleted nucleosides may be sed throughout the antisense compound, for example, in an nse compound having one nucleoside d from the 5’ end and one nucleoside deleted from the 3’ When a single additional subunit is present in a lengthened antisense compound, the additional subunit may be located at the 5’ or 3’ end of the antisense compound. When two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in an antisense compound having WO 02971 two subunits added to the 5’ end (5’ addition), or alternatively to the 3’ end (3’ addition), of the antisense compound. Alternatively, the added subunits may be sed throughout the antisense compound, for example, in an antisense compound having one subunit added to the 5’ end and one subunit added to the 3’ It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al.

(Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model.

Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including those with l or 3 mismatches.

Gautschi et al. (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide demonstrated potent anti-tumor activity in vivo.

Maher and Dolnick (Nuc. Acid. Res. 1-335 8,1988) tested a series of tandem 14 nucleobase nse oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest ation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.

Certain Antisense Compound Motifs and Mechanisms In certain embodiments, antisense compounds have ally modified subunits ed in patterns, or motifs, to confer to the antisense compounds properties such as ed tory activity, increased binding affinity for a target nucleic acid, or resistance to degradation by in vivo nucleases.

Chimeric antisense compounds typically contain at least one region d so as to confer increased resistance to se degradation, increased ar uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense compound WO 02971 may confer another desired property e.g., serve as a substrate for the ar endonuclease RNase H, which cleaves the RNA strand of an RNA:DNA .

Antisense activity may result from any mechanism ing the hybridization of the antisense compound (e.g., ucleotide) with a target nucleic acid, wherein the hybridization ultimately results in a biological effect. In certain embodiments, the amount and/or activity of the target nucleic acid is modulated.

In certain embodiments, the amount and/or activity of the target nucleic acid is reduced. In certain embodiments, hybridization of the antisense nd to the target nucleic acid ultimately results in target nucleic acid degradation. In n embodiments, hybridization of the antisense compound to the target nucleic acid does not result in target nucleic acid degradation. In certain such embodiments, the presence of the antisense compound hybridized with the target nucleic acid (occupancy) results in a modulation of antisense activity. In certain embodiments, antisense compounds having a particular al motif or pattern of chemical modifications are particularly suited to exploit one or more mechanisms. In certain embodiments, antisense compounds function h more than one mechanism and/or through mechanisms that have not been elucidated. Accordingly, the antisense compounds described herein are not limited by particular mechanism.

Antisense mechanisms include, without limitation, RNase H mediated antisense; RNAi mechanisms, which utilize the RISC pathway and include, without limitation, siRNA, ssRNA and microRNA isms; and occupancy based mechanisms. Certain antisense compounds may act through more than one such ism and/or through additional mechanisms.

RNase H—Mediated Antisense In certain embodiments, antisense activity s at least in part from degradation of target RNA by RNase H. RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA2DNA duplex. It is known in the art that single-stranded nse compounds which are “DNA-like” elicit RNase H activity in mammalian cells. Accordingly, antisense compounds comprising at least a portion of DNA or ke nucleosides may activate RNase H, resulting in cleavage of the target c acid. In certain embodiments, antisense compounds that utilize RNase H comprise one or more modified sides. In certain embodiments, such antisense compounds comprise at least one block of 1-8 modified nucleosides. In certain such embodiments, the modified nucleosides do not support RNase H activity. In certain embodiments, such antisense compounds are s, as described herein. In certain such embodiments, the gap of the gapmer comprises DNA nucleosides. In certain such embodiments, the gap of the gapmer ses DNA-like nucleosides. In certain such ments, the gap of the gapmer comprises DNA sides and DNA-like nucleosides.

Certain nse compounds having a gapmer motif are considered chimeric antisense compounds.

In a gapmer an internal region having a plurality of nucleotides that supports RNaseH ge is oned between external regions having a plurality of nucleotides that are chemically distinct from the nucleosides of the internal region. In the case of an nse oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for clease cleavage, while the wing segments comprise modified nucleosides. In certain embodiments, the regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may in some embodiments e B-D-ribonucleosides, B-D-deoxyribonucleosides, 2'- modified nucleosides (such 2’-modified nucleosides may include 2’-MOE and H3, among others), and bicyclic sugar modified nucleosides (such bicyclic sugar modified nucleosides may include those having a constrained ethyl). In certain embodiments, nucleosides in the wings may include l modified sugar es, including, for example 2’-MOE and bicyclic sugar moieties such as constrained ethyl or LNA. In certain embodiments, wings may include several modified and unmodified sugar moieties. In certain embodiments, wings may include various combinations of 2’-MOE nucleosides, bicyclic sugar moieties such as constrained ethyl nucleosides or LNA sides, and 2’-deoxynucleosides.

Each distinct region may comprise uniform sugar moieties, variant, or alternating sugar moieties.

The wing-gap-wing motif is frequently described as “X-Y-Z”, where “X” represents the length of the 5’- 2O wing, “Y” represents the length of the gap, and “Z” ents the length of the 3’-wing. “X” and “Z” may comprise uniform, variant, or alternating sugar es. In certain embodiments, “X” and “Y” may include one or more 2’-deoxynucleosides.“Y” may comprise 2’-deoxynucleosides. As used herein, a gapmer described as “X-Y-Z” has a configuration such that the gap is positioned immediately adjacent to each of the ’-wing and the 3’ wing. Thus, no intervening nucleotides exist between the 5’-wing and gap, or the gap and the 3’-wing. Any of the nse compounds described herein can have a gapmer motif. In certain embodiments, “X” and “Z” are the same; in other embodiments they are different. In certain embodiments, “Y” is between 8 and 15 nucleosides. X, Y, or Z can be any of l, 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, 12, l3, 14, 15, l6, l7, l8, 19, 20, 25, 30 or more nucleosides.

In certain embodiments, the antisense compound targeted to a GHR nucleic acid has a gapmer motif in which the gap consists of6, 7, 8, 9, 10, ll, l2, l3, 14, 15, or 16 linked nucleosides.

In n embodiments, the antisense ucleotide has a sugar motif described by Formula A as follows: (J)m-(B)n-(J)p'(B)r'(A)t'(D)g_(A)V_(B)W_(J)x‘(B)y'(J)z wherein: each A is independently a 2’-substituted nucleoside; each B is independently a bicyclic nucleoside; each J is independently either a 2’—substituted side or a 2’—deoxynucleoside; each D is a 2’—deoxynucleoside; m is 0-4; 11 is 0-2; p is 0-2; r is 0-2; t is 0-2; V is 0-2; W is 0-4; X is 0-2; y is 0-2; 2 is 0-4; g is 6-14; provided that: at least one of m, n, and r is other than 0; at least one of W and y is other than 0; the sum ofm, n, p, r, and t is from 2 to 5; and the sum ofV, W, x, y, and z is from 2 to 5.

RNAi Compounds In certain embodiments, antisense nds are interfering RNA compounds (RNAi), Which include double-stranded RNA compounds (also referred to as short-interfering RNA or siRNA) and single- stranded RNAi compounds (or . Such compounds work at least in part through the RISC pathway to degrade and/or sequester a target nucleic acid (thus, include microRNA/microRNA-mimic compounds). In certain embodiments, nse compounds comprise modifications that make them particularly suited for such mechanisms. 1'. ssRNA compounds In certain embodiments, antisense compounds including those particularly suited for use as single- stranded RNAi compounds (ssRNA) comprise a modified 5’-terminal end. In n such embodiments, the ’-terminal end comprises a modified phosphate moiety. In certain embodiments, such modified phosphate is stabilized (e.g., resistant to ation/cleavage ed to unmodified 5’-phosphate). In certain embodiments, such 5’-terminal nucleosides stabilize the 5’-phosphorous moiety. Certain modified 5’- terrninal nucleosides may be found in the art, for example in WO/2011/139702.

In n embodiments, the leoside of an ssRNA compound has Formula He: J4 J5 J6 J7 wherein: T1 is an optionally protected orus moiety; T2 is an intemucleoside linking group linking the compound of Formula 11c to the oligomeric compound; A has one of the formulas: Q1_Q2 Q1_H7"' Q2 12—32%, E: Q1 Q3 Q2: in? ’\ ”a; [be Q1 and Q2 are each, independently, H, halogen, C1-C5 alkyl, substituted C1-C5 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl 0r N(R3)(R4); Q3 is O, S, N(R5) or R7); each R3, R4 R5, R6 and R7 is, independently, H, C1-C6 alkyl, substituted C1-C5 alkyl or C1-C5 alkoxy; M3 is O, S, NR14, C(R15)(R16), C(R15)(R15)C(R17)(R18), C(R15)=C(R17), OC(R15)(R16) 01' OC(R15)(BX2), R14 is H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 l or substituted C2-C6 alkynyl; R15, R16, R17 and R18 are each, independently, H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 , tuted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl or substituted C2-C6 alkynyl; Bxl is a heterocyclic base moiety; or if BX2 is present then BXZ is a heterocyclic base moiety and BX1 is H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 , substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C5 alkenyl, C2- C6 l or substituted C2-C6 alkynyl; J4, J5, J6 and J7 are each, independently, H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 , C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl or tuted C2-C6 alkynyl; or J4 forms a bridge With one of J5 or J7 wherein said bridge comprises from 1 to 3 linked biradical groups selected from O, S, NR19, C(R20)(R21), C(R20)=C(R21), C[=C(R20)(R21)] and C(=O) and the other two of J5, J6 and J7 are each, independently, H, n, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl or substituted C2-C6 alkynyl; each R19, R20 and R21 is, independently, H, C1-C6 alkyl, tuted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl or substituted C2-C6 alkynyl; G is H, OH, halogen or O-[C(Rg)(R9)]n-[(C=O)m-X1],--Z; each R8 and R9 is, independently, H, halogen, C1-C6 alkyl or tuted C1-C6 alkyl; X1 is O, S or N(E1); Z is H, halogen, C1-C6 alkyl, tuted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl or N(E2)(E3); E1, E2 and E3 are each, independently, H, C1-C6 alkyl or substituted C1-C6 alkyl; 11 is from 1 to about 6; m is 0 or 1; j is 0 or 1; each substituted group comprises one or more optionally protected substituent groups independently selected from halogen, 0J1, N(J1)(J2), =NJ1, SJ 1, N3, CN, OC(=X2)J1, OC(=X2)N(J1)(J2) and C(=X2)N(J1)(J2); X2 is O, S or NJ3; each J1, J2 and J3 is, independently, H or C1-C6 alkyl; when j is 1 then Z is other than halogen or N(E2)(E3); and n said oligomeric compound comprises from 8 to 40 monomeric subunits and is hybridizable to at least a portion of a target nucleic acid.

In certain embodiments, M3 is O, CH=CH, OCHZ or OC(H)(BX2). In certain embodiments, M3 is O.

In certain embodiments, J4, J5, J6 and J7 are each H. In certain embodiments, J4 forms a bridge with one ofIs or J7.

In certain embodiments, A has one of the formulas: Q‘HQz Q19“ “’H .4“ ‘5. Q2 wherein: Q1 and Q2 are each, independently, H, halogen, C1-C5 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy or substituted C1-C6 alkoxy. In certain embodiments, Q1 and Q2 are each H. In n ments, Q1 and Q2 are each, ndently, H or n. In certain embodiments, Q1 and Q2 is H and the other of Q1 and Q2 is F, CH3 or OCH3.

In certain embodiments, T1 has the formula: REEF—5 Rc R, and R0 are each, independently, protected hydroxyl, protected thiol, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, protected amino or substituted amino; and R, is O or S. In certain ments, Rb is O and R, and R0 are each, independently, OCH3, 3 or CH(CH3)2.

In certain embodiments, G is halogen, OCH3, OCHZF, OCHFZ, OCF3, OCH2CH3, O(CH2)2F, OCHZCHFQ, OCH2CF3, OCHg-CH=CH2, 0(CH2)2-OCH3, 0(CH2)2-SCH3, 0(CH2)2-OCF3, 0(CH2)3- N(R10)(R11), 0(CH2)2-ON(R10)(R11), 0(CH2)2-O(CH2)2-N(R10)(R11), OCH2C(=O)-N(R10)(R11), OCH2C(=O)- N(R12)-(CH2)2-N(R10)(R11) or O(CH2)2-N(R12)-C(=NR13)[N(R10)(R11)] wherein R10, R11, R12 and R13 are each, independently, H or C1-C6 alkyl. In certain embodiments, G is halogen, OCH3, OCF3, OCHQCHg, OCHZCFg, HZCHz, O(CH2)2-OCH3, O(CH2)2-O(CH2)2-N(CH3)2, OCH2C(=O)-N(H)CH3, OCH2C(=O)-N(H)- (CH2)2-N(CH3)2 or OCHZ-N(H)-C(=NH)NH2. In certain embodiments, G is F, OCH3 or 2-OCH3. In certain embodiments, G is O(CH2)2-OCH3.

In certain embodiments, the 5'-terminal nucleoside has a He: \,P\ ,OH HO _ 0 BX] (I) G T2 In certain embodiments, antisense compounds, ing those particularly suitable for ssRNA comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif. Such motifs may include any of the sugar modifications discussed herein and/or other known sugar modifications.

In certain embodiments, the oligonucleotides comprise or consist of a region having m sugar modifications. In certain such embodiments, each nucleoside of the region comprises the same RNA-like sugar modification. In certain embodiments, each nucleoside of the region is a 2’-F nucleoside. In certain embodiments, each nucleoside of the region is a 2’-OMe nucleoside. In certain embodiments, each nucleoside of the region is a 2’-MOE nucleoside. In certain embodiments, each nucleoside of the region is a cEt nucleoside. In certain embodiments, each nucleoside of the region is an LNA side. In certain ments, the uniform region constitutes all or essentially all of the oligonucleotide. In n embodiments, the region constitutes the entire ucleotide except for 1-4 terminal nucleosides.

In certain embodiments, oligonucleotides comprise one or more regions of alternating sugar modifications, wherein the nucleosides alternate between tides having a sugar modification of a first type and nucleotides having a sugar modification of a second type. In certain embodiments, nucleosides of both types are RNA-like nucleosides. In n embodiments the alternating nucleosides are selected from: 2’-OMe, 2’-F, 2’-MOE, LNA, and cEt. In certain embodiments, the alternating modificatios are 2’-F and 2’- OMe. Such s may be contiguous or may be interupted by differently modified sides or conjugated nucleosides.

In certain embodiments, the alternating region of alternating modifications each consist of a single nucleoside (i.e., the patem is (AB)XAy wheren A is a nucleoside having a sugar modification of a first type and B is a nucleoside having a sugar modification of a second type; X is 1-20 and y is O or 1). In certan embodiments, one or more ating regions in an alternating motif includes more than a single nucleoside of a type. For example, oligonucleotides may include one or more regions of any of the following nucleoside motifs: AABBAA; ABBABB; AABAAB; ABBABAABB; ABABAA; AABABAB; ABABAA; ABBAABBABABAA; BABBAABBABABAA; or ABABBAABBABABAA; wherein A is a nucleoside of a first type and B is a nucleoside of a second type. In certain embodiments, A and B are each selected from 2’-F, 2’-OMe, BNA, and MOE.

In certain embodiments, oligonucleotides having such an alternating motif also comprise a d ’ temiinal nucleoside, such as those of formula IIc or IIe.

In certain embodiments, ucleotides comprise a region having a 23 motif. Such regions comprises the following motif: -(A)2-(B)x-(A)2-(C)y-(A)3- wherein: A is a first type fed nucleosde; B and C, are nucleosides that are differently modified than A, r, B and C may have the same or different ations as one another; X andy are from 1 to 15.

In certain embodiments, A is a 2’-OMe d nucleoside. In certain embodiments, B and C are both 2’-F modified nucleosides. In certain embodiments, A is a 2’-OMe modified nucleoside and B and C are both 2’-F modified sides.

In certain embodiments, oligonucleosides have the following sugar motif: ’- (Q)- (AB)xAy'(D)z wherein: Q is a nucleoside comprising a stabilized phosphate moiety. In certain embodiments, Q is a nucleoside having a IIc or IIe; A is a first type of d nucleoside; B is a second type of modified nucleoside; D is a d nucleoside comprising a modification different from the nucleoside adjacent to it.

Thus, if y is 0, then D must be differently modified than B and if y is 1, then D must be differently modified than A. In certain embodiments, D differs from both A and B.

X is 5-15; Y is 0 or 1; Z is 0-4.

In certain embodiments, oligonucleosides have the following sugar motif: ’- (Q)- (A)X'(D)z wherein: Q is a nucleoside comprising a stabilized phosphate moiety. In certain embodiments, Q is a nucleoside having a IIc or IIe; A is a first type of modifed nucleoside; D is a modified nucleoside comprising a modification different from A.

X is 1 1-30; Z is 0-4.

In certain embodiments A, B, C, and D in the above motifs are selected from: 2’-OMe, 2’-F, 2’- MOE, LNA, and cEt. In certain embodiments, D represents terminal nucleosides. In certain embodiments, such terminal nucleosides are not designed to hybridize to the target nucleic acid (though one or more might hybridize by chance). In certiain embodiments, the nucleobase of each D nucleoside is adenine, regardless of the identity of the base at the corresponding position of the target c acid. In certain embodiments the nucleobase of each D nucleoside is thymine.

In certain embodiments, nse compounds, ing those particularly suited for use as ssRNA comprise modified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or modified ucleoside linkage motif. In n embodiments, oligonucleotides comprise a region having an alternating internucleoside linkage motif. In certain embodiments, oligonucleotides comprise a region of uniformly modified internucleoside linkages. In certain such ments, the oligonucleotide comprises a region that is uniformly linked by phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide is uniformly linked by phosphorothioate internucleoside linkages.

In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate. In certain embodiments, each internucleoside linkage of the ucleotide is ed from phosphodiester and phosphorothioate and at least one ucleoside linkage is phosphoro- In certain embodiments, the oligonucleotide comprises at least 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide ses at least 10 phosphorothioate internucleoside linkages. In certain ments, the oligonucleotide comprises at least one block of at least 6 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 8 consecutive phosphorothioate ucleoside es. In certain ments, the oligonucleotide comprises at least one block of at least 10 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least one 12 consecutive phosphorothioate internucleoside linkages. In certain such embodiments, at least one such block is located at the 3’ end of the oligonucleotide. In certain such embodiments, at least one such block is located within 3 nucleosides of the 3’ end ofthe oligonucleotide.

Oligonucleotides having any of the various sugar motifs described herein, may have any linkage motif. For example, the ucleotides, including but not limited to those bed above, may have a linkage motif selected from non—limiting the table below: ’ most linkage Central region 3 ’ —region Alternating PO/PS Alternating PO/PS ii. siRNA compounds In certain embodiments, antisense compounds are double—stranded RNAi compounds (siRNA). In such embodiments, one or both strands may comprise any modification motif described above for ssRNA. In certain embodiments, ssRNA compounds may be unmodified RNA. In certain embodiments, siRNA compounds may comprise unmodified RNA nucleosides, but modified internucleoside linkages.

Several ments relate to double—stranded itions wherein each strand comprises a motif defined by the location of one or more modified or unmodified nucleosides. In certain embodiments, compositions are provided comprising a first and a second oligomeric compound that are fully or at least partially hybridized to form a duplex region and filrther comprising a region that is complementary to and hybridizes to a nucleic acid target. It is suitable that such a composition comprise a first eric compound that is an antisense strand having full or partial complementarity to a nucleic acid target and a second oligomeric compound that is a sense strand having one or more regions of complementarity to and forming at least one duplex region with the first oligomeric compound.

The itions of l embodiments modulate gene expression by hybridizing to a nucleic acid target resulting in loss of its normal function. In some embodiments, the target nucleic acid is GHR. In certain embodiment, the degradation of the ed GHR is facilitated by an activated RISC complex that is formed with compositions of the ion.

Several embodiments are directed to double-stranded compositions wherein one of the strands is useful in, for example, influencing the preferential loading of the opposite strand into the RISC (or cleavage) complex. The compositions are useful for targeting selected nucleic acid molecules and ting the expression of one or more genes. In some embodiments, the compositions of the present ion ize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Certain embodiments are drawn to double-stranded compositions wherein both the strands comprises a hemimer motif, a fully modified motif, a positionally modified motif or an alternating motif.

Each strand of the compositions of the present invention can be modified to fulfil a particular role in for e the siRNA pathway. Using a different motif in each strand or the same motif with different chemical modifications in each strand permits targeting the antisense strand for the RISC complex while inhibiting the oration of the sense . Within this model, each strand can be independently modified such that it is ed for its particular role. The antisense strand can be modified at the 5'-end to enhance its role in one region of the RISC while the 3'-end can be modified differentially to enhance its role in a different region of the RISC.

The double-stranded oligonucleotide molecules can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense s, wherein the antisense region ses tide sequence that is complementary to tide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a n thereof. The double-stranded oligonucleotide molecules can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (ie. each strand comprises nucleotide sequence that is complementary to nucleotide ce in the other ; such as where the antisense strand and sense strand form a duplex or double-stranded structure, for example wherein the double-stranded region is about to about 30, e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs; the antisense strand comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion f and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof (e.g., about 15 to about 25 or more nucleotides of the double-stranded oligonucleotide le are complementary to the target nucleic acid or a portion thereof).

Alternatively, the -stranded oligonucleotide is assembled from a single oligonucleotide, where the selfcomplementary sense and antisense regions of the siRNA are linked by means of a nucleic acid based or non- nucleic acid-based linker(s). 2O The double-stranded oligonucleotide can be a cleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having tide sequence corresponding to the target nucleic acid sequence or a n thereof. The double-stranded oligonucleotide can be a ar single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be sed either in vivo or in vitro to generate an active siRNA molecule capable of mediating RNAi.

In n embodiments, the double—stranded ucleotide comprises separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linkers molecules as is known in the art, or are alternately valently linked by ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic interactions, and/or stacking ctions. In n embodiments, the double-stranded oligonucleotide comprises nucleotide sequence that is complementary to nucleotide ce of a target gene. In another embodiment, the double-stranded oligonucleotide interacts with nucleotide ce of a target gene in a manner that causes inhibition of expression of the target gene.

As used herein, double-stranded oligonucleotides need not be limited to those molecules containing only RNA, but further encompasses chemically modified nucleotides and cleotides. In certain embodiments, the short interfering nucleic acid molecules lack 2'-hydroxy (2'—OH) containing nucleotides. In certain embodiments short interfering nucleic acids ally do not include any ribonucleotides (e.g., nucleotides having a 2'-OH . Such double-stranded oligonucleotides that do not e the presence of ribonucleotides within the molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains ning one or more nucleotides with 2'—OH groups.

Optionally, double-stranded oligonucleotides can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. As used herein, the term siRNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of ing sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, ranscriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term RNAi is meant to be lent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics. For example, -stranded oligonucleotides can be used to epigenetically silence genes at both the post-transcriptional level and the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siRNA molecules of the invention can result from siRNA mediated modification of chromatin structure or methylation pattern to alter gene sion (see, for example, Verdel et al., 2004, Science, 303, 672-676; Pal-Bhadra et al., 2004, Science, 303, 669-672; Allshire, 2002, Science, 297, 1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein, 2002, Science, 297, 2215-2218; and Hall et al., 2002, Science, 297, 237).

It is contemplated that compounds and compositions of several embodiments provided herein can target GHR by a mediated gene silencing or RNAi mechanism, including, e. g., in" or stem- loop double—stranded RNA effector molecules in which a single RNA strand with self—complementary sequences is capable of ng a double—stranded conformation, or duplex dsRNA effector molecules comprising two separate strands of RNA. In various embodiments, the dsRNA consists entirely of ribonucleotides or consists of a mixture of ribonucleotides and deoxynucleotides, such as the RNA/DNA hybrids sed, for example, by WO 00/63364, filed Apr. 19, 2000, or US. Ser. No. 60/130,377, filed Apr. 21, 1999. The dsRNA or dsRNA effector molecule may be a single molecule with a region of self- complementarity such that nucleotides in one segment of the molecule base pair with nucleotides in another segment of the molecule. In s embodiments, a dsRNA that consists of a single molecule consists entirely of ribonucleotides or includes a region of ribonucleotides that is complementary to a region of deoxyribonucleotides. atively, the dsRNA may include two different strands that have a region of complementarity to each other.

In various embodiments, both strands t entirely of ribonucleotides, one strand consists entirely of ribonucleotides and one strand consists entirely of deoxyribonucleotides, or one or both strands n a mixture of ribonucleotides and deoxyribonucleotides. In n embodiments, the regions of complementarity are at least 70, 80, 90, 95, 98, or 100% complementary to each other and to a target c acid sequence. In n embodiments, the region of the dsRNA that is t in a double-stranded conformation includes at least 19, 70, 71, 77, 73, 74, 75, 76, 77, 78, 79, 30, 50, 75,100, 200, 500, 1000, 2000 or 5000 nucleotides or includes all of the nucleotides in a cDNA or other target nucleic acid sequence being represented in the dsRNA. In some embodiments, the dsRNA does not contain any single stranded regions, such as single stranded ends, or the dsRNA is a hairpin. In other embodiments, the dsRNA has one or more single stranded regions or overhangs. In certain ments, RNA/DNA hybrids include a DNA strand or region that is an antisense strand or region (e. g, has at least 70, 80, 90, 95, 98, or 100% mentarity to a target nucleic acid) and an RNA strand or region that is a sense strand or region (6.g, has at least 70, 80, 90, 95 or 100% identity to a target nucleic acid), and vice versa. , 98, In various embodiments, the RNA/DNA hybrid is made in vitro using enzymatic or chemical 2O synthetic methods such as those described herein or those described in WO 00/63364, filed Apr. 19, 2000, or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999. In other embodiments, a DNA strand synthesized in vitro is complexed with an RNA strand made in vivo or in vitro before, after, or rent with the transformation of the DNA strand into the cell. In yet other embodiments, the dsRNA is a single circular nucleic acid containing a sense and an antisense region, or the dsRNA includes a circular nucleic acid and either a second ar c acid or a linear nucleic acid (see, for example, WO 00/63364, filed Apr. 19, 2000, or U.S.

Ser. No. 60/130,377, filed Apr. 21, 1999.) Exemplary circular nucleic acids include lariat structures in which the free 5 ' phosphoryl group of a nucleotide s linked to the 2' hydroxyl group of another nucleotide in a loop back fashion.

In other embodiments, the dsRNA includes one or more modified nucleotides in which the 2' position in the sugar contains a halogen (such as fluorine group) or contains an alkoxy group (such as a methoxy group) which increases the half-life of the dsRNA in vitro or in vivo compared to the corresponding dsRNA in which the ponding 2' position contains a hydrogen or an hydroxyl group. In yet other embodiments, the dsRNA includes one or more linkages between adjacent nucleotides other than a naturally— occurring odiester linkage. Examples of such linkages include oramide, phosphorothioate, and phosphorodithioate linkages. The dsRNAs may also be chemically modified nucleic acid les as taught in US. Pat. No. 6,673,661. In other embodiments, the dsRNA contains one or two capped strands, as disclosed, for example, by WO 64, filed Apr. 19, 2000, or US. Ser. No. 60/130,377, filed Apr. 21, 1999.

In other embodiments, the dsRNA can be any of the at least partially dsRNA molecules disclosed in WO 00/63364, as well as any of the dsRNA molecules described in US. ional Application 60/399,998; and US. Provisional Application 60/419,532, and , the teaching of which is hereby incorporated by reference. Any of the dsRNAs may be expressed in vitro or in vivo using the methods bed herein or standard methods, such as those described in WO 00/63364.

Occupancy In certain embodiments, antisense compounds are not expected to result in cleavage or the target nucleic acid via RNase H or to result in cleavage or sequestration through the RISC pathway. In certain such embodiments, antisense activity may result from occupancy, n the presence of the hybridized antisense compound disrupts the activity of the target nucleic acid. In certain such embodiments, the antisense compound may be mly modified or may comprise a mix of modifications and/or modified and unmodified sides.

Target c Acids, Target Regions and Nucleotide Sequences Nucleotide ces that encode growth hormone receptor (GHR) targetable with the compounds provided herein include, t limitation, the following: GENBANK Accession No. NM_000163.4 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NT_006576.16 ted from nucleotides 42411001 to 42714000 (incorporated herein as SEQ ID NO: 2), GENBANK Accession No X06562] (incorporated herein as SEQ ID NO: 3), GENBANK Accession No. DR006395.1 (incorporated herein as SEQ ID NO: 4), GENBANK Accession No. DB052048.1 (incorporated herein as SEQ ID NO: 5), GENBANK Accession No. AF230800.1 (incorporated herein as SEQ ID NO: 6), the ment of GENBANK Accession No. AA398260.1 (incorporated herein as SEQ ID NO: 7), K Accession No.

BC136496.1 (incorporated herein as SEQ ID NO: 8), GENBANK Accession No. NM_001242399.2 (incorporated herein as SEQ ID NO: 9), GENBANK ion No. NM_001242400.2 (incorporated herein as SEQ ID NO: 10), GENBANK Accession No. NM_001242401.3 (incorporated herein as SEQ ID NO: 11), GENBANK Accession No. NM_001242402.2 (incorporated herein as SEQ ID NO: 12), GENBANK Accession No. NM_001242403.2 (incorporated herein as SEQ ID NO: 13), GENBANK Accession No.

NM_001242404.2 (incorporated herein as SEQ ID NO: 14), GENBANK Accession No. NM_001242405.2 porated herein as SEQ ID NO: 15), GENBANK Accession No. NM_001242406.2 (incorporated herein as SEQ ID NO: 16), K Accession No. NM_001242460.1 (incorporated herein as SEQ ID NO: 17), GENBANK Accession NM_001242461.1 (incorporated herein as SEQ ID NO: 18), GENBANK Accession No. NM_001242462.1 (incorporated herein as SEQ ID NO: 19), or GENBANK Accession No 120958.1 truncated from nucleotides 4410000 to 4720000 (incorporated herein as SEQ ID NO: 2296).

Hybridization In some embodiments, hybridization occurs between an antisense compound disclosed herein and a GHR nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson- Crick, Hoogsteen or reversed een hydrogen g) between complementary nucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Stringent conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.

Methods of determining r a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In certain ments, the antisense compounds provided herein are cally hybridizable with a GHR nucleic acid.

Complementarity An antisense nd and a target nucleic acid are complementary to each other when a sufficient number of nucleobases of the antisense compound can hydrogen bond with the corresponding nucleobases of the target nucleic acid, such that a desired effect will occur (e. g., antisense inhibition of a target nucleic acid, such as a GHR nucleic acid).

Non-complementary nucleobases between an antisense compound and a GHR nucleic acid may be tolerated provided that the antisense compound remains able to specifically hybridize to a target nucleic acid.

Moreover, an antisense compound may hybridize over one or more segments of a GHR nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e. g., a loop structure, mismatch or hairpin structure).

In certain embodiments, the antisense nds provided , or a specified portion f, are, or are at least, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a GHR nucleic acid, a target region, target segment, or specified portion f. Percent complementarity of an antisense compound with a target nucleic acid can be determined using routine methods.

For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary bases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense compound which is 18 bases in length having four noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an nse compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local ent search tools) and PowerBLAST programs known in the art (Altschul er al., J. M01. Biol, 1990, 215, 403 410; Zhang and Madden, Genome Res, 1997, 7, 649 656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, sity Research Park, Madison Wis), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math, 1981, 2, 482 489).

In certain embodiments, the antisense compounds provided herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof. For example, an antisense compound may be fully complementary to a GHR nucleic acid, or a target , or a target segment or target sequence thereof. As used herein, “fully complementary” means each base of an antisense compound is capable of precise base pairing with the corresponding nucleobases of a target nucleic acid. For example, a 20 nucleobase nse compound is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 base portion of the target nucleic acid that is fully complementary to the antisense compound. Fully complementary can also be used in reference to a specified portion of the first and /or the second nucleic acid. For e, a 20 nucleobase portion of a 30 nucleobase nse compound can be “fully complementary” to a target sequence that is 400 nucleobases long. The 20 base n of the 30 nucleobase oligonucleotide is fully complementary to the target sequence if the target ce has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the antisense compound. At the same time, the entire 30 nucleobase antisense nd may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the antisense compound are also complementary to the target sequence.

The location of a non-complementary nucleobase may be at the 5’ end or 3’ end of the antisense compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the antisense compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e. ) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.

In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleobases in length se no more than 4, no more than 3, no more than 2, or no more than 1 non— complementary nucleobase(s) relative to a target c acid, such as a GHR nucleic acid, or specified portion thereof.

In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, , 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a GHR nucleic acid, or specified portion thereof.

The antisense compounds provided also include those which are complementary to a portion of a target nucleic acid. As used herein, on” refers to a defined number of contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A on” can also refer to a defined number of contiguous nucleobases of an antisense compound. In certain embodiments, the antisense compounds, are complementary to at least an 8 nucleobase portion of a target t. In certain embodiments, the antisense compounds are complementary to at least a 9 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 10 nucleobase portion of a target segment. In certain ments, the antisense compounds are complementary to at least an 11 nucleobase portion of a target segment. In certain embodiments, the antisense nds are complementary to at least a 12 nucleobase portion of a target t. In certain embodiments, the antisense compounds are complementary to at least a 13 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 14 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 15 nucleobase portion of a target segment. Also contemplated are antisense compounds that are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase portion ofa target segment, or a range defined by any two of these values.

Identity The antisense compounds provided herein may also have a defined t identity to a ular nucleotide sequence, SEQ ID NO, or compound represented by a specific Isis , or portion thereof. As used , an antisense compound is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, a RNA which contains uracil in place of thymidine in a disclosed DNA ce would be considered cal to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened ns of the antisense compounds described herein as well as nds having non-identical bases relative to the antisense compounds ed herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the antisense compound. t identity of an nse compound is calculated according to the number of bases that have cal base pairing relative to the sequence to Which it is being compared.

In certain embodiments, the antisense nds, or portions thereof, are, or are at least, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the antisense compounds or SEQ ID NOs, or a portion thereof, disclosed herein.

In certain embodiments, a portion of the antisense compound is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

In certain embodiments, a portion of the nse oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, ll, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

Modifications A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is ly a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2‘, 3' or 5' hydroxyl moiety of the sugar.

Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide ure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

Modifications to antisense compounds encompass substitutions or s to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense nds are often preferred over native forms because of desirable properties such as, for example, enhanced ar uptake, enhanced affinity for c acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated nse oligonucleotide for its target nucleic acid. uently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.

Modified Internucleoside Linkages The naturally occuring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over nse compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom.

Representative phosphorus containing ucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of ation of phosphorous-containing and osphorous-containing linkages are well known.

In certain embodiments, antisense nds targeted to a GHR nucleic acid comprise one or more modified internucleoside linkages. In n embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an nse compound is a phosphorothioate internucleoside linkage.

Modified Sugar Moieties Antisense compounds can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain ments, nucleosides comprise chemically modified ribofuranose ring moieties. Examples of chemically modified ribofuranose rings include without tion, addition of substitutent groups ding 5' and 2' substituent groups, bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA), replacement of the l ring oxygen atom with S, N(R), or C(R1)(R2) (R, R1 and R2 are each independently H, C1-C12 alkyl or a protecting group) and combinations thereof. Examples of chemically d sugars include 2'-F-5'—methyl substituted nucleoside (see PCT International Application WC 01 157 Published on 8/21/08 for other disclosed 5',2'—bis substituted nucleosides) or replacement of the ribosyl ring oxygen atom with S with further substitution at the 2'-position (see published U.S. Patent Application US2005-0130923, published on June 16, 2005) or alternatively 5 ‘-substitution of a BNA (see PCT ational Application Published on 11/22/07 wherein LNA is tuted with for example a 5'-methyl or a 5 l group). es of nucleosides having d sugar moieties include without limitation nucleosides comprising 5'-vinyl, 5'-methyl (R or S), 4'-S, 2'—F, 2'-OCH3, 2’-OCH2CH3, 2’-OCH2CH2F and 2'- O(CH2)20CH3 substituent groups. The substituent at the 2’ position can also be selected from allyl, amino, azido, thio, O-allyl, O-Cl-Clo alkyl, OCF3, OCHZF, O(CH2)ZSCH3, 0(CH2)2-O-N(Rm)(Rn), O-CHz-C(=O)- N(Rm)(Rn), and O-CHz-C(=O)-N(R1)-(CH2)2-N(Rm)(Rn), where each R1, RIn and R11 is, independently, H or substituted or unsubstituted C1-C10 alkyl.

As used herein, “bicyclic nucleosides” refer to modified sides comprising a bicyclic sugar moiety. Examples of ic nucleosides include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides comprising a 4’ to 2’ bridge. Examples of such 4’ to 2’ bridged bicyclic nucleosides, include but are not limited to one of the formulae: 4'-(CH2)-O-2' (LNA); 2)-S-2'; 4'-(CH2)2-O-2' (ENA); 4‘-CH(CH3)-O-2' (also referred to as constrained ethyl or cEt) and 4'-CH(CH20CH3)- 0-2' (and analogs thereof see US. Patent 7,399,845, issued on July 15, 2008); 4'—C(CH3)(CH3)-O-2' (and analogs thereof see published International Application WO/2009/006478, published January 8, 2009); 4'- CHZ-N(OCH3)-2' (and analogs thereof see published International Application WO/2008/150729, published er 11, 2008); -O-N(CH3)-2' (see published US. Patent Application -0171570, hed September 2, 2004 ); 4'-CH2-N(R)-O-2', wherein R is H, C1-C12 alkyl, or a protecting group (see US. Patent 7,427,672, issued on September 23, 2008); 4'-CH2—C(H)(CH3)-2' (see Chattopadhyaya et al., J.

Org. Chem., 2009, 74, 118-134); and 4'-CH2-C(=CH2)-2' (and analogs thereof see published International ation Further reports related to bicyclic sides can also be found in published literature (see for example: Singh et al., Chem. Commun, 1998, 4, 6; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem.

Lett., 1998, 8, 222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem.

Soc., 2007, 129(26) 8362-8379; Elayadi et 51]., Curr. Opinion Invest. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol, 2001, 8, 1-7; and Orum et al., Curr. Opinion Moi. Ther, 2001, 3, 239-243; US. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 748; 6,794,499; 7,034,133; 7,053,207; 7,399,845; 7,547,684; and 7,696,345; US. Patent Publication No. -0039618; US2009-0012281; US. Patent Serial Nos. 60/989,574; 61/026,995; 61/026,998; ,564; 61/086,231; 61/097,787; and 61/099,844; Published PCT ational applications 2008/150729; prepared having one or more chemical sugar configurations ing for example d—L—ribofuranose and B—D—ribofuranose (see PCT international application PCT/DK98/00393, hed on March 25, 1999 as W0 99/14226).

In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4' and the 2’ position of the pentofuranosyl sugar moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently selected from - [C(Rfi)(Rb)]11'a 'C(Rfi)=C(Rb)'a 'C(Ra)=N'a 'C(=O)'7 'C(=NRfi)'a 'C(=S)'a '0': 'Si(Rfi)2'a 'S(=O)X'a and 'N(Ra)'; wherein: X is 0, 1, or 2; nis l, 2, 3, or 4; each Ra and Rb is, independently, H, a protecting group, hydroxyl, C1—C12 alkyl, substituted C1—C12 alkyl, C2—C9 l, substituted C2—C12 l, C2—C12 alkynyl, substituted C2—C12 alkynyl, C5—C20 aryl, substituted C5—C20 aryl, heterocycle radical, substituted cycle radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic l, substituted C5-C7 alicyclic radical, halogen, OJ 1, NJ1J2, SJ 1, N3, COOJ 1, acyl (C(=O)- H), substituted acyl, CN, sulfonyl (S(=O)2-J1), or sulfoxyl (S(=O)-J1); and each J1 and J2 is, independently, H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 l, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, acyl (C(=O)- H), substituted acyl, a heterocycle l, a substituted heterocycle radical, C1-C12 aminoalkyl, substituted C1-C12 aminoalkyl or a protecting group.

In certain embodiments, the bridge of a bicyclic sugar moiety is -[C(R,)(Rb)]n-, -[C(Ra)(Rb)]n-O- or b)-O-N(R)-. In certain embodiments, the bridge is 4'-CH2-2', 4'—(CH2)2-2', 4'- , -C(RaRb)-N(R)-O- (CH2)3-2', 4'-CH2-O-2', 4'-(CH2)2-O-2', 4'-CH2-O-N(R)-2' and 4'—CH2-N(R)-O-2'- wherein each R is, independently, H, a protecting group or C1-C12 alkyl, In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a 4’-2’ methylene-oxy bridge, may be in the (x-L configuration or in the B- D configuration. Previously, (x-L-methyleneoxy (4’-CH2-O-2’) BNA's have been incorporated into antisense ucleotides that showed antisense activity (Frieden er al., Nucleic Acids Research, 2003, 21, 6365- 6372).

In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) (x-L-methyleneoxy (4’-CH2-O-2’) BNA BNA BNA , (B) B-D-methyleneoxy (4’-CH2-O-2’) , (C) ethyleneoxy (4’-(CH2)2-O-2’) , (D) xy (4’-CH2-O-N(R)-2’) BNA, (E) oxyamino (4’-CH2-N(R)-O-2’) BNA, and (F) (methyleneoxy) (4’-CH(CH3)-O-2’) BNA, (G) methylene-thio (4’-CH2-S-2’) BNA, (H) methylene- amino 2-N(R)-2’) BNA, (I) methyl carbocyclic (4’-CH2-CH(CH3)-2’) BNA, (I) ene carbocyclic (4’-(CH2)3-2’) BNA and (K) Vinyl BNA as depicted below: O,O BX E o BX E o BX E 0 BX %\O l“'LLRO ‘111. \O_ (A) R (B) (C) (D) EXZJBX é o Bx g 0 BX g o Bx .121 ;N—O H3C %\O %\S R %\N\R (E) (F) (G) (H) EQBX EQ/BX E 0 BX "m ”a, "but (I) CH3 (J) (K) CH2 wherein BX is the base moiety and R is independently H, a protecting group, C1-C12 alkyl or C1-C12 alkoxy.

In certain embodiments, bicyclic nucleosides are ed having Formula 1: Ta—0 BX Qa\ \Q/QC (l) b Tb I wherein: Bx is a heterocyclic base ; -Qa-Qb-QC- is -CH2-N(RC)-CH2-, -C(=O)-N(RC)-CH2-, -CH2-O-N(RC)-, -CH2-N(RC)-O- or -N(RC)-O- RC is C1-C12 alkyl or an amino protecting group; and Ta and Tb are each, independently H, a hydroxyl protecting group, a ate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium.

In certain embodiments, bicyclic nucleosides are ed having Formula II: wherein: Bx is a heterocyclic base moiety; Ta and Tb are each, independently H, a hydroxyl ting group, a conjugate group, a reactive orus group, a phosphorus moiety or a covalent attachment to a support medium; Za is C1-C6 alkyl, C2-C6 alkenyl, C2-C5 alkynyl, substituted C1-C6 alkyl, substituted C2-C6 alkenyl, substituted C2-C6 alkynyl, acyl, substituted acyl, substituted amide, thiol or substituted thio.

In one embodiment, each of the substituted groups is, independently, mono or poly substituted with substituent groups independently selected from halogen, oxo, hydroxyl, OJ C, NJCJd, SIC, N3, OC(=X)JC, and NJeC(=X)NJCId, wherein each Jo, Jd and J6 is, independently, H, C1-C5 alkyl, or substituted C1-C6 alkyl and X is O or NJC.

In certain embodiments, bicyclic nucleosides are ed having a III: o Bx | III wherein: Bx is a heterocyclic base moiety; Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium; Zb is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, tuted C2-C6 alkenyl, tuted C2-C6 alkynyl or tuted acyl (C(=O)—).

In certain embodiments, bicyclic nucleosides are provided having Formula IV: cla (lb Ta 0_ BX wherein: Bx is a heterocyclic base moiety; Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a ve phosphorus group, a phosphorus moiety or a covalent attachment to a support medium; Rdis C1—C6 alkyl, substituted C1—C6 alkyl, C2—C6 alkenyl, substituted C2—C6 alkenyl, C2—C6 alkynyl or substituted C2—C6 l; each qa, qb, qC and qd is, independently, H, n, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2—C6 alkenyl, C2—C6 alkynyl or substituted C2—C6 alkynyl, C1—C5 l, substituted C1— C6 alkoxyl, acyl, substituted acyl, C1—C5 aminoalkyl or substituted C1—C6 aminoalkyl; In certain embodiments, bicyclic nucleosides are provided having Formula V: Ta—O BX wherein: Bx is a heterocyclic base moiety; Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent ment to a support medium; qa, qb, qe and qf are each, independently, hydrogen, halogen, C1—C12 alkyl, substituted C1—C12 alkyl, C2— C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C1-C12 alkoxy, substituted C1-C12 alkoxy, 0]], SJj, SOJj, SOZJj, NJJ-Jk, N3, CN, C(=O)OJJ-, C(=O)NJJ-Jk, j, O-C(=O)NJJ-Jk, N(H)C(=NH)NJJ-Jk, N(H)C(=O)NJJ-Jk or N(H)C(=S)NJJ-Jk; or qe and qf together are =C(qg)(qh); qg and qh are each, independently, H, halogen, C1—C12 alkyl or tuted C1—C12 alkyl.

The synthesis and preparation of the methyleneoxy (4’—CH2—O—2’) BNA monomers adenine, cytosine, guanine, yl—cytosine, thymine and uracil, along with their oligomerization, and c acid recognition properties have been described (Koshkin et al., Tetrahedron, 1998, 54, 3607—3630). BNAs and ation thereof are also bed in WO 98/39352 and W0 99/14226.

Analogs of methyleneoxy (4’—CH2—O—2’) BNA and 2'—thio—BNAs, have also been prepared (Kumar et al., . Med. Chem. Lett., 1998, 8, 2219—2222). Preparation of locked nucleoside analogs comprising oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described l et al., WO 99/14226 ). Furthermore, synthesis of 2'-amino-BNA, a novel comformationally restricted high-affinity oligonucleotide analog has been described in the art (Singh et al., J. Org. Chem, 1998, 63, 10035-10039). In on, 2'—amino- and 2'-methylamino-BNA's have been prepared and the l stability of their duplexes with complementary RNA and DNA strands has been previously reported.

In certain embodiments, bicyclic nucleosides are provided having Formula VI: Tet—O BX qj V1 wherein: Bx is a heterocyclic base moiety; Ta and Tb are each, independently H, a yl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium; each qi, qj, qk and q1 is, independently, H, halogen, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C1-C12 alkoxyl, substituted C1- C12 alkoxyl, OJ], 8],, SOJj, SOZJj, NJJ-Jk, N3, CN, C(=O)OJJ-, C(=O)NJJ-Jk, C(=O)JJ-, O-C(=O)NJJ-Jk, N(H)C(=NH)NJJ-Jk, N(H)C(=O)NJJ-Jk or N(H)C(=S)NJJ-Jk; and qi and qJ- or ql and qk together are =C(qg)(qh), wherein qg and qh are each, independently, H, halogen, C1-C12 alkyl or substituted C1-C12 alkyl.

One carbocyclic bicyclic nucleoside having a 4'-(CH2)3-2‘ bridge and the alkenyl analog bridge 4'- CH=CH-CH2-2' have been described r et al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek el al., J. Org. Chem, 2006, 71, 7731-7740). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (Srivastava et al., J. Am. Chem. Soc, 2007, 129(26), 8362-8379).

As used herein, “4’-2’ bicyclic nucleoside” or “4’ to 2’ bicyclic nucleoside” refers to a bicyclic nucleoside comprising a furanose ring comprising a bridge connecting two carbon atoms of the furanose ring ts the 2’ carbon atom and the 4’ carbon atom of the sugar ring.

As used herein, “monocylic sides” refer to nucleosides comprising modified sugar moieties that are not bicyclic sugar moieties. In certain embodiments, the sugar moiety, or sugar moiety analogue, of a nucleoside may be modified or substituted at any position.

As used herein, dified sugar” means a furanosyl sugar modified at the 2’ position. In certain ments, such modifications include substituents selected from: a halide, including, but not d to tuted and unsubstituted alkoxy, substituted and unsubstituted thioalkyl, tuted and unsubstituted amino alkyl, tuted and unsubstituted alkyl, substituted and unsubstituted allyl, and tuted and tituted alkynyl. In certain embodiments, 2’ modifications are selected from substituents ing, but not limited to: O[(CH2)nO]mCH3, O(CH2)nNH2, O(CH2)nCH3, 0(CH2)nF, O(CH2)nONH2, =O)N(H)CH3, and O(CH2)nON[(CH2)nCH3]2, Where n and m are from 1 to about 10. Other 2'- substituent groups can also be selected from: C1-C12 alkyl, substituted alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or kyl, SH, SCH3, OCN, Cl, Br, CN, F, CF3, OCF3, SOCH3, SOzCHg}, ONOg, N02, N3, NHZ, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving pharmacokinetic properties, or a group for improving the pharmacodynamic ties of an nse compound, and other substituents having similar properties. In certain embodiments, modifed nucleosides comprise a 2’-MOE side chain (Baker et 011., J.

Biol. Chem, 1997, 272, 11944-12000). Such 2'—MOE substitution have been described as having improved binding affinity compared to fied sides and to other modified nucleosides, such as 2’- 0- , O-propyl, and O-aminopropyl. Oligonucleotides having the 2'-MOE substituent also have been shown to be antisense inhibitors of gene expression with promising features for in vivo use (Martin, Helv.

Chim. Acta, 1995, 78, 486-504; Altmann et £11., Chimia, 1996, 50, 168-176; Altmann et £11., Biochem. Soc.

Trans., 1996, 24, 630-637; and Altmann et £11., Nuc1e0si£1es Nucleotides, 1997, 16, 917-926).

As used herein, a “modified tetrahydropyran nucleoside” or “modified THP nucleoside” means a nucleoside having a six-membered tetrahydropyran ” substituted in for the pentofuranosyl e in normal nucleosides (a sugar surrogate). Modified THP nucleosides include, but are not limited to, what is ed to in the art as heXitol nucleic acid (HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (see Leumann, Bioorg. Med. Chem, 2002, 10, 841-854) or fluoro HNA (F-HNA) having a tetrahydropyran ring system as illustrated below: H0101* HCRKOl HOT) HO BX Ho‘s~ = BX HO§ Bx OCH3 In certain embodiments, sugar surrogates are selected having Formula VII: ql (12 Ta_0 <13 <17 (14 C16 BX Tb/ R1 R2 q5 wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula VII: Bx is a cyclic base moiety; Ta and Tb are each, independently, an internucleoside g group linking the tetrahydropyran nucleoside analog to the antisense compound or one of Ta and Tb is an ucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound and the other of Ta and Th is H, a hydroxyl protecting group, a linked conjugate group or a 5' or 3'—terminal group; WO 02971 2014/045088 q1, q2, q3, q4, q5, q6 and q7 are each independently, H, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl or substituted C2-C6 alkynyl; and each of R1 and R2 is selected from hydrogen, hydroxyl, halogen, subsitituted or unsubstituted alkoxy, NJ 1J2, SJ 1, N3, OC(=X)J1, OC(=X)NJ1J2, NJ3C(=X)NJ1J2 and CN, wherein X is O, S or NJ 1 and each J1, J2 and J3 is, independently, H or C1-C6 alkyl.

In certain embodiments, the d THP nucleosides of Formula VII are provided wherein q1, q2, q3, q4, q5, q6 and q7 are each H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6 and q7 is other than H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6 and q7 is methyl. In certain embodiments, THP nucleosides of Formula VII are provided wherein one of R1 and R2 is fluoro. In certain embodiments, R1 is fluoro and R2 is H; R1 is y and R2 is H, and R1 is methoxyethoxy and R2 is H.

In certain embodiments, sugar ates comprise rings having more than 5 atoms and more than one heteroatom. For example nucleosides comprising morpholino sugar moieties and their use in oligomeric compounds has been reported (see for example: Braasch er al., Biochemistry, 2002, 41, 4503-4510; and US.

Patents 5,698,685; 5,166,315; 5,185,444; and 5,034,506). As used here, the term “morpholino” means a sugar surrogate having the following formula: In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as “modifed morpholinos.” Combinations of modifications are also provided without limitation, such as 2'-F-5'-methyl substituted sides (see PCT ational Application disclosed 5', 2'-bis substituted nucleosides) and replacement of the ribosyl ring oxygen atom with S and further tution at the 2'-position (see published US. Patent Application -0130923, hed on June 16, 2005) or atively 5'-substitution of a bicyclic nucleic acid (see PCT International Application the 5' position with a 5'—methyl or a 5'—vinyl group). The synthesis and ation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (see, e.g., Srivastava et al., J. Am. Chem. Soc. 2007, 129(26), 8362-8379).

In certain embodiments, antisense compounds comprise one or more d cyclohexenyl nucleosides, Which is a nucleoside having a six-membered cyclohexenyl in place of the pentofuranosyl residue in naturally ing nucleosides. Modified cyclohexenyl nucleosides include, but are not limited to those described in the art (see for example commonly owned, published PCT Application published on April 10, 2010, Robeyns et al., J. Am. Chem. Soc., 2008, 130(6), 1979-1984; HorVath et al., Tetrahedron Letters, 2007, 48, 3621-3623; Nauwelaerts et al., J. Am. Chem. Soc., 2007, 129(30), 9340-9348; Gu et al.,, Nucleosides, Nucleotides & Nucleic Acids, 2005, 24(5-7), 993-998; Nauwelaerts et al., Nucleic Acids Research, 2005, 33(8), 2452-2463; s et al., Acta Crystallographica, Section F.‘ Structural Biology and Crystallization Communications, 2005, F61(6), 585-586; Gu et al., Tetrahedron, 2004, 60(9), 2111-2123; Gu et al., Oligonucleotides, 2003, 13(6), 479-489; Wang et al., J. Org. Chem., 2003, 68, 4499- 4505; re et al., Nucleic Acids Research, 2001, 29(24), 4941-4947; Wang et al., J. Org. Chem., 2001, 66, 8478-82; Wang et al., Nucleosides, Nucleotides & Nucleic Acids, 2001, 20(4-7), 785-788; Wang et al., J.

Am. Chem, 2000, 122, 8595-8602; Published PCT application, WO 06/047842; and Published PCT Application WO 01/049687; the text of each is incorporated by reference herein, in their entirety). Certain modified cyclohexenyl nucleosides have Formula X.

C18 BX /0 (15 C17 (16 wherein independently for each of said at least one cyclohexenyl nucleoside analog of a X: Bx is a heterocyclic base ; T3 and T4 are each, independently, an internucleoside linking group linking the cyclohexenyl side analog to an antisense nd or one of T3 and T4 is an internucleoside linking group linking the tetrahydropyran nucleoside analog to an antisense compound and the other of T3 and T4 is H, a hydroxyl protecting group, a linked conjugate group, or a 5'-or 3'-terminal group; and q1, qz, q3, q4, q5, q6, q7, qg and q9 are each, independently, H, C1-C6 alkyl, substituted C1-C6 alkyl, C2- C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl or other sugar substituent group.

As used herein, dified” or “2’-substituted” refers to a nucleoside comprising a sugar comprising a tuent at the 2’ on other than H or OH. ified nucleosides, include, but are not limited to, bicyclic nucleosides wherein the bridge connecting two carbon atoms of the sugar ring connects the 2’ carbon and another carbon of the sugar ring; and nucleosides with non-bridging 2’substituents, such as allyl, amino, azido, thio, O-allyl, O-Cl-Clo alkyl, -OCF3, O-(CH2)2-O-CH3, 2'—O(CH2)ZSCH3, O-(CH2)2-O- Rn), or C(=O)-N(Rm)(Rn), where each RIn and RH is, ndently, H or substituted or unsubstituted C1-C10 alkyl. 2’-modifed nucleosides may further comprise other modifications, for example at other positions of the sugar and/or at the base.

As used herein, ‘2’-F” refers to a nucleoside comprising a sugar comprising a fluoro group at the 2’ position of the sugar ring.

As used herein, e” or “2’-OCH3” or “2’-O-methyl” each refers to a nucleoside comprising a sugar comprising an -OCH3 group at the 2’ position of the sugar ring.

As used herein, “MOE” or “2’-MOE” or H2CHZOCH3” or “2’-O-methoxyethyl” each refers to a side comprising a sugar comprising a -OCH2CHZOCH3 group at the 2’ position of the sugar ring.

As used herein, nucleotide” refers to a compound comprising a plurality of linked nucleosides.

In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or deoxyribonucleosides (DNA).

Many other bicyclo and tricyclo sugar surrogate ring systems are also known in the art that can be used to modify nucleosides for incorporation into antisense compounds (see for e review article: Leumann, Bioorg. Med. Chem, 2002, 10, 841-854). Such ring systems can undergo various additional substitutions to enhance activity.

Methods for the preparations of modified sugars are well known to those skilled in the art. Some representative U.S. patents that teach the preparation of such modified sugars include without limitation, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,670,633; ,700,920; 5,792,847 and 6,600,032 and International Application 2005/019219, filed June 2, 2005 and published as nce in its entirety.

In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified or a combination thereof) are maintained for ization with an appropriate nucleic acid target.

In certain embodiments, nse compounds comprise one or more nucleosides having modified sugar moieties. In certain ments, the modified sugar moiety is 2’-MOE. In certain embodiments, the 2’-MOE modified nucleosides are arranged in a gapmer motif In certain embodiments, the modified sugar moiety is a bicyclic nucleoside having a (4’-CH(CH3)-O-2’) bridging group. In certain embodiments, the (4’- CH(CH3)-O-2’) modified nucleosides are ed throughout the Wings of a gapmer motif.

Modified Nucleobases Nucleobase (or base) modifications or substitutions are structurally distinguishable from, yet functionally interchangeable With, naturally ing or synthetic unmodified nucleobases. Both natural and modified nucleobases are capable of ipating in hydrogen bonding. Such nucleobase modifications can impart nuclease stability, binding affinity or some other beneficial biological ty to antisense compounds. Modified nucleobases include synthetic and natural nucleobases such as, for example, 5- methylcytosine (S-me-C). Certain nucleobase tutions, including 5-methylcytosine substitutions, are particularly useful for increasing the binding affinity of an antisense compound for a target nucleic acid. For example, S-methylcytosine substitutions have been shown to increase c acid duplex stability by 0.6- 1.2°C (SanghVi, Y.S., Crooke, S.T. and Lebleu, B., eds., Antisense Research and ations, CRC Press, Boca Raton, 1993, pp. 276-278).

Additional modified nucleobases include 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2- aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, -propynyl (-CEC-CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo , cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other S- substituted s and cytosines, 7—methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8- azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Heterocyclic base moieties can also include those in Which the purine or pyrimidine base is replaced With other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and done.

Nucleobases that are particularly useful for increasing the binding y of antisense compounds include S- substituted pyrimidines, 6-azapyrimidines and N—2, N—6 and 0-6 tuted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

In certain embodiments, antisense compounds ed to a GHR nucleic acid comprise one or more modified nucleobases. In certain embodiments, shortened or gap-widened antisense oligonucleotides ed to a GHR nucleic acid comprise one or more modified bases. In n embodiments, the modified nucleobase is S-methylcytosine. In certain embodiments, each cytosine is a S-methylcytosine.

Conjugated Antisense compounds Antisense compounds may be covalently linked to one or more moieties or conjugates Which enhance the activity, cellular bution or cellular uptake of the resulting antisense oligonucleotides.

Typical conjugate groups include cholesterol moieties and lipid moieties. Additional conjugate groups e carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.

Antisense compounds can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of antisense nds to enhance properties such as, for e, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect the antisense compound having terminal nucleic acid from exonuclease degradation, and can help in delivery and/or localization Within a cell. The cap can be t at the 5'-terminus (5'-cap), or at the 3'-terminus (3'- cap), or can be present on both termini. Cap structures are well known in the art and include, for example, inverted deoxy abasic caps. Further 3' and 5 '-stabilizing groups that can be used to cap one or both ends of an antisense nd to impart nuclease stability include those disclosed in WO 03/004602 published on January 16, 2003.

In certain embodiments, antisense compounds, including, but not limited to those ularly suited for use as ssRNA, are modified by attachment of one or more conjugate groups. In general, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, g, absorption, cellular distribution, cellular , charge and clearance. Conjugate groups are routinely used in the chemical arts and are linked directly or via an optional conjugate linking moiety or conjugate linking group to a parent compound such as an oligonucleotide. Conjugate groups includes Without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, ines, coumarins and dyes. Certain conjugate groups have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. NY. Acad. Sci, 1992, 660, 306-309; Manoharan et al., . Med. Chem. Let., 1993, 3, 2765—2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 8), an aliphatic chain, e.g., do—decan—diol or undecyl es n—Behmoaras et al., EMBO J., 1991, 10, 118; v et al., FEBS Lett., 1990, 259, 327—330; Svinarchuk et al., Biochimie, 1993, 75, 49—54), a phospholipid, e.g., di—hexadecyl—rac—glycerol or triethyl—ammonium 1,2—di—O—hexadecyl—rac—glycero—3—H— phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. col. Exp. Ther., 1996, 277, 923-937).

For additional conjugates including those useful for ssRNA and their placement within antisense compounds, see e.g., US Application No.; 61/583,963.

In vitro testing ofantisense oligonucleotides Described herein are methods for treatment of cells with antisense oligonucleotides, which can be modified appropriately for treatment with other antisense compounds.

Cells may be treated with antisense oligonucleotides when the cells reach approximately 60—80% confluency in culture.

One reagent commonly used to introduce antisense oligonucleotides into cultured cells includes the cationic lipid transfection reagent LIPOFECTIN (Invitrogen, ad, CA). Antisense oligonucleotides may be mixed with CTIN in OPTI-MEM 1 rogen, Carlsbad, CA) to achieve the desired final concentration of antisense oligonucleotide and a LIPOFECTIN concentration that may range from 2 to 12 ug/mL per 100 nM antisense oligonucleotide.

Another reagent used to introduce antisense oligonucleotides into cultured cells includes LIPOFECTAMINE (lnvitrogen, Carlsbad, CA). nse oligonucleotide is mixed with CTAMINE in OPTI-MEM 1 reduced serum medium (Invitrogen, Carlsbad, CA) to achieve the desired tration of antisense oligonucleotide and a LIPOFECTAMINE concentration that may range from 2 to 12 ug/mL per 100 nM antisense oligonucleotide. r technique used to introduce antisense oligonucleotides into cultured cells includes electroporation.

Yet another que used to introduce antisense oligonucleotides into cultured cells includes free uptake of the oligonucleotides by the cells.

Cells are treated with antisense ucleotides by routine methods. Cells may be harvested 16-24 hours after nse oligonucleotide ent, at which time RNA or protein levels of target nucleic acids are measured by methods known in the art and described herein. In general, when treatments are performed in multiple replicates, the data are presented as the average of the replicate treatments.

The concentration of nse oligonucleotide used varies from cell line to cell line. Methods to determine the optimal antisense oligonucleotide concentration for a particular cell line are well known in the art. Antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300 nM when transfected with LIPOFECTAMINE. Antisense oligonucleotides are used at higher concentrations ranging from 625 to 20,000 nM when transfected using electroporation.

RNA ion RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in the art. RNA is prepared using methods well known in the art, for example, using the TRIZOL t (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocols.

Certain Indications Certain embodiments provided herein relate to methods of treating, preventing, or ameliorating a disease associated with excess growth hormone in a subject by administering a GHR specific inhibitor, such as an antisense compound or oligonucleotide targeted to GHR. In certain s, the disease associated with excess growth hormone is acromegaly. In certain aspects, the disease associated with excess growth hormone is ism.

Certain embodiments provide a method of treating, preventing, or ameliorating acromegaly in a subject by stering a GHR specific tor, such as an antisense compound or oligonucleotide targeted to GHR. Acromegaly is a disease associated with excess growth hormone (GH). In over 90 t of acromegaly patients, the overproduction of growth hormones is caused by a benign tumor of the pituitary gland, called an adenoma, which produces excess growth e and compresses surrounding brain tissues.

Expansion of the adenoma can cause headaches and visual impairment that often accompany acromegaly. In some instances, acromegaly is caused by tumors of the pancreas, lungs, or adrenal glands that lead to an excess of GH, either by producing GH or by producing Growth Hormone Releasing Hormone (GHRH), the hormone that stimulates the ary to make GH.

Acromegaly most commonly affects adults in middle age and can result in severe disfigurement, complicating conditions, and premature death. Because of its pathogenesis and slow progression, acromegaly often goes undiagnosed until changes in external features become noticeable, such as changes in the face.

Acromegaly is often associated with gigantism.

WO 02971 Features of acromegaly e soft tissue swelling resulting in enlargement of the hands, feet, nose, lips and ears, and a general thickening of the skin; soft tissue swelling of internal organs, such as the heart and kidney; vocal cord swelling resulting in a low voice and slow speech; expansion of the skull; pronounced w sion, often with ocular distension; pronounced lower jaw protrusion and enlargement of the tongue; teeth gapping; and carpal tunnel syndrome. In certain embodiments, any one or combination of these features of acromegaly can be treated, prevented, or ameliorated by administering a compound or composition targeted to GHR provided herein.

EXAMPLES Non-limiting disclosure and incorporation by reference While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the nds described herein and are not intended to limit the same. Each of the references recited in the present application is orated herein by reference in its entirety.

Example 1: Antisense inhibition of human growth hormone receptor in Hep3B cells by MOE gapmers Antisense oligonucleotides were designed targeting a growth hormone receptor (GHR) nucleic acid and were tested for their effects on GHR mRNA in vitro. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below. Cultured Hep3B cells at a density of 20,000 cells per well were ected using electroporation with 4,500 nM antisense oligonucleotide. After a treatment period of imately 24 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3437_MGB (forward sequence CGAGTTCAGTGAGGTGCTCTATGT, designated herein as SEQ ID NO: 2297; reverse sequence AAGAGCCATGGAAAGTAGAAATCTTC, designated herein as SEQ ID NO: 2298; probe sequence AGATGAGCCAATT, designated herein as SEQ ID NO: 2299) was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. s are presented as percent inhibition of GHR, relative to untreated control cells.

The newly designed chimeric antisense oligonucleotides in the Tables below were ed as 55 MOE or 34 MOE gapmers. The 55 MOE gapmers are 20 nucleosides in , wherein the central gap t comprises often 2’-deoxynucleosides and is flanked by wing ts on the 5’ direction and the 3’ direction sing five nucleosides each. The 34 MOE gapmers are 17 nucleosides in length, wherein the central gap t comprises of ten 2’-deoxynucleosides and is flanked by wing segments on the 5’ direction and the 3’ direction comprising three and four nucleosides respectively. Each nucleoside in the 5’ wing segment and each side in the 3’ wing segment has a 2’-MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. “Start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the human gene sequence. “Stop site” indicates the 3’-most nucleoside to which the gapmer is ed human gene sequence. Each gapmer listed in the Tables below is targeted to either the human GHR mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_000163.4) or the human GHR genomic sequence, designated herein as SEQ ID NO: 2 (GENBANK Accession No.

NT_006576. 16 truncated from nucleotides 42411001 to 42714000). ‘n/a’ indicates that the nse oligonucleotide does not target that particular gene ce with 100% complementarity. In case the sequence alignment for a target gene in a particular table is not shown, it is understood that none of the ucleotides presented in that table align with 100% complementarity with that target gene.

Table 1 Inhibition of GHR mRNA b 55 MOE _amers tar__etin exonic reions of SEQ ID NO: 1 and 2 ID SE? SE ISIS NO NO: 1 Target ce . .% . IDQ 1 Region 1nh1b1tion Start Slop 523266 164 183 Exon 1 ACCTCCGAGCTTCGCCTCTG 20 Exon- 523267 171 190 exon CTGTAGGACCTCCGAGCTTC junction 21 Exon- 523268 178 197 exon TCCATACCTGTAGGACCTCC 'unction 22 523271 206 225 Exon 2 23 523272 213 232 Exon 2 24 523273 220 239 Exon 2 CTTGATCCTGCCAGTGCCAA 49 25 523274 227 246 Exon 2 AGCATCACTTGATCCTGCCA 67 145011 145030 26 523275 234 253 Exon 2 CAGAAAAAGCATCACTTGAT 0 145018 145037 27 523276 241 260 Exon 2 28 523284 361 380 Exon 4 29 523285 368 387 Exon 4 TGAAAAAGTCTCTCGCTCAG 15 268031 268050 30 523286 375 394 Exon 4 268038 268057 31 523287 382 401 Exon 4 32 523301 625 644 Exon 6 GGATCTGGTTGCACTATTTC 36 n/a n/a 33 523302 632 651 Exon 6 AATGGGTGGATCTGGTTGCA 28 278926 278945 34 523303 647 666 Exon 6 AGTCCAGTTGAGGGCAATGG 26 278941 278960 35 523304 654 673 Exon6 36 523305 675 694 Exon6 GAATCCCAGTTAAACTGACG 19 37 523306 682 701 Exon6 TCTGCATGAATCCCAGTTAA 39 278976 278995 38 523309 736 755 Exon6 CCTTTCTGAATATC 34 279030 279049 39 523310 743 762 Exon6 40 523311 750 769 Exon6 41 523312 757 776 Exon6 TGAAGTTCATACTCCAGAAC 23 279051 279070 42 523313 764 783 Exon6 TTTGTATTGAAGTTCATACT 6 279058 279077 43 523314 771 790 Exon6 279065 279084 44 523315 778 797 Exon6 GTTTCATTTACTTCTTTGTA 3 279072 279091 45 523316 785 804 Exon6 CCATTTAGTTTCATTTACTT 0 279079 279098 46 Exon 4- 523317 792 811 exon 5 TCATTTTCCATTTAGTTTCA n/a n/a junction 47 523323 862 881 Exon7 ACACGCACTTCATATTCCTT 290360 290379 48 523324 869 888 Exon7 GGATCTCACACGCACTTCAT 80 49 523328 926 945 Exon7 AAGTGTTACATAGAGCACCT 56 50 523329 933 952 Exon7 GAAGTGTTACATAG 53 51 523330 957 976 MW 52 523331 964 983 exon 6 TAGAAATCTTCTTCACATGT 4 n/a n/a 'unction 53 Exon 5- on 54 523333 978 997 Exon8 AGAGCCATGGAAAGTAGAAA 46 55 523334 985 1004 Exon8 ATAATTAAGAGCCATGGAAA 0 56 TableZ Inhibition of GHR mRNA by 55 MOE gapmers targeting exonic regions of SEQ ID NO: 1 and 2 Sequence . . SEQ 1nh1b1tlon Start Stop 533002 207 226 exon2 GTGCCAAGGTCAACAGCAGC 63 144991 145010 58 533004 225 244 exon2 CATCACTTGATCCTGCCAGT 53 145009 145028 60 533005 226 245 exon2 GCATCACTTGATCCTGCCAG 80 145010 145029 61 533020 868 887 exon7 GATCTCACACGCACTTCATA 47 290366 290385 65 889 exon 7 TGGATCTCACACGCACTTCA 66 533022 871 890 exon7 TTGGATCTCACACGCACTTC 70 290369 290388 67 533037 1360 1379 exon 10 TCCAGAATGTCAGGTTCACA 59 297777 297796 68 533038 1361 1380 exon10 AATGTCAGGTTCAC 74 297778 297797 69 533040 1364 71 533042 1525 72 533043 1526 1545 exon 10 TGCTTGGATAACACTGGGCT 46 297943 297962 73 533044 1528 1547 exon 10 TCTGCTTGGATAACACTGGG 55 297945 297964 74 533045 1529 1548 exon 10 CTCTGCTTGGATAACACTGG 47 297946 297965 75 533046 1530 1549 exon 10 TCTCTGCTTGGATAACACTG 54 297947 297966 76 533047 1744 1763 exon 10 CAGAGTGAGACCATTTCCGG 47 298161 298180 77 533040 4545 50 533050 4243 30 533054 4543 34 533055 2535 32 533055 2535 33 533053 2533 34 533053 2533 35 533050 2520 35 533072 3206 3225 exon 10 TTGTACCTTATTCCCTTCCT 61 299623 299642 88 533023 3203 30 533024 3203 30 Table 3 Inhibition of GHR mRNA by 5—10—5 MOE gapmers targeting intronic and exonic regions of SEQ ID NO: 1 and 2 SEQ SEQ ID ID ISIS : Tar et % SE sequence NO Regzigon inhibition 1:213 2(3):; ID 130 Site Site 532174 11566111 ACATGTACCCAAACCAACAC 18731 18750 91 533086 Exon 10 GTACCTTATTCCCT 299627 299646 92 533087 Exon 10 TGCTTCTTGTACCTTATTCC 77 93 533088 Exon10 ATGCTTCTTGTACCTTATTC 63 94 533089 Exon10 AAATGCTTCTTGTACCTTAT 67 95 533090 Exon10 AAAATGCTTCTTGTACCTTA 50 96 533091 Exon10 CAAAATGCTTCTTGTACCTT 44 97 533092 Exon10 CTTCTGAATGCTTGCTTTGA 29 98 533093 Exon10 TCTTCTGAATGCTTGCTTTG 47 99 533094 Exon10 TTTCTTCTGAATGCTTGCTT 63 100 wo 2015/002971 533095 ExonIO TTTTCTTCTGAATGCTTGCT 51 101 533096 3523 3542 EXOHIO TTTTTCTTCTGAATGCTTGC 34 102 533097 4041 4060 ExonIO TGCGATAAATGGGAAATACT 36 300458 300477 103 533098 4042 4061 ExonlO CTGCGATAAATGGGAAATAC 52 300459 300478 104 533099 105 533100 106 533101 4046 4065 EX0n10 AGGTCTGCGATAAATGGGAA 39 300463 300482 107 533102 4048 4067 ExonlO AAAGGTCTGCGATAAATGGG 34 300465 300484 108 533103 4049 4068 ExonIO AAAAGGTCTGCGATAAATGG 35 300466 300485 109 533104 4050 4069 ExonlO AAAAAGGTCTGCGATAAATG 15 300467 300486 110 533115 n/a n/a 111110111 CATGAAGGCCACTCTTCCAA 63 12777 12796 111 533116 n/a n/a Intronl CCATGAAGGCCACTCTTCCA 78 12778 12797 112 533117Intr0n1 CCCATGAAGGCCACTCTTCC 71 113 533118 114 533119 115 533120 116 533121 117 533122 118 333333 133 533124 120 533125 111 CTGATGGTCTTTCATGAATC 82 17932 17951 121 533126 n/a n/a 111110111 GCTGATGGTCTTTCATGAAT 74 17933 17952 122 533127 n/a n/a 111116111 GTACCCAAACCAACACTAAT 57 123 533128 124 533129 125 533130 126 533131 127 533132 128 533133 11160111 CAGGAATGGAAAACCAAATA 74 129 533134 n/a n/a 111110111 TCAGGAATGGAAAACCAAAT 73 130 121987 122006 26498 26517 533135 n/a n/a Intronl ACTCAGGAATGGAAAACCAA 113032113051 131 26499 26518 533136 n/a n/a Intronl AACTCAGGAATGGAAAACCA 113033 113052 132 533137 n/a n/a 111 AGGAATGGAAAACC 133 533138 134 533139 n/a n/a 111110111 ACAAAATTACTGCAGTCACA 81 135 WO 02971 533140 136 533141 n/a n/a 11166111 CATACAAAATTACTGCAGTC 67 39720 39739 137 533142 n/a n/a 11166111 ACATACAAAATTACTGCAGT 48 39721 39740 138 53314311166111 AACATACAAAATTACTGCAG 53 39722 39741 139 533144 n/a n/a 111116111 TTTTAGTATGAACCTTAAAA 0 140 533145 533146 n/a n/a 11166111 TCTTTTAGTATGAACCTTAA 57 42141 42160 142 533147 n/a n/a Intron] AATCTTTTAGTATGAACCTT 60 42143 42162 143 533148 n/a n/a Intron] CAATCTTTTAGTATGAACCT 70 42144 42163 144 533149 n/a n/a 11 ACAATCTTTTAGTATGAACC 60 42145 42164 145 533150 n/a n/a ] AAGTTATGTGACTCTGAGCA 67 43174 43193 146 533151 n/a n/a Intron] CAAGTTATGTGACTCTGAGC 67 43175 43194 147 533152 148 533153 149 533154 Na Na 150 533155 151 533156 152 533157 n/a n/a Intron] GAAGCAGGTTGGCAGACAGA 60 153 533158 533159 155 533160 n/a n/a Intron] GTCTTCTTGTGAGCTGGCTT 83 64883 64902 156 5331611nt1‘0n1 AGTCTTCTTGTGAGCTGGCT 81 64884 64903 157 Table4 Inhibition of GHR rnRNA by 5 -1 0-5 MOE gapmers targeting intronic and exonic regions of SEQ ID NO: 1 and 2 113138 Sequence inhiOb/ition 811518: 12) SEDQ Start Site NO 533133 Intron 1 CAGGAATGGAAAACCAAATA 121986 122005 129 26496 26515 53 3134 Intron 1 TCAGGAATGGAAAACCAAAT 130 121987 122006 53 3 174 Intron 1 TAAGTCTTCTTGTGAGCTGG 158 53 3 175 Intron 1 TTAAGTCTTCTTGTGAGCTG 159 53 3 1 76 Intron 1 ATTAAGTCTTCTTGTGAGCT 160 53 3 177 Intron 1 TCTCTTCCACTCACATCCAT 161 53 3 178 Intron 1 TCCACTCACATCCA 162 53 3 179 Intron 1 AGTCTCTTCCACTCACATCC 163 53 3 1 8 O Intron 1 TAAGTATTTGTAGCAGTTGC 1 64 53 3 1 81 Intron 1 CTAAGTATTTGTAGCAGTTG 165 888182 188 188 53 3 1 83 n/a n/a Intron 1 TGGCTAAGTATTTGTAGCAG 34 78199 78218 167 53 3 1 84 n/a n/a Intron 1 TTGGCTAAGTATTTGTAGCA 18 78200 78219 168 53 3 1 85 n/a n/a Intron 1 TTTGGCTAAGTATTTGTAGC 21 78201 78220 169 533186 n/a n/a Intron 1 AAAATGTCAACAGTGCATAG 61 80636 80655 170 533187 n/a n/a Intron 1 CAAAATGTCAACAGTGCATA 78 80637 80656 171 533188 n/a n/a Intron 1 CCAAAATGTCAACAGTGCAT 85 80638 80657 172 533189 n/a n/a Intron 1 GCCCAAAATGTCAACAGTGC 82 80640 80659 173 533190 n/a n/a Intron 1 GGCCCAAAATGTCAACAGTG 60 80641 80660 174 533191 n/a n/a Intron 1 TGGCCCAAAATGTCAACAGT 31 80642 80661 175 53 3192 n/a n/a Intron 1 CAGAATCTTCTCTTTGGCCA 66 98624 98643 176 53 3193 n/a n/a Intron 1 GCAGAATCTTCTCTTTGGCC 81 98625 98644 177 53 3194 n/a n/a Intron 1 TGCAGAATCTTCTCTTTGGC 72 98626 98645 178 533195 n/a n/a Intron 1 TTTGCAGAATCTTCTCTTTG 33 98628 98647 179 53 3196 n/a n/a Intron 1 ATTTGCAGAATCTTCTCTTT 27 98629 98648 180 888187 188 181 53 3198 n/a n/a Intron 1 ATAAAGCTATGCCATAAAGC 37 99478 99497 182 533199 n/a n/a Intron 1 CATAAAGCTATGCCATAAAG 14 99479 99498 183 888281 188 184 533201 n/a n/a Intron 1 GACCATAAAGCTATGCCATA 54 99482 99501 185 533202 n/a n/a Intron 1 TGACCATAAAGCTATGCCAT 64 99483 99502 186 533203 n/a n/a Intron 1 CTGACCATAAAGCTATGCCA 61 99484 99503 187 533204 n/a n/a Intron 1 CAAAAAGTTGAGCTGAGAAA 0 101078 101097 188 888288 188 188 533206 n/a n/a Intron 1 AAGTTGAGCTGAGA 52 101080 101099 190 533207 n/a n/a Intron 1 CACCCAAAAAGTTGAGCTGA 60 101082 101101 191 533208 n/a n/a Intron 1 ACACCCAAAAAGTTGAGCTG 34 101083 101102 192 533209 n/a n/a Intron 1 TACACCCAAAAAGTTGAGCT 36 101084 101103 193 888218 188 184 533211 n/a n/a Intron 1 GCTTTTAATGGCACCCAAGC 54 103567 1035 86 195 533212 n/a n/a Intron 1 TGCTTTTAATGGCACCCAAG 67 103568 103587 196 53 3213 Intron 1 AATGCTTTTAATGGCACCCA 103 570 1035 89 197 533214 Intron 1 AAATGCTTTTAATGGCACCC 103571 103590 198 533215 Intron 1 GAAATGCTTTTAATGGCACC 103572 103591 199 533216 n/a n/a Intron 1 TAATTCTTAAGGGCCCTCTG 36 106963 106982 200 533217 n/a n/a Intron 1 ATAATTCTTAAGGGCCCTCT 45 106964 106983 201 533218 n/a n/a Intron 1 TCTTAAGGGCCCTC 50 106965 106984 202 533219 n/a n/a Intron 1 ATTCTTAAGGGCCC 48 106967 106986 203 53 3220 n/a n/a Intron 1 AATTCTTAAGGGCC 52 106968 106987 204 53 3 221 n/a n/a Intron 1 TTAGCATAATTCTTAAGGGC 28 106969 10698 8 205 533222 n/a n/a Intron 1 AGGAATGGAAAACCAAACAT 13 113028 113047 206 533223 n/a n/a Intron 1 CAGGAATGGAAAACCAAACA 64 113029 113048 207 533224 n/a n/a Intron 1 TCAGGAATGGAAAACCAAAC 61 113030 113049 208 533225 Na 209 53 3226 n/a n/a Intron 1 CATGACTATGTTCTGGCAAG 37 125591 125610 210 53 3227 n/a n/a Intron 1 ACATGACTATGTTCTGGCAA 44 125592 12561 1 21 1 533228 n/a n/a Intron 1 CACATGACTATGTTCTGGCA 63 125593 125612 212 53 3229 n/a n/a Intron 1 GTCACATGACTATGTTCTGG 47 125595 125614 213 53 323 0 n/a n/a Intron 1 GGTCACATGACTATGTTCTG 49 125596 125615 214 53 3231 n/a n/a Intron 1 TGGTCACATGACTATGTTCT 30 125597 125616 215 533232 n/a n/a Intron 2 CTGAATTCTGAGCTCTGGAA 73 145428 145447 216 533233 n/a n/a Intron 2 CCTGAATTCTGAGCTCTGGA 88 145429 145448 217 533234 n/a n/a Intron 2 GCCTGAATTCTGAGCTCTGG 92 145430 145449 218 533235 n/a n/a Intron 2 AAGCCTGAATTCTGAGCTCT 83 145432 145451 219 533236 n/a n/a Intron 2 CAAGCCTGAATTCTGAGCTC 68 145433 145452 220 53 323 7 n/a n/a Intron 2 ACAAGCCTGAATTCTGAGCT 81 145434 145453 221 53 323 8 n/a n/a Intron 2 GGATCTCAGCTGCAATTCTT 72 14623 5 146254 222 53 323 9 n/a n/a Intron 2 AGGATCTCAGCTGCAATTCT 53 14623 6 146255 223 53 3240 n/a n/a Intron 2 GAGGATCTCAGCTGCAATTC 69 14623 7 146256 224 53 3241 n/a n/a Intron 2 CAGAGGATCTCAGCTGCAAT 69 14623 9 14625 8 225 53 3242 n/a n/a Intron 2 GATCTCAGCTGCAA 76 146240 146259 226 533243 230 249 Exon 2 AAAAGCATCACTTGATCCTG 23 145014 145033 227 Table 5 Inhibition of GHR mRNA by 34 MOE gapmers targeting intronic and exonic regions of SEQ ID NO: 1 and 2 SEQ SEQ ID ID SEQ SEQ ID ISIS NO: NO: Target % ID NO: NO: 2 SEQ Sequence NO 1 1 Reglon 1nh1b1t10n- . 2 Start Stop ID NO Start Stop Site Site Site Site 539284 206 222 Exon 2 CAAGGTCAACAGCAGCT 62 228 539285 207 223 Exon 2 CCAAGGTCAACAGCAGC 74 144991 145007 229 539286 208 224 Exon 2 GCCAAGGTCAACAGCAG 73 144992 145008 230 539290 869 885 Exon 7 TCTCACACGCACTTCAT 29 231 539291 Exon 7 CACGCACTTCA 290368 290384 232 539292 Exon 7 GATCTCACACGCACTTC 290369 290385 233 53 9299 Intron 1 CTTTCATGAATCAAGCT 17927 17943 234 539300 n/a n/a Intron 1 TCTTTCATGAATCAAGC 49 235 539301 Iva Iva Intronl 236 333303 33 33 1 237 539303 238 539304 239 539305 Iva Iva l 240 333303 539307 Na Na Intronl 242 wo 2015/002971 2014/045088 539308 243 339399 539310 n/a n/a Intronl GCTTTCTTTAGCAATAG 22520 22536 245 26497 26513 539311 n/a n/a Intronl GGAAAACCAAA 246 26498 26514 539312 Intron] CAGGAATGGAAAACCAA 113032 113048 247 121989 122005 26499 26515 539313 Intronl TCAGGAATGGAAAACCA 113033 113049 248 121990 122006 539314 1999 Na Intronl 249 539315 250 539316 Iva Iva Intronl 251 539317 252 539318 253 539319 1999 Na Intronl 254 339329 539321 256 539322 n/a n/a Intron] 64886 64902 257 539323 n/a n/a Intronl AGTCTTCTTGTGAGCTG 70 64887 64903 258 539324 199 Iva Intronl 259 539325 260 539326 261 539327 1999 Na Intronl 262 539328 263 339329 399 93 139331 334 539330 n/a n/a Intron] GCATAGATTTTGACTTC 53 265 539331 1999 Na Intronl 266 539332 n/a n/a 11 CAAAATGTCAACAGTGC 73 267 539333 Intron] CCAAAATGTCAACAGTG 80641 80657 268 539334 Intron] CCCAAAATGTCAACAGT 80642 80658 269 539335 Intronl CATGACTATGTTCTGGC 125594 125610 270 539336 n/a n/a Intronl ACATGACTATGTTCTGG 42 271 539337 n/a n/a Intronl CACATGACTATGTTCTG 29 125596 125612 272 539338 n/a n/a Intron2 GAATTCTGAGCTCTGGA 77 145429 145445 273 539339 TGAATTCTGAGCTCTGG 84 274 539340 m 999 1999192 275 339349 373 539342 Iva Iva 11999192 277 539343 278 539344 1999 Na 11999192 279 539345 280 539346 Intron 2 TGATATTGTAATTCTTG 13 281 539347 Intron 2 CTGATATTGTAATTCTT 8 148062 148078 282 539348 Intron 2 CCTGATATTGTAATTCT 67 148063 148079 283 539349 Intron 2 GCCTGATATTGTAATTC 73 284 539350 285 539351 Intron 2 AATTATGTGCTTTGCCT 58 148907 148923 286 539352 Intron 2 CAATTATGTGCTTTGCC 82 148908 148924 287 539353 Intron 2 TCAATTATGTGCTTTGC 68 148909 148925 288 539354 Intron 2 GTCAATTATGTGCTTTG 80 148910 148926 289 539355 Intron 2 GCCATCACCAAACACCA 94 150972 150988 290 539356 Intron 2 TGCCATCACCAAACACC 84 150973 150989 291 539357 Intron 2 TTGCCATCACCAAACAC 74 292 539358 Intron 2 TGGTGACTCTGCCTGAT 85 293 539359 Intron 2 CTGGTGACTCTGCCTGA 86 294 Table 6 Inhibition of GHR mRNA b 5 5 MOE flamers tarnetin intron 1 of SEQ ID NO: 2 ID SEQ Sequence NO: 2 ID inhibition Stop NO 523561 TATTTCAGAAAGACTTTCTG 11 10373 10392 295 523562 AGGAAAAAATCAAGGAGTTA 8 1 1 173 1 1 192 296 523563 TATTTACTGAACACCTATTC 12 11973 11992 297 523564 GCCCATGAAGGCCACTCTTC 70 12780 12799 298 523565 ACCTATAAATAAAGTGAGGA 0 135 81 13600 299 523566 GTTTCATAACCTGCTAATAA 40 14451 14470 300 523567 ATGTGCCTTACAGTTATCAG 36 15251 15270 301 523568 TTCTGAATTTAGAATTATAG 0 16051 16070 302 523569 GTTTATAATCTAGCAGTTAC 26 17130 17149 303 523570 GATGGTCTTTCATGAATCAA 62 17930 17949 304 523571 CCCAAACCAACACT 65 18730 18749 305 523572 TAAAATACAGCCTACATCAT 0 19637 19656 306 20470 307 523574 ATCTGAAATGATCCCCTTTC 33 21283 21302 308 523575 CCCTCCAAAAAGAC 12 22144 22163 309 523576 ATTAAAATTTTAAATGATGT 0 22944 22963 310 26516 523577 CTCAGGAATGGAAAACCAAA 113031 113050 311 121988 122007 523578 AAAATTCTAGAAGATAACAT 0 27838 27857 312 523579 CTAGAAGTCCTAGCCAGAGT 2 28748 28767 313 22222 2 44 523 5 81 AAGATAGACAGTAACATAAT 0 3 0348 3 0367 3 15 523582 GCACTACAAGAACTGCTTAA 40 31 172 31 191 316 5235 83 TTTCCAGACAAAGAATTCAG 6 31978 31997 317 523584 GTAGACAGCCTTTCTGGAAC 20 32827 32846 318 523585 CATCCTACATAGTGGCTGTG 47 33635 33654 319 523586 CAGAACAGTGTGTGGAGACT 8 34452 34471 320 523587 AGCTTTAAAAATACCTCTGC 52 35466 35485 321 523588 CCCAGGTACTTGCTCTCAGA 22 36266 36285 322 523589 TTACACCTGATTCTAGAAAT 30 37066 37085 323 523590 CTTTTCTCTACAACCTCACA 34 38094 38113 324 523591 TAGTAGTTTGAATTTCAAAG 1 3 8909 3 8928 325 523592 ATACAAAATTACTGCAGTCA 60 39719 39738 326 523593 GCCACTGCCAAAAAGGAGGA 30 40519 40538 327 523594 TGACAGAAACAGAGCTATGA 33 41342 41361 328 42 4 24 222 523596 AGTTATGTGACTCTGAGCAC 63 43173 43192 330 523597 ACTATGCCCTAGTTACTTCT 29 43973 43992 331 4422 4 222 523599 CTGAAATGGAATGT 0 45733 45752 333 523600 GCTGTAAATGTAATGAGTGT 34 46553 46572 334 523601 GAGAGAAGCCATGGCCCTAG 20 47392 47411 33 5 523602 CTCTCTTTCCCAGAACAAGA 32 48210 48229 336 20224 222 523604 GTTCTCCATTAGGGTTCTGG 74 50947 50966 33 8 523605 TTAGTCACCCATCCACCACT 41 51747 51766 339 523606 CATGAATTCACCGAGTTAGG 51 52573 52592 340 523607 AGCAGGTTGGCAGACAGACA 62 53466 53485 341 24222 242 22242 242 523 610 AAACAGGGTCTGGAGTGGAC 3 61243 61262 344 523 61 1 GATAATTAAAAAGA 62481 345 523 612 ATAAAGATACATTTTCTGGG 63296 346 523613 CAGGATTCTTCCTGCCTGGC 64104 347 523614 AAGTCTTCTTGTGAGCTGGC 71 64885 64904 348 523615 CTCTTCCACTCACATCCATT 63 65988 66007 349 523616 CCTATATCAGAAGACAAATG 5 66806 66825 350 523617 TCAAAACCCTGCCAAGGTAC 44 67662 67681 3 51 523618 TCATATTCTACTTCTGTTTA 11 68462 68481 352 523619 CATTCCAGTGTTTCAGTAAG 13 69262 69281 3 53 523620 GGCCTGGAATTAATCCTCAG 49 70114 70133 3 54 523621 CTCTCCCTGTGCCT 48 70925 70944 355 523622 TTTATAATCAACCTTTGCTA 9 71741 71760 356 523 623 ATATAACTACTTAAAATAAT 72560 3 5 7 523 624 TTAGCCAGGATATGGTTGCC 73 369 3 5 8 523 625 CTACCTCCATCAAAGAAAAT 74209 3 59 523 626 GCATGCATAGATAAGTTTGA 75009 3 60 523 627 GTAAATGGATTTTC 75 809 361 523 628 TTGGCAATCCTTGCTTAAAA 76617 362 523 629 GAATTAAGCCAGACTTATTT 77417 3 63 523 63 0 GGCTAAGTATTTGTAGCAGT 78217 3 64 523631 GTGTGCAACTGGCG 79024 365 523632 GTGGCCTTAGTAGGCCAGCT 79846 366 523633 CCCAAAATGTCAACAGTGCA 80658 367 523634 TTAAGCCTTCAATTTGAAAA 81474 368 523 63 5 TGCTCAGAAGGTTGAGCATA 82280 3 69 523636 TTAATGCTTTCCCAAAGCTC 83080 370 523 63 7 CTTCATACCTTTAC 8 3 903 3 71 Table 7 Inhibition of GHR mRNA b 55 MOE flamers tarnetin intron 1 of SEQ ID NO: 2 113138 sequence 111111310611 SEDQ 532146 GGCCCCCTGGCACAACAGGA 60 372 532147 TCTAGGGTGATTCAGGTGGA 62 373 532148 CTTAGATTAATGCAAAACAA 25 4875 4894 374 532149 AGGCAGAGGAGGGTGGAACC 34 6246 6265 375 532150 AGTCTAATGAGATCTGATGG 76 376 532151 377 532152 ACTTTGGACTGTGGATTTTT 78 6765 6784 378 532153 GCATATTTACACAATGCCTG 84 6871 6890 379 532154 380 532155 CTGCTGATTTTGGAATGGAG 68 10660 10679 381 532156 ACTGAACACCTATTCTATGG 51 11968 11987 382 532157 TTTACTGAACACCTATTCTA 23 383 532158 384 532159 385 532160 TTACATCCTGTAGGCTAATT 82 12469 12488 386 532161 CCACTAGCCTGGCCAGACTT 73 12487 12506 387 532162 388 532163 AAAGAATTGAGTTATAAATC 23 389 532164 390 532165 CAACATCATTGTATTTTCTG 33 391 532166 TCTTAGCTTACCAATGAGGA 81 392 532167 393 532168 394 532169 GTTTGCAAATCTTCATTCAC 71 16447 16466 395 532171 TTTCCCCAGATTAAATGCCC 85 397 532172 398 532173 AAATTCTTGGGCTTAAGCAC 69 18638 18657 399 532174 ACCCAAACCAACAC 71 18731 18750 91 532175 TGATCCAAATTCAGTACCTA 82 18752 18771 400 532177 CAATATTCATCTTTATATTC 25 19106 19125 402 532179 404 532180 405 532181 GTACAGTCAACTTTACTTCA 89 406 532182 407 532183 408 532184 ACTGCTGAGCACCTCCAAAA 73 409 552155 410 532186 411 532187 TATACCATCTTCCCCATAAA 32 22038 22057 412 532188 GGCTTTCTTTAGCAATAGTT 86 22518 22537 413 532189 414 532190 415 532191 416 532192 CTAGACATGTCATCAAGACA 19 417 532193 418 532194 TATTCTTATATCAGACAAAA 30 419 532195 420 532196 421 532197 CCCAGTCTCCAGCT 83 422 532198 TTTCTCCAGCAGAAGTGTCA 423 532199 AAGTCCTCTTCCGCCTCCCT 424 532200 GGAATTTACCAAAAACAGTT 425 532201 AGTTAGGTATTGTCCATTTT 74 426 532202 ACATGGGTATCTTCTAGGAA 77 37111 37130 427 532204 429 532205 ATTCCCTTTTCTCTACAACC 70 430 552205 451 532207 GAAAAAAGGTCCACTGTGGT 49 432 532208 433 532209 TAGAAAAGTAAATAAGGAAT 15 434 532210 435 532211 436 532212 CATGAATTACAGCTAAAGAT 20 42741 437 532214 439 532215 440 532216 CTATGCCCTAGTTACTTCTA 47 43972 441 532218 TCATTAAAGATTATTATAAC 0 44222 443 532220 GGAAATGGCCTTTTTCCTTA 72 45400 445 532222 AAACCATATTGTCCACCAGA 84 447 Table 8 tion of GHR mRNA b 5 5 MOE Jamers tarnetin intron 1 of SEQ ID NO: 2 11338 ce inhiOb/ition SEDQ 532223 CTCAAACCATATTGTCCACC 90 448 532224 GTGTAAATAGTGACTTGTAC 76 449 532225 450 532226 451 532227 TTACTTGCTGACTAAGCCAT 69 51071 51090 452 532228 GTTTGTCAACTCAACATCAA 73 51215 51234 453 532229 GACTATTTGTATATATATAC 33 454 532230 532231 ACTCTTCCTTATATTTGCTC 76 51778 51797 456 532232 ATACACTGACTTTTAACATT 67 52039 52058 457 532233 458 532234 CTGAGCTTTGCCTTAAGAAT 79 52633 52652 459 532235 CACCAGACAGCAGGTAGAGC 81 53540 53559 460 532236 GAGATGGAGTAGAAGGCAAA 43 461 532237 462 532238 463 532239 AAGTTGGATCTGGCATGCAT 64 64574 64593 464 532240 AAAGTTGGATCTGGCATGCA 70 64575 64594 465 532241 466 532242 467 532243 468 532244 TGAGCAGCTGTCCTCAGTTC 43 469 532245 470 wo 02971 2014/045088 532246 471 532247 69223 69242 472 532248 TTTGCATTCAAAGCCCTGGG 91 69565 69584 473 532250 475 532251 476 532252 ACCTCCCTAGGATTACCTCA 56 71617 71636 477 532253 AAAATCTGATTTATAATCAA 40 71750 71769 478 532254 AGCATAGATTTTGACTTCCC 92 72107 72126 479 532255 AAAGTCATATACACAGGTCT 53 72584 72603 480 532256 CTCATAGCAAATTCCCAGAA 66 73689 73708 481 532257 CAACATGGAGGCTAGCATGT 55 74112 74131 482 532258 AGACTAAGTGGCCTGAATGT 52 483 532259 484 532260 485 532261 486 532262 487 532263 AGTGCTTTGCTTTCTCTTAT 79 488 552254 452 532265 490 532266 AAACAATGCCCTTGTAGTGA 57 76703 76722 491 532267 TATTCTAGGTTTTGAGGTGA 60 76752 76771 492 532268 493 532269 494 532270 495 532271 AATTATGGCAAAATGGAAAA 37 496 532272 497 532273 GCAGAGATAATCCTATGATG 42 498 532274 499 532275 TTTGCCTGAAGGGCAGAACC 40 500 532276 GAAAAAATCAGATTTTCACA 0 501 532277 AACTTAATTTAATCATTTCT 502 532278 TTTGGTTGTCATGAGTTGAG 503 532279 TTCCATCTCTAGGGCACTTT 504 532280 AGAGCTTATTTTCAAAATTC 36 505 532281 ATAAAGAGCAAACAAACATA 42 81524 81543 506 532283 508 532284 TTTTATAACAGCCTCTGACA 38 509 552255515 532286 511 532287 512 532288 AGGGCTAGCTGATGCCTCTC 69 513 532289 84381 514 532290 85713 515 532291 TCCTTGTTTTCTTGTAATGA 50 85945 516 532293 86629 518 532294 86901 519 532296 AAAGAGAATGGATCAAAGCT 36 91930 521 532298 TGGTTATGAAGGTTGGACCA 52 94839 523 532299 TGGCTAATTAATGGGCAATT 63 95292 9531 1 524 Table 9 Inhibition of GHR mRNA by 5 5 MOE gapmers targeting intron 1 of SEQ ID NO: 2 SEQ SEQ ID ID SE 11358 Sequence inhiob/ition NO: 2 NO: 2 IDQ Start Stop NO Site Site 532300 CTGTGCCATATTGCCTCTAA 87 95471 95490 5323 01 GATTTCAACCAGCTCACCTG 48 95510 95529 532302 GCAAAAGGGAACCCTGAAGC 71 95564 95583 532303 CTAAGTGTTATAACAAACAC 43 96137 96156 532304 GTCCATTGGTATAAAACTCA 84 96282 96301 532305 TTTCAATACAATAAGATTTA 34 96793 96812 532306 GTCCTTAGACCCCTCAATGG 97006 5323 07 TTATTCATCTAGGC 68 97806 97825 532308 CAGTGGGAGGATCAGATATC 46 97870 97889 5323 09 ATCCCATCCAGCAGCTGGAC 67 98132 98151 5323 10 AACTTGGGATGAGTTACTGA 56 98653 98672 53231 1 GAAGGCTACCTAAAAGAAAT 43 98810 98829 532312 AAAGAAATATTCACAACATT 39 99096 99115 532313 ATGCTTATACTGCTGCTGTA 69 99791 99810 532314 CTTCAATCACCTTT 70 99819 99838 532315 CTCTTTCTTCATAAATAAGT 33 100809 100828 532316 TGGTAATCTGTGTCCCTTTA 96 101242 101261 532317 TAATAAAAAAGTTTGAAACA 41 102549 102568 532318 GGTGGTGGCAAGAGAAAAAT 56 103015 103034 5323 19 CAAAAGGCCCTTTTTACATG 28 103034 103053 532320 ACTCTACTGGTACCAATTTA 31 103173 103192 532321 TCTGAACTTTTATGCTCTGT 76 103606 103625 532322 AACTTTTGCCTGGGCATCCA 16 104067 104086 532323 TGACTCCATGTCTCACATCC 66 104392 10441 1 532324 TTACTTCCTAGATACAACAG 5 3 104541 104560 532325 CTGGCCCCCATGATTCAATT 44 104835 104854 532326 AAGACTGGCCCCCATGATTC 49 104839 104858 532327 TGTCACTGGTCTGTGTATTT 60 106233 106252 532328 ACAGAGTAGATTTAGCATAA 23 106980 106999 532329 TAAACAGGTGTACTATTACA 27 107030 107049 532330 GCTTTATCAACTAAGTTTAT 22 107716 107735 532331 CAGAACTTCTTTTAAAATTG 8 107763 107782 532332 GAATACAGACATACCTTGAA 25 108514 108533 532333 CCATGACAACAATTTCAGAG 5 8 109486 109505 532334 ACAAATAGCAATGAATGGGT 45 110878 110897 532335 ATAGCAATGAATGG 47 110880 110899 532336 GTACACAAATCAGTAGCTCT 72 115087 115106 532337 CTATGTCAAAAAGACTGAAA 4 116370 116389 532338 ATATACAGAACATTTCATCC 1 3 116743 116762 532339 AGAATAGATAAGAACTCACC 32 117195 117214 532340 AGGAAAGATACAGTCATTTT 5 117507 117526 532341 GCACAAAGAACACCTGGGAA 4 112522 532342 CAAGAAGTCTGGGATTATGT 0 117938 117957 532343 GTTAGTTATTAAGCTAATCA 48 118245 118264 532344 AACCATTATTTATAGGCTAA 1 112145 532345 CCAGAATGCGATCACTTCTT 76 120826 120845 532346 ATTATCCTCCTCTC 70 121209 121228 532347 AGGGAAATGCAAATTAAAAC 2 122425 532348 GCATCAAGATACAGAAAAAT 24 122751 122770 532349 GAATGTTTATGAGATTTTTC 0 125522 532350 GCCAATTATATTGCCACATT 23 124452 532351 ATACTTGCTTATGTAGAAAT 5 124522 532352 TAATACTTGCTTATGTAGAA 3 124512 532353 ATGGCATTCTGATA 6 22 532354 CAGAATTTGCAGTATAAATC 0 125222 532355 TATGTTTTGAAATCTTATTT 0 125125 532356 ACTCACTGCTACCTCATTAA 11 126998 127017 532357 AAGCAGTGATAGGGTATCTG 59 127080 127099 532358 ATGAGGCCTATTACAATGGA 1 4 127170 127189 532359 CTGGAGTCTCATGAGGCCTA 53 127180 127199 584 532360 TGACTATCAGCCTTTTAATC 585 532361 TTCAGAGAACAACCTTTGAA 0 127959 127978 586 532362 AGCCATGTGTGATCTGATGT 587 532363 GAAATTTACTCCAAACTAGC 17 532364 AACATCCAGACCACCATCTA 35 532365 AACCATTCATGCTC 590 532366 AGTACCAAACCATTCATGCT 24 131037 131056 591 532367 TTATAGAGCTTGAGATTGAC 7 132165 132184 592 532368 AGTCCATTATAGAGCTTGAG 5 8 132171 132190 593 532369 AACCATGAGATGCAATGCAG 40 132498 1325 17 594 532370 AGGATTGAGAATCGCTGATT 42 133168 133187 595 532371 GCATGGCCAGGATT 6 532372 GGGACTGAGTATTGATACTT 44 13 3222 133241 597 532374 AGAAATAGTCTTCCTACTAA 0 133547 133566 599 532375 GCCTCCTTTAAGCTTCTATG 22 134240 134259 6OO 532376 GGCCTGCCTTTACTTTCCCA 36 134598 134617 6O 1 Table 10 Inhibition of GHR mRNA by 55 MOE gapmers targeting introns 1 and 2 of SEQ ID NO: 2 Sequence Target % ID NO: SEQ ID . . reglon 1nh1b1t10n 2 Stop NO ACCTCAGTGGACTCTTTCCA 111116111 4 84684 84703 602 523639 n/a n/a CAAACCTAAGTTCAAGTCCT 111110111 62 85523 85542 603 AGTTTCACTTCTTGAATCAA 111 38 86373 86392 604 AAGATCAAATGAGGTCAAGG 111116111 30 87181 87200 605 TAGATACAAATTTCATCACA 111116111 23 88063 88082 606 523643 n/a 11/1 ATTCCTAAAATAGGAGCAGG 111110111 45 88870 88889 607 TTTTTATGTTGTATAAGATA 111116111 0 89670 89689 608 GTTCAGCCAATACATGAGTA 111110111 48 90473 90492 609 CCAGAGGGAGTTCATTACCA 111116111 62 91273 91292 610 TCTCTCTAATTCAACCTTAT 111110111 44 92107 92126 611 CTCAGACCTCTTTA 111116111 29 92925 92944 612 CACTGTGGCAGAATTCCAAG 111116111 28 93762 93781 613 ACACCTTGGTGCCTAGAAGC 111110111 54 94581 94600 614 ATGACACCTAAGAA 111116111 58 95394 95413 615 TTTAAAATAATAAATGCTTA 111116111 0 96194 96213 616 TCATTTGGTCCTTAGACCCC 111116111 27 96994 97013 617 TTATTCATCTAGGCCGAGTG 111116111 57 97800 97819 618 523655 TTGCAGAATCTTCTCTTTGG 11111611 1 98627 98646 619 523656 ACCATAAAGCTATGCCATAA 11111011 1 99481 99500 620 523657 GGCAAGGAGCACAATAGGAC 111110111 100281 100300 621 AAAGTTGAGCTGAG 111116111 66 101081 101100 622 TAGATTTTCAGACTCTTTCT 111116111 46 101887 101906 623 523660 n/a n/a AATTTCAATATTGTTGTGTT 111110111 0 102760 102779 624 ATGCTTTTAATGGCACCCAA 111110111 69 103569 103588 625 CATGTCTCACATCCAGGTCA 111110111 37 104386 104405 626 TTCACTGGAGTAGACTTTTA 111116111 45 105255 105274 627 wo 2015/002971 523664 n/a CTTATAAGGGAGGTCTGGTA l 41 106147 106166 628 GCATAATTCTTAAGGGCCCT Intronl 71 106966 106985 629 523666 n/a n/a CCACAGAACTTCTTTTAAAA Intron] 27 107766 107785 630 GGTGACCATGATTTTAACAA Intron] 25 108566 108585 631 AACAGCTGCATGACAATTTT l 50 109382 109401 632 AGAAACAGAATCAGTGACTT Intronl 44 110403 110422 633 523670 n/a n/a CAGATTCCAGAGAAAAGCCA Intron] 14 111203 111222 634 AAGAACTCTATCAC Intron] 12 112030 112049 635 523672 n/a n/a CTCACAAATCACCACTAAAG l 31 112842 112861 636 CAACGAGTGGATAAAGAAAC Intronl 28 113646 113665 637 523674 n/a n/a ATAAAACTGGATCCTCATCT Intron] 13 114446 114465 638 ATTAAAACTCTCAGCAAAAT Intron] 0 115450 115469 639 AAAGACTGAAAGAACACAAA Intronl 0 116361 116380 640 TATCTGCTGCCTTCAGGAGA Intronl 0 117168 117187 641 TTTGAATTAACCCAATTCAA Intronl 0 117999 118018 642 TCTTAATTTACAACAGAGGA Intronl 25 118821 118840 643 AGAAAAGTGACAGGCTTCCC Intronl 31 119659 119678 644 CTTGAAGATCCCAA Intron] 37 120478 120497 645 ATGAATAACACTTGCCACAA Intron] 0 121379 121398 646 GTATGTTTATCACAGCACAG Intronl 56 122180 122199 647 523684 n/a n/a AAACACTGCAATATTAGGTT Intron] 34 123031 123050 648 GATTGGTGCTTTTCAAACTG Intronl 39 123936 123955 649 ATTTGTAAGACAAACATGAA Intronl 9 124764 124783 650 TCACATGACTATGTTCTGGC Intronl 72 125594 125613 651 AGTCCTGTCCACACTATTAA Intronl 6 126415 126434 652 CTGGGCTCTGCCTGCTGAAC Intronl 17 127217 127236 653 CTTAAGTATTTCCT Intronl 12 128054 128073 654 CTCTGTTTCAAACCCCCCAG Intronl 21 128854 128873 655 GGACAGAACACCAATCACAA Intronl 18 129654 129673 656 ACCTACCCTTCAAAGTCACG l 0 130486 130505 657 TTCAGTTCCCAGGAGGCTTA Intronl 5 131286 131305 658 523695 n/a n/a TTTTGCAATGTCTAGCAATT Intron] 132086 132105 659 523696 n/a n/a ATTAAGATCAGAAAATATTA Intron] 132953 132972 660 523697 n/a n/a TTAATGAGATATTTTGCACC Intronl 133858 133877 661 GAGAGGTTAAGTAAATCTCC Intronl 0 134678 134697 662 523699 n/a n/a CAGACTCAAATTTGAAAATT Intron] 14 135500 135519 663 GATAAGGCAATAATACAGCC Intronl 1 136306 136325 664 ATCATTTGCCAATTTCTGTG Intronl 137133 137152 665 CAAGAAGAAAAGATGCAAAA Intronl 08 138035 138054 666 138876 667 TTTTGGAAATGTGAGAAACG Intronl 0 139771 139790 668 AAACACATGAGAAAAGATGA Intronl 0 140593 140612 669 TGTTGGCTCAGTGGGAATGA Intronl 0 141412 141431 670 TGAACAGGTTTGCATTTCTC Intron1 142229 142248 671 TCCTAGGTGAACAGGCTATG Intronl 143029 143048 672 523709 n/a n/a CCCTAATCAGGCTGAAATAA Intron] 143829 143848 673 AGGGCCAGTAAGGTTTGCTT Intron] 144631 144650 674 AGCCTGAATTCTGAGCTCTG Intron2 145431 145450 675 AGAGGATCTCAGCTGCAATT IntI‘OIIZ 146238 146257 676 523713 n/a n/a GAAAATCCCTGCTCAAGTGC Intr0n2 147262 147281 677 523714 n/a TGCCTGATATTGTAATTCTT Intron2 148062 148081 678 Table 11 Inhibition of GHR mRNA b 5 5 MOE :anmers tar__etin s 1 and 2 of SEQ ID \IO: 2 Target % Region inhibition 532377 CTCATACAGTGAAGTCTTCA Intron 1 135450 532378 CTCACTAAGCTTGATTCACT Intron 1 135837 532379 GATACAGAAATCCCAGTGAC Intron 1 136130 532380 TGTGCTTGGGTGTACAGGCA Intron 1 136301 532381 TCAAGCACTTACATCATATG Intron 1 42 136377 136396 532382 AGGGTTAGTTATTACACTTA Intron 1 60 136576 136595 532383 AGGCTTCATGTGAGGTAACA Intron 1 58 136996 137015 532384 TGAAAGCTTAGTACAAGAAG Intron 1 51 138048 138067 532385 CTCTCCTCTTGGAGATCCAG Intron 1 58 138782 138801 532386 GCTGAGATTTCTCTCCTCTT Intron 1 138811 532387 CTGAGATTTCTCTC Intron 1 58 138797 138816 532388 GAACATATGTCCATAGAATG Intron 1 141719 532389 GCTATGTAATCAAA Intron 1 143040 532390 TTTTTATTACTGTGCAAACC Intron 1 41 143878 143897 532391 ACTGAGGGTGGAAATGGAAA Intron 2 23 145059 145078 532392 ATGCCATACTTTTCATTTCA Intron 2 87 146351 146370 532393 TCTTTAAAGATTTCCTATGC Intron 2 66 146367 146386 532394 TCACAATTAAATTATGTTTA Intron 2 47 149858 149877 532395 ATCACCAAACACCA Intron 2 94 150972 150991 532396 TCAGAATGCTGAAGGATGGG Intron 2 70 152208 152227 532397 ACAATTGCAGGAGAGAACTG Intron 2 57 152296 152315 532398 GTTCAGTCACCTGGAAAGAG Intron 2 152568 532399 CGGAGTTCAGTCACCTGGAA Intron 2 77 152553 152572 532400 AATCTAAAGTTCAATGTCCA Intron 2 152771 532401 CCACCTTTGGGTGAATAGCA Intron 2 153940 532402 CAACATCAAAAGTTTCCACC Intron 2 153955 532403 AAGCTTCTATCAACCAACTG Intron 2 154112 532404 ACCATTTTCTAATAATTCAC Intron 2 154521 532405 ACCTGCACTTGGACAACTGA 60 154727 154746 532406 GTCAGTGCTTTGGTGATGTA 1 1 155255 155302 532407 TAGAAGCACAGGAACTAGAG hnnn12 68 155889 155908 532408 TTTAATTTTATTAGAAGCAC 1 4 155919 532409 GAGCAAGAATTAAGAAAATC 29 155992 532410 CTCTGCAGTCATGTACACAA 93 156613 532411 TTTGTCAATCCTTT Intron 2 95 156889 156908 532412 GTTCTCAAGCAGGAGCCATT Intron 2 70 157330 157349 532413 AGGGTGATCTTCCAAAACAA hnnn12 87 158612 158631 532414 TCTCCTATGCTTCCTTTAAT InH0n2 25 158813 158832 532415 GACATAAATATGTTCACTGA 1nH0n2 8 1 159216 159235 532416 TTACTGAGTGACAGTACAGT hnnn12 65 161588 161607 532417 CCAGGCACCAGCACAGGCAC 47 161950161969 532418 TTAATGTCAGTAGAAAGCTG 0 162349 162368 532419 GCAGGTGGAAAGAAGATGTC 50 162531 162550 532420 GCCAGGGTCTTTACAAAGTT 93 162751 162770 532421 CATTACCTTTGTACATGTAC 8 164858 532422 GAAGCAACTTCTCTGAGGTC 68 165040 165059 532423 GCCTGGCAAGAAGGGCCCTT 56 155555 165875 532424 ACACATGTTTTTAAATTTAT 2 1 166241 166260 532425 TGCACTAAAAGAAA Intron 2 5 3 168760 168779 532426 TCCCAATGACTTACTGTAGA 8 169092 532427 TAAGCATTTATGGAGGAATG 6 169153 532428 TGAGGTGGGTGGCCAACAGG 6 170100 532429 GTTTTTCATTTTGATTGCAG 8 8 170177 532430 AGCTCAAGTGTTTTTCATTT 170186 532431 CAATGTCACAGCTGTTTCCT 170291 532432 GAACTTTGGAGGCTTTTAGA 5 170722 532433 TGTATGCCCCAAACTCCCAT 8 3 171450 532434 ACACAAATAAGGGAATAATA 4 171568 532435 TAGTTCAGCCACTATGGAAA 7 171945 532436 CTCCAAATTCCAGTCCTAGG Intron 2 93 172746 172765 53287 AGTTGGCACTGCTATATCAG InH0n2 66 173668 173687 532438 GGCCTTAGATTGTAAGTTTT hnnn12 69 174122 174141 532439 TTTTAGTATTATTGTAGGAA 114201 741 532440 TTTCATTAATGAAACCTGAT Inflon2 39 174812 174831 742 532441 CCCTCAGCTGCCTCTTCAAT 532442 TATTGTATCCTGGCCCCTAA 532443 AGAGCCTAGAAGTA 532444 ATGTCACTGAATTT 532445 GCCCTACCCAGCAGCCTGTG 532446 CAAACATAAAGAGAGTTCCA 532447 CTTTAAATGAAGTAGAGCTC 0 178090 178109 749 532450 AAAGAGTGATGTCTAGCCTA Intron 2 55 179147 179166 752 532451 CACTTCTTACTCCTTTGAGG Intron 2 50 179631 179650 753 Table 12 Inhibition of GHR mRNA b 5 5 MOE flamers tarnetin intron 2 of SEQ ID NO: 2 ID SEQ ISIS % sequence NO: 2 : ID NO tion Start NO Site ' 533249 AGCAGAGGATCTCAGCTGCA 146241 146260 756 533250———- 533253———- 533252 533253 533254 533255 CAAGAAAATCCCTGCTCAAG 46 147265 147284 762 533256 CTGATATTGTAATTCTTGGT 91 148059 148078 763 533257 CCTGATATTGTAATTCTTGG “ 148060 148079 533258 GCCTGATATTGTAATTCTTG 148061 148080 533259 ATGCCTGATATTGTAATTCT 148063 148082 533260 AATGCCTGATATTGTAATTC 74 148064 148083 767 533261 533262 533263 533264 TCAATTATGTGCTTTGCCTG 83 148906 148925 771 533265 TGTCAATTATGTGCTTTGCC 91 148908 148927 772 533266 ATGTCAATTATGTGCTTTGC 148909 148928 533267 GATGTCAATTATGTGCTTTG 74 148910 148929 774 533268 CTGGTGACTCTGCCTGATGA 77 151385 151404 775 533269 GCTGGTGACTCTGCCTGATG 151386 151405 533270 TGCTGGTGACTCTGCCTGAT “ 151387 151406 533271 GCTGCTGGTGACTCTGCCTG 151389 151408 533272 533273 TGGCTGCTGGTGACTCTGCC 82 151391 151410 780 533274 533275 533275 533277—m-— 533273 533279 533280 533281 ATCCAGTAGTCAATATTATT 85 153002 153021 533283 533284 533285 TGGTTATCCAGTAGTCAATA 153007 153026 533287 TCAACTTGAGGACAATAAGA 155592 155611 533289 AACTCAACTTGAGGACAATA 82 155595 155614 533291 533292 533293 533294—1“— 533295 533296 333337 533298 533299 CTACAATGCACAGGACACGC 157199 157218 533300 83 157200 157219 807 533301—-M— 533302 533303 533304 533305—-_ 333303—m— 533307—-_- 533308 GAATTACCCATGCA 165550 165569 533309 AGAATTACCCATGC 165551 165570 533310 TTCCAGAAGAATTACCCATG 8 1 165552 165571 817 533311 TCTTCCAGAAGAATTACCCA 58 165554 165573 818 533312 ATCTTCCAGAAGAATTACCC 64 165555 165574 819 533313 533314 TTTCTGCAGTATCCTAGCCT 78 166350 166369 533316—-_ 533317 333313 533319—“— 533320 GTTTCCATTTTCTTGATTCC 169601 169620 533321 TGTTTCCATTTTCTTGATTC 169602 169621 533322 GTGTTTCCATTTTCTTGATT 533323 TGGTGTTTCCATTTTCTTGA 169605 169624 - 533324 ATGGTGTTTCCATTTTCTTG 169606 169625 I 533325 AATGGTGTTTCCATTTTCTT 78 169607 169626 Table 13 Inhibition of GHR mRNA by 55 MOE gapmers ing introns 2 and 3 of SEQ ID NO: 2 Target % Sequence _ _ SEQ ID region inhibition ' ' NO 533326 AACCCATTTCATCCATTTAA 175369 175388 2333 533327 GAACCCATTTCATCCATTTA Intron2 83 175370 175389 834 533328 GGAACCCATTTCATCCATTT 175371 175390 835 533332 TGAGGGATTGCCTCAGTAGC-“ 179616 179635 839 533333 TTGAGGGATTGCCTCAGTAG -6_ 179617 179636 840 533334 GGATTGCCTCAGTA 11166112 179618 179637 841 533335 CCTTTGAGGGATTGCCTCAG Intron2 179620 179639 842 533336 TCCTTTGAGGGATTGCCTCA -“: 179621 179640 843 533337 CTCCTTTGAGGGATTGCCTC -_ 179622 179641 844 533338 AACTTAGGACTTGGGACATT 184575 184594 845 533339 TAACTTAGGACTTGGGACAT Intron2 54 184576 184595 846 533340 CTAACTTAGGACTTGGGACA 184577 184596 847 533343 GTCACTAACTTAGGACTTGG Intron 2 83 184581 184600 850 533344 TGGGCTAGATCAGGATTGGT Intron 2 81 188617 188636 851 533345 ATGGGCTAGATCAGGATTGG 188618 188637 852 533346 CATGGGCTAGATCAGGATTG Intron2 64 188619 188638 853 533347 ACCATGGGCTAGATCAGGAT 11166112 82 188621 188640 854 533348 TACCATGGGCTAGATCAGGA 188622 188641 855 533349 CTACCATGGGCTAGATCAGG 188623 188642 856 533350 ATGAGCTTAGCAGTCACTTA 189482 189501 857 533351 CATGAGCTTAGCAGTCACTT 11166112 87 189483 189502 858 533352 CCATGAGCTTAGCAGTCACT 189484 189503 859 533356 CTCAGCAAACCTGG 190287 190306 863 533357 GGAATGTCTCAGCAAACCTG 190288 190307 864 533358 AGGAATGTCTCAGCAAACCT 190289 190308 865 533359 TACAGACATAGCTCTAACCT 191139 191158 866 533360 ATACAGACATAGCTCTAACC Intr0n2 79 191140 191159 867 533361 GATACAGACATAGCTCTAAC 191141 191160 868 5333 64 GCTGGATACAGACATAGCTC Intron 2 95 191145 191164 871 533365 ACACTGTTTGTGAGGGTCAA Intron 2 87 191939 191958 872 533366 AACACTGTTTGTGAGGGTCA Intron 2 81 191940 191959 873 533367 TGTTTGTGAGGGTC Intron 2 85 191941 191960 874 533368 AACAACACTGTTTGTGAGGG 2 65 191943 191962 875 533369 AAACAACACTGTTTGTGAGG 191944 191963 876 —-_880 —-—n882 533376 CAGGGCTTCAAGTTTAGGAT 196542 196561 883 533377 TGTGGCTTTAATTCACTAAT 198145 198164 884 533378 ATGTGGCTTTAATTCACTAA 198146 198165 885 533379 TATGTGGCTTTAATTCACTA Intr0n2 79 198147 198166 886 —-_889 —-—m892 —-_—894 —-6_—895 533389 ATTGGTACTCATGAGGAGGC Intron 2 201417 201436 896 533390 AATTGGTACTCATGAGGAGG Intr0n2 201418 201437 897 533391 GTACTCATGAGGAG Intron 2 201419 20143 8 898 533392 AAACTCTGCAACTCCAACCC-« 205549 205568 899 533393 GAAACTCTGCAACTCCAACC Intr0n2- 205550 205569 900 533394 GGAAACTCTGCAACTCCAAC 83 205551 205570 901 —m—904 533401 TGTCACATCTGGATGTGAGG 533402 CTGTCACATCTGGATGTGAG m Table 14 Inhibition of GHR mRNA by 5 5 MOE gapmers targeting introns 2 and 3 of SEQ ID NO: 2 Target % Sequence region inhibition 21—1 523715 GTCAATTATGTGCTTTGCCT Intron 2 91 148907 148926 523 716 ACATTCAAAATTCTTCCTTG Intron 2 50 149787 149806 00 523 717 ATCCTGCATATATTTTATTG Intron 2 20 150588 150607 0 1 [\J 523718 CTGCTGGTGACTCTGCCTGA Intron 2 77 151388 151407 913 523719 AATGCTGAAGGATGGGCATC Intron 2 66 152204 152223 0._i J; 523 720 TTATCCAGTAGTCAATATTA Intron 2 71 15 3 004 153023 91 UI 523721 TCTCATGTTAAAGTTCTTAA Intron 2 48 153831 153850 Q._i 0 523 722 TGCACTTGGACAACTGATAG Intron 2 29 154724 154743 O 1 \l 523 723 CTTGAGGACAATAA Intron 2 8 8 155594 155613 C._i 00 523724 GAAGAAAGGAACCT Intron2 72 156394 156413 0 p—A Q 523725 TGCTACAATGCACAGGACAC Intron 2 80 157201 157220 920 523726 TCTGATATTTATTGCTGTAC Intron 2 73 158007 158026 921 523727 ATGCTTCCTTTAATAAATGT Intron 2 0 158807 158826 523728 AACATTTAGAACCTAGGAGA Intron 2 20 159610 159629 Hi00 LAN 523729 CAAGCTTGCAAGTAGGAAAA Intron 2 5 1 160410 160429 924 523730 CCAGGCTGTTCATGCCAAGG Intron 2 26 161248 161267 925 523731 CCTGCCAAGGGCAAGCCAGG Intron 2 17 162064 162083 523732 TTTCACCTGGTGACTGGAAG Intron 2 51 163019 163038 OKDNM OO\]0\ 523733 ATTTTCTACCATCAAAGAGA 2 4 163943 163962 92 523734 GATTAAGTTTTCTTTAAAAA Intron 2 0 164746 164765 929 523735 CTTCCAGAAGAATTACCCAT Intron 2 56 165553 165572 523736 CTGCAGTATCCTAG Intron2 77 166353 166372 i\DWU) b—‘O 523737 TATTTTGAAAATGAGATTCA Intron 2 0 167195 167214 932 523738 GTGGCCCGAGTAAAGATAAA Intron 2 21 167995 168014 523739 CCTGTCAATCCTCTTATATG Intron 2 37 168804 168823 523740 GGTGTTTCCATTTTCTTGAT Intron 2 65 169604 169623 523741 ACAGGGTCAAAAGTTCACTT Intron 2 44 170407 170426 @000 WWWW OLA-PU.) 523 742 TAGGAAAGCTGAGAGAATCC Intron 2 35 171207 171226 QU) \] 523 743 AGCATATGAAAAAATACTCA Intron 2 0 172101 172120 OU) 00 OU) © Intron2 28 173737 173756 940 Intron2 83 175372 175391 942 Intron2 18 176263 176282 943 523 749 CTGACTCATTTCTG Intron 2 16 177072 177091 944 523750 AAATAAGACAAAGAAAATTC Intr0n2 0 177872 177891 ll 94 523751 TTTTAAAAATAACCAATTCA Intron 2 0 178788 178807 946 523752 CTTTGAGGGATTGCCTCAGT Intron 2 66 179619 179638 \0A \l 523753 ACAGTCCTCATGAACAGATT Intron 2 37 180513 180532 0A 523754 ACTATCATTAATAATATTGT Intron 2 0 181323 181342 H0094 523755 ATCTAGATTTGCCTTATAAG Intron 2 27 182123 182142 523756 TGGTTGAGGAAGACAGTCTC Intron 2 16 182962 182981 523757 TGGCTCATAACTTCCTTAGC Intron 2 43 183762 183781 952 523758 ACTAACTTAGGACTTGGGAC Intron 2 72 184578 184597 953 523759 CTTATAGCATTACTAAGTGG Intron 2 49 185403 185422 523760 TGGTGGCAGGAGAGAGGGAA Intron 2 48 186203 186222 523 761 TTTGCCAGGAAATCTTGAAA Intron 2 35 187003 187022 000 UlUlU] 523 762 ATAACTTTTCTCTGAAATTT Intron 2 8 187803 187822 95 \lGLh-h 523763 CCATGGGCTAGATCAGGATT Intron 2 59 188620 188639 523764 TGAGCTTAGCAGTCACTTAG Intron 2 62 189481 189500 \00 0101 00\D 523765 AATGTCTCAGCAAACCTGGG Intron 2 62 190286 190305 523766 AGACATAGCTCTAA Intron 2 75 191142 191161 96u—A 523 767 ACAACACTGTTTGTGAGGGT Intron 2 66 191942 191961 523 76 8 TTCTAATAGCTGTT Intron 2 49 192742 192761 523769 GGCCCCACCTCTGACCTTCA Intron 2 7 193542 193561 000 000 #LAJN 523770 TGGTAAAGCTAGAAAAAAAA Intron 2 0 194346 194365 965 Intronz 23 195159 195178 \DO O\O\ \] Intronz 7 1 198148 198167 523776 CTGTGTTCAGTTGCATCACG Intron 2 75 199816 199835 1 523777 AATGTGGAAGTTTCCTAACA Intron 2 1 5 200616 200635 523778 TTGGTACTCATGAGGAGGCA Intr0n2 58 201416 201435 COG \l\]\] LAN 523779 TTTCTCTGTGTTTAAAATTG Intron 2 1 3 202308 202327 974 523780 GTAAAGCACAATGAACAAAA Intron 2 203115 203134 523781 ATCACAGATCTTTGCTACAA Intron 2 203915 203934 523782 TCCTGCCTTTCTGAACCAAA Intron 2 204721 204740 COG \l\]\] \IGLII 523783 TGGAAACTCTGCAACTCCAA Intron 2 LII 00 205552 205571 978 523784 ACACAGTAGGGAACAATTTT Intron 2 000 206412 206431 523785 AGACAGATGGTGAAATGATG Intron 2 207219 207238 523786 AAACAGAAAGAGAAGAAAAC IIntron2 208117 208136 000 0000\] i—‘OO m3 208938 208957 982 mos CO 209742 209761 muons 80 210561 210580 m3 7 211399 211418 000 000000 LII-PU.) m3 44 212204 212223 986 Table 15 Inhibition of GHR mRNA by 34 MOE gapmers targeting s 2 and 3 of SEQ ID NO: 2 SEQ SEQ ISIS Target % ID NO: ID NO: Sequence ID NO region inhibition 2 Start 2 Stop Site Site 539360 GCTGGTGACTCTGCCTG Intron 2 95 1513 89 151405 987 539361 TGCTGGTGACTCTGCCT 111110112 988 539362 CTGCTGGTGACTCTGCC 111110112 989 539364 CAGTAGTCAATATTATT Intron2 991 539365 CCAGTAGTCAATATTAT Intron2 992 539366 CCTTTGGGTGAATAGCA 111110112 993 539367 ACCTTTGGGTGAATAGC Intron2 994 539369 CAACTTGAGGACAATAA Intron2 996 539370 TCAACTTGAGGACAATA Intron 2 63 155595 155611 997 539371 TTGAGGACAAT Intron 2 81 155596 155612 998 539372 CAGGAAGAAAGGAACCT Intron 2 70 156394 156410 999 539373 CCAGGAAGAAAGGAACC Intron 2 59 156395 156411 1000 539374 ACCAGGAAGAAAGGAAC Intron 2 43 156396 156412 1001 539375 TGCAGTCATGTACACAA Intron 2 93 156594 156610 1002 539376 CTGCAGTCATGTACACA Intron 2 91 156595 156611 1003 539377 GTCATGTACAC Intron 2 87 156596 156612 1004 539378 TGGTTTGTCAATCCTTT Intron 2 95 156889 156905 1005 539379 TTGGTTTGTCAATCCTT Intron 2 97 156890 156906 1006 5393 80 CTTGGTTTGTCAATCCT Intron 2 97 156891 156907 1007 5393 81 GCACAGGACAC Intron 2 65 157201 157217 1008 5393 82 CTACAATGCACAGGACA Intron 2 85 157202 157218 1009 5393 83 GCTACAATGCACAGGAC Intron 2 96 157203 157219 1010 539387 AGGGTCTTTACAAAGTT 111110112 1014 539388 CAGGGTCTTTACAAAGT 11166112 1015 539390 TTCTGCAGTATCCTAGC Intron2 1017 539391 TTTCTGCAGTATCCTAG 111110112 1018 539392 GTTTCTGCAGTATCCTA Intron2 1019 539393 AGTTTCTGCAGTATCCT Intron2 1020 539394 CAGTTTCTGCAGTATCC Intron 2 77 166356 166372 1021 539395 CAAATTCCAGTCCTAGG Intron 2 60 172746 172762 1022 539396 CCAAATTCCAGTCCTAG Intron 2 75 172747 172763 1023 539398 AACCCATTTCATCCATT 111110112 1025 539399 GAACCCATTTCATCCAT 111110112 86 175373 175389 1026 539400 GGAACCCATTTCATCCA 111110112 84 175374 175390 1027 539401 GCTTCATGTCTTTCTAG 111110112 1028 539402 TGCTTCATGTCTTTCTA 111110112 1029 539403 GTGCTTCATGTCTTTCT Intron 2 95 189121 189137 1030 539404 TGAGCTTAGCAGTCACT Intron 2 92 189484 189500 1031 539405 CATGAGCTTAGCAGTCA Intron 2 82 189486 189502 1032 539406 TACAGACATAGCTCTAA Intron 2 45 191 142 191 158 103 3 539407 ATACAGACATAGCTCTA Intron 2 53 191 143 191159 1034 539408 GATACAGACATAGCTCT Intron 2 67 191 144 191 160 103 5 539409 TGTGGCTTTAATTCACT 111110112 1036 539410 ATGTGGCTTTAATTCAC 111110112 1037 539411 TATGTGGCTTTAATTCA 112 1038 539413 GTGTTCAGTTGCATCAC 111110112“— 1040 539414 TGTGTTCAGTTGCATCA 111110112 1041 539416 ACATCTGGATGTGAGGC 111110113“— 1043 539417 CACATCTGGATGTGAGG Intr0n3 55 210563 210579 1044 539418 TCAGGTAATTTCTGGAA Intr0n3 35 219019 219035 1045 539419 CTCAGGTAATTTCTGGA 111110113 1046 539421 ATTTACCTGGG 113n— 1048 539422 TTTGCTTATTTACCTGG 111110113 1049 539423 TTTTGCTTATTTACCTG 111110113 1050 539424 ATGATGTTACTACTACT 111110113 1051 539426 TGTTACTACTA 111110113n— 1053 539427 CCCCTAGAGCAATGGTC 111110113 1054 539428 CCCCCTAGAGCAATGGT 113 65 232827 232843 1055 539429 TCCCCCTAGAGCAATGG 111110113 45 232828 232844 1056 539430 TCAATTGCAGATGCTCT 111110113 78 237675 237691 1057 539431 CTCAATTGCAGATGCTC 111110113 1058 539432 GCTCAATTGCAGATGCT 111110113 92 237677 237693 1059 539433 AGCTCAATTGCAGATGC 111110113 85 237678 237694 1060 539434 GTATATTCAGTCCAAGG 111110113 1061 539435 AGTATATTCAGTCCAAG 111110113 1062 539436 CAGTATATTCAGTCCAA 111110113 1063 Table 16 Inhibition of GHR mRNA by 55 MOE gapmers targeting introns 1 and 3 of SEQ ID NO: 2 SEQ SEQ ID ID ISIS Target 0/0 SEQ ID Sequence NO . . . .. N012 N012 region 1nh1b1t10n NO Start Stop Site Site 532502 GAGTATTTCAGGCTGGAAAA Intron 3 43 214623 214642 1064 533404 GTAACTCAGGAATGGAAAAC l 113035 113054 1065 121992 122011 533405 AGTAACTCAGGAATGGAAAA Intr0n1 113036 113055 1066 121993 122012 533406 AAGTAACTCAGGAATGGAAA Intr0n1 113037 113056 1067 121994 122013 143207 143226 143235 143254 143263 143282 143291 143310 143319 143338 533407 GAGATTTCAAATAAATCTCA Intron] 1068 143347 143366 143375 143394 143403 143422 143431 143450 143459 143478 143208 143227 143236 143255 143264 143283 143292 143311 143320 143339 533408 ATIWXZAquT%nA£{IC11: Innonl 1069 143348 143367 143376 143395 143404 143423 143432 143451 143460 143479 143209 143228 143237 143256 143265 143284 533409 GTGAGATTTCAAATAAATCT Intron] 143293 143312 1070 143321 143340 143349 143368 143377 143396 143405 143424 143433 143452 143461 143480 143210 143229 143238 143257 143266 143285 143294 143313 143322 143341 533410 1K3T(hkChkTTWXZAquTAukAJT: 1071 143350 143369 143378 143397 143406 143425 143434 143453 143462 143481 143183 143202 143211 143230 143239 143258 143267 143286 143295 143314 533411 TWKETChACH¥TTTILAA04TA0XAI‘ hflron] 143323 143342 1072 143351 143370 143379 143398 143407 143426 143435 143454 143463 143482 143184 143203 143212 143231 143240 143259 143296 143315 533412 'TTTKYTChXChkTTWXZAquTPu&A. huronl 1073 143324 143343 143352 143371 143380 143399 143464 143483 143185 143204 143213 143232 143241 143260 143297 143316 533413 TChAChATTTTLAfiuATfiuA hnronl 1074 143325 143344 143353 143372 143381 143400 143465 143484 143186 143205 533414 ACTTTGTGAGATTTCAAATA Intron] 143214 143233 1075 143242 143261 143298 143317 143326 143345 143354 143373 143382 143401 143466 143485 143187 143206 143215 143234 143243 143262 143299 143318 53 3415 CACTTTGTGAGATTTCAAAT Intron 1 1076 143327 143346 143355 143374 143383 143402 143467 143486 533902 ATTTTTGTGTTATGCCTTGA 1084 533903 TTGTGTTATGCCTT 111116113 56 221487 221506 1085 533913 AATGATGTTACTACTACTCA Intron 3 229616 229635 1095 533914 CAATGATGTTACTACTACTC Intron 3 229617 229636 1096 533915 TCCAATGATGTTACTACTAC Intron 3 229619 229638 1097 533916 TTCCAATGATGTTACTACTA 74 229620 229639 1098 533917 ATTCCAATGATGTTACTACT 111116113 1099 533918 CCCCTAGAGCAATGGTCTAG 71 232823 232842 1100 533925 GGCTCACATTTGGAAGACAG 74 233624 233643 1107 533926 AGGCTCACATTTGGAAGACA 56 233625 233644 1108 533927 AGAGGCTCACATTTGGAAGA 111116113 34 233627 233646 1109 533928 CTCACATTTGGAAG 1110 533931 GCTCAATTGCAGATGCTCTG Intron 3 72 237674 237693 1113 533932 AGCTCAATTGCAGATGCTCT Intron 3 74 237675 237694 1114 533933 AAAGCTCAATTGCAGATGCT 3 66 237677 237696 1115 533934 TAAAGCTCAATTGCAGATGC Intr0n3 59 237678 237697 1116 533935 ATAAAGCTCAATTGCAGATG Intr0n3 23 237679 237698 1117 533945 GGAAAATATTGAAAGGCCCA 1127 533946 AGGAAAATATTGAAAGGCCC 111116113 28 246504 246523 1128 533956 AGTTTCTATTGTTGCCACCT Intron 3 252842 252861 1138 53 3 957 CAGTTTCTATTGTTGCCACC Intron 3 252843 252862 1139 53 3 95 8 CCAGTTTCTATTGTTGCCAC Intron 3 252844 252863 1140 Table 17 Inhibition of GHR mRNA by 5 5 MOE gapmers targeting intron 3 of SEQ ID NO: 2 SEQ SEQ ID ID SEQ ISIS % Sequence NO. 2. NO. 2. ID NO inhibition Start Stop NO Site Site 532454 GCAGAACTGATTGCTTACTT 182862 182881 1141 532455 AGGTCATAAGATTTTCATTT 183533 183552 1142 wo 2015/002971 532456 1143 532457 1144 532458 GAATAAGCACAAAAGTTTAA 28 184519 184538 1145 532459 GAACCAAATAAACCTCTCTT 52 185452 185471 1146 532460 ATGTTGAAATTTGATCCCCA 791147 532461 1148 532462 CTTGTGAGAGCTCACTCACT 72 186136 186155 1149 532463 ACATGGTGGCAGGAGAGAGG 42 186206 186225 1150 532464 CTAGAAAGAAACTACCTGAG 12 186341 186360 1151 532466 GAAAAGGATTTTGAGATTTC 43 188897 188916 1153 532467 CTTAGCTGTCAAGGCCCTTT 80 189084 189103 1154 532468 TGTGCTTCATGTCTTTCTAG 881155 532469 1156 532470 1157 532471 1158 532472 1159 532473 1160 424242 1441 532475 1162 532476 AGGAATGTTTGCCT 86 192904 192923 1163 532477 TGACTCAATCATTTAGACTT 45 192990 193009 1164 532478 1165 532479 1166 532480 1167 532481 CTGTATGGCTTTAAGTATTC 631168 532482 1169 532483 AATAAGCTTGAAGTCTGAAG 631170 532484 1171 532485 1172 532486 ACAACTTCAAGCTTCACATA 651173 532487 ATGTTCTGGCAAGA 201842 201861 1174 532488 CAGCCTTTCAGCTGTGAAAG 204181 204200 1175 532489 AACAATGCCAAGAAATCTAT 204369 204388 1176 532490 CCCACAGTAACAATGCCAAG 901177 532491 TTTTACCTCCCAGTGAAACT 34 205896 205915 1178 532493 1180 532494 AGTCATAAAATTCAAATTAT 391181 522424 1182 532497 AAGAAAAATTAGGAAGCTAG 311184 532498 1185 532499 ATTTAATACACATTGGAATA 15 1186 532500 CTATTTATGATTCC 86 213914 213933 1187 532501 CACTCTCTTGGGCTGTTAAG 82 214479 214498 1188 532502 GAGTATTTCAGGCTGGAAAA 66 214623 214642 1064 532503 TTGTTTGAGTTCCAAAAGAA 39 214932 214951 1189 532504 TTTGCCATGAGACACACAAT 77 215932 215951 1190 532505 CACCAAACCTCAGAGACATG 80 216468 216487 1191 532506 CCACTGTTAAGTGATGCATG 83 217480 217499 1192 532507 CTCTCAGGTAATTTCTGGAA 86 219019 219038 1193 532508 GCTCCTCACAATGACCCTTT 84 219452 219471 1194 532509 GGGACTGGCACTGGTAATTT 56 220062 220081 1195 532510 ATTAGTTACTGTAT 69 1196 532511 1197 532512 TGAATCATATACTGATATCA 63 1198 532513 1199 532514 1200 532515 AAATATTTGATAGCTCACAT 18 1201 532516 1202 532517 1203 532518 GCAGGAAGAGTGGCATGGAC 59 224750 224769 1204 532519 CACTTATCCAAATGCAGAGA 82 225742 225761 1205 532520 CAAGGTAATGGGAGGCTAGC 47 1206 532521 1207 532522 1208 532523 1209 532524 1210 532525 1211 532526 1212 532527 AGATTCCTCAAATTCAGTGA 66 1213 532528 TAAGCGGAAAAGGAGAAAAG 0 1214 532529 AAAGCAAGAGAATTCCTAAA 32 234203 234222 1215 532530 AATGAACCTTTAACTTAGTA 40 234876 234895 1216 Table 18 Inhibition of GHR mRNA by 55 MOE gapmers targeting introns 3-8 and intron-exonic s of SEQ ID NO: 2 ISIS % Sequencc Target region NO inhibition 523792 AAAGCTTTGTGGATAAAGTT 213025 213044 1217 523793 GAAGGAAAGGTTCTGTGGAA 213825 213844 1218 523794 CTGAGTATTTCAGGCTGGAA 214625 214644 1219 wo 2015/002971 523795 523796 Intron3 66 216365 216384 523797 GATATGTCCACATTGATTAG Intr0n3 65 218132 218151 523798 Intron3 44 218973 218992 1223 523799 11166113 26 219886 219905 1224 523800 Intron3 18 220686 220705 523801 TATTTTTGTGTTATGCCTTG Intr0n3 73 221486 221505 1226 523802 11166113 16 223110 223129 1227 523803 TCTATTTTTATTTT 11166113 33 223948 223967 1228 523805 CTTTTGCTTATTTACCTGGG Intron3 84 225568 225587 1230 523806 13 31 226371 226390 1231 523807 Intron3 53 227218 227237 1232 523808 Intron3 28 228018 228037 523809 Intron3 45 228818 228837 523810 523811 11166113 28 230418 230437 523812 Intr0n3 46 231218 231237 1237 523813 523814 Intr0n3 79 232826 232845 523815 GAGGCTCACATTTGGAAGAC Intron3 69 233626 233645 523817 Intron3 35 235258 235277 1242 523818 523819 Intron3 80 237676 237695 523820 Intr0n3 81 244875 244894 1245 523821 Intron3 51 245701 245720 523822 Intr0n3 68 246501 246520 523823 523824 Intr0n3 82 248231 248250 523825 Intron3 45 250001 250020 523826 TTCAAGTACTGTCATGAATA 11166113 251214 251233 1251 523827 TTTCTTTTTCTTAAACTAAG 11166113 252041 252060 1252 523828 GTTTCTATTGTTGCCACCTT 13 252841 252860 1253 523829 AAGGCCACATATTATAGTAT Intron3 29 253698 253717 523830 ACCTGAACTATTAATTTCTT Intron3 19 255397 255416 1255 523832 3 26 257018 257037 523833 11166113 17 257818 257837 1258 523834 Intron3 9 258774 258793 523835 Intron3 25 261294 261313 523836 Intron3 57 263338 263357 523837 Intron3 0 266514 266533 1262 WO 02971 523838 GCCGAGGCAGGCACCTGAGT 11166113 43 267375 267394 1263 523839 TGGTACCTATATTGAGAGGT 111116114 46 269052 269071 1264 523840 TTAAGGAAAAATATAGTATA 11166114 7 269854 269873 1265 523841 TTATTTATGTGTCAGGGATG IntI‘OIl4 28 270668 270687 1266 523842 CAAAAGTTAAGTGCTTTAGG Il4 10 271468 271487 1267 523843 TTCATAGATGTCTAAGGAAT 11166114 32 273341 273360 1268 523844 ACCTGTGATTTACCTATTTC Emiluigflons 18 274185 274204 1269 523845 TGCCTAGAAAACCACATAAA Intr0n5 38 274985 275004 1270 523846 AAACATCCTCAAAGGTACCT IntronS 64 275808 275827 523847 CTTCCCTGAGACACACACAT IntronS 35 276617 276636 1272 523848 CAATCTTCTCATAC S 33 278288 278307 1273 523849 TACCATTTTCCATTTAGTTT 3?“ 7 279088 279107 1274 523850 ATTGGCATCTTTTTCAGTGG Intr0n6 279902 279921 523851 TCAAGCTCACGGTTGGAGAC Intr0n6 280799 280818 523 852 AAATGAAATCAGTATGTTGA Intron 6 281622 281641 523853 TGATTTATCACAAAGGTGCT Intr0n6 29 282437 282456 523854 AAAACAGTAGAAAAGATTAA Intron6 14 284073 284092 523855 CTACATCACAGCAGTCAGAA Introné 23 285187 285206 286349 286368 523856 AAAAGATGTAAGTGTGACAT It“on 6 28 1281 286919 286938 523857 TTACAAGAACTGCTAAAGGG 111116116 15 287151 287170 1282 523858 ATAAAGAAAAAGTTAACTGA IntI'OIl6 9 287982 288001 1283 523859 AGATAATATACTTCTTCTAT 111116116 4 288809 288828 1284 523860 CCTTCTTCACATGTAAATTG EXOJTLEEOM 19 290456 290475 1285 523861 TGTAGCTTGTGGTT 11166117 30 291258 291277 1286 523862 AGGCAGAGTTTTTATTGATA 111116117 19 292058 292077 1287 523863 ATAGTCACCAGCCTAAGCCT Intr0n8 28 292858 292877 1288 523864 AGACTTTTAGCATGCTTGAC Intron8 56 293658 293677 523865 TTTACAGCCCTACAGTTCTA 111116118 7 294464 294483 1290 523866 CCAGAGAACCTGACTCCAAA IntronS 6 295330 295349 1291 523867 CAGAAGAAAATATTAGACAG Intr0n8 10 296993 297012 Table 19 Inhibition of GHR mRNA by 55 MOE gapmers targeting s 3-8 of SEQ ID NO: 2 SEQ SEQ ISIS Target % ID_ ID_ SEQ sequence NO‘ 2 NO' 2 ID NO Region inhibition Start Stop NO Site Site 532531 TATTATACTTCTAAATTCCC Intron 3 70 236716 236735 1293 532532 TAAAAGCAAGAAAAAGGAAC Intr0n3 52 236889 236908 1294 532533 CCTAATTTATATGAACAAAC Intr0n3 56 237177 237196 1295 532534 TGCAATGCCTTAGCCTAAAA Intron 3 86 23 8087 23 8106 1296 53253 5 CACCACCATTATTACACTAC Intron 3 75 23 8186 23 8205 1297 532536 AAATAAATCAGATTATTATA Intron 3 52 23 8242 23 8261 1298 532537 CTTAGATCTGTGCTGTCCAA Intron 3 81 24575 8 245777 1299 53253 8 GTTAGTGTTAGATTCTTTGA Intron 3 67 246152 246171 13 00 532539 CATGCTCACGGCTGTGTTAC Intron 3 66 246248 246267 1301 532540 CCCATCAAATACTGAGTTCT Intron 3 86 246487 246506 1302 532541 GAAAGTAGTGATTAATGAGA Intron 3 3 8 247012 247031 13 03 3 2542 ATTAATCAACAAGTGGCATT Intron 3 72 247203 247222 13 04 3 2543 TTTAATTTTAGGGTTTAGAG Intron 3 48 248344 2483 63 13 05 532544 CTTGCTACCACTAGAGCCTT Intron 3 69 248694 248713 13 06 532545 ACCACTGACTTATATCATTT Intron 3 5 8 248743 248762 13 07 532546 TTCCCCATTGCTAATTTTGT Intron 3 48 251601 251620 1308 532547 TCCTGAAACTTAGTAGCTGG Intron 3 83 253147 253166 1309 532548 TGTCTTAAAAAGGAATAAAA Intron 3 52 253785 253 804 1310 532549 CCTATAATAAAGTATTGTCT Intron 3 70 253 800 253 819 131 1 532550 ATGTAAAATGGTATAGCTAC Intron 3 50 254040 254059 1312 532551 AACCCTCACACACTTCTGTT Intron 3 71 254064 254083 1313 532552 CATAAGCAGTGTTT Intron 3 53 254246 254265 1314 532553 TTACTACCCTGAAGAAGAAC Intron 3 35 254314 254333 1315 532554 AAGACCTATAACTTACTACC Intron 3 49 254326 254345 1316 532555 TTTCACAAGATTTACTTGGT Intron 3 77 254641 254660 1317 532556 CAGTTGTGATTGTCAACCTA Intron 3 77 257073 257092 1318 532557 AATCTTGCCTCGATGAAAGT Intron 3 57 257819 257838 1319 532558 TGGCCTAAATGTATCAGTTA Intron 3 66 259157 259176 1320 532559 TGGGTAAAATCTTT Intron 3 67 259184 259203 1321 532560 TATGATTTTTAAAGATTAAA Intron 3 20 261419 261438 1322 532561 GTACAGTGAAAAAGATGTGT Intron 3 56 263666 263685 1323 532562 GACAGGTATGAAGCAAAACA Intron 3 64 267033 267052 1324 532563 TGAGCTGAGGGTCTTTGCCG Intron 3 61 267391 267410 1325 532564 AGGCTGAGTTGTACACAAAC Intr0n4 52 269422 269441 1326 532565 AGGCTGAGTTGTAC Intr0n4 43 269428 269447 1327 532566 TCATAAAGTGGGCCCAGCTT Intr0n4 70 270044 270063 1328 532567 ACTCCTAATCCCTCAGTTTT Intr0n4 62 270492 270511 1329 532568 TTTACATGCAAGGAGCTGAG Intron 4 61 271047 271066 13 3 0 532569 TAATGCCCTTTCTCCCTACT Intron 4 60 271215 271234 1331 532570 CCTGTTTAGATTATCCCAAA Intron 4 62 271763 271782 1332 532571 CATGATTCACAGAATTTCTC Intron 4 56 271831 271850 1333 532572 AGTTAGAAAACTCAAAGTAT Intron 4 2 271915 271934 1334 532573 TCAAATGTACTTAGCATAAG Intron 4 9 271947 271966 13 3 5 532574 ATATCAAATGTACTTAGCAT Intron 4 59 271950 271969 1336 532575 CAGAAGAGGGAATG Intr0n4 51 273233 273252 1337 532576 AATTCCCATCTGAGTAGTTT 1ntr0n4 56 273440 273459 1338 532577 GTCCCCTAATTTCAGGCTAA 111tr0114 31 273471 273490 1339 532578 CTATGTCAAATGAAACAAAA Intron 5 38 274205 274224 1340 532579 TGATTATGCTTTGTGATAAA Intron 5 42 274624 274643 1341 5325 80 TCCAGCTGACTAGGAGGGCT Intron 5 7 275732 275751 1342 532581 CATACCAGTCTCCTCGCTCA Intron 5 0 27673 8 276757 1343 47 277045 277064 5325 82 ATATAACAGAATCCAACCAT Intron 5 1 344 2783 61 2783 80 5325 83 TGCAAAATGGCCAAACTACA Intron 5 56 277577 277596 1345 5325 84 TCTTCCTAGCCACATGTGAT Intron 5 32 278227 278246 1346 5325 85 TACCATGCTCTCTAATTGCC Intron 6 47 279624 279643 1347 532586 CTGTGCCAGGCTGC Intron 6 65 279848 279867 1348 5325 87 AAGTTACAGAACAGATATCT Intron 6 61 280012 280031 1349 532588 GTATTGTGAAAATAGTACTG Intron 6 45 280226 280245 1350 532589 AAACACTATCAAGCTCACGG Intron 6 54 280807 280826 1351 532590 TTCAAGAAAAGTCTTCAAAT Intron 6 24 280831 280850 1352 532591 GGATCATTTCCCCATGCATG Intron 6 52 280982 281001 1353 532592 ATATTATATTAAGAAAAATG Intron 6 4 281422 281441 13 54 532593 TGTTCATTACTTAT Intron 6 49 281587 281606 1355 532594 CATGACATTGGTTTGGGCAA Intron 6 43 282229 282248 13 56 532595 AATGTTGTTGGGAAAATTGG Intron 6 42 2823 83 282402 13 57 532596 AGGATACAAAGTCA Intron 6 49 282986 283005 1358 532597 ATATCCTTTCATGATAAAAA Intron 6 31 283354 283373 1359 532598 ATGGGCTAATATCTCTGATA Intron 6 50 283590 283609 1360 3 2599 ACATTACTAATAATTAGAGA Intron 6 0 28523 6 285255 13 61 532600 ATAAAAACATATGAAAGTAT Intron 6 12 287093 287112 1362 532601 TTCTGAATTAAATCTATTAG Intron 6 16 287408 287427 1363 532602 TTACATTTTTGCAAATTTAT Intron 6 3 1 287472 287491 13 64 532603 TGAACAGTTGATTAACAAAG Intron 6 15 287887 287906 1365 532604 AAGTTATTGGTTTACTAGAT Intron 6 0 28 8598 28 8617 13 66 532605 TTGGAAAAGGTCCTAGAAAA Intron 6 24 289808 289827 1367 532606 CATGACAGAAACTTCTTAGA Intron 7 25 292035 292054 1368 532607 CCATACTTGCTGACAAATAT Intron 8 39 2943 89 294408 1369 WO 02971 Example 2: Dose-dependent nse inhibition of human GHR in Hep3B cells by MOE gapmers Gapmers from Example 1 exhibiting significant in vitro inhibition of GHR mRNA were selected and tested at various doses in Hep3B cells. The antisense oligonucleotides were tested in a series of experiments that had r culture conditions. The results for each experiment are presented in separate tables shown below. Cells were plated at a density of 20,000 cells per well and transfected using oporation with 0.625 MM, 1.25 MM, 2.50 uM, 5.00 uM and 10.00 uM concentrations of antisense oligonucleotide, as specified in the Tables below. After a treatment period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real—time PCR. Human primer probe set RTS34377MGB was used to e mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to untreated control cells.

The half maximal inhibitory concentration (ICSO) of each oligonucleotide is also presented. GHR mRNA levels were cantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

Table 20 0.625 1.250 2.50 5.00 10.00 leo ISIS No HM HM HM HM mum-n 523324 35 45 68 91 90 1.2 Table 21 wmmflmmnNM NM NM NM NM (NM) ————m--— ——————n Table 22 -525525 525522 -523595 21 50 62 76 90 1.6 555555 45 55 55 55 -525552 -525515 523630 4 28 54 79 78 2.6 523665 4 28 54 73 79 2.7 523687 30 56 61 78 81 523711 42 66 78 94 95 0.7 523712 6 37 60 72 89 -523713 -523714 ——————m 55 52 ——————m 523725 45 64 79 89 95 0.6 Table 24 -----0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 523719 24 46 65 84 93 1.5 523720 18 49 72 85 93 1.5 523724 43 61 77 91 91 0.7 ------n -523740 -523752 “nu-=0- 523763 8 32 57 70 80 2.6 -----m 523772 29 39 54 62 61 523774 28 59 63 88 91 1.2 523778 32 63 78 84 523783 0 22 53 72 88 2.8 Table 25 mammmmmM M M M M M 532151---M 532153 43 54 80 532158 46 58 81 87 532160 532162 532164 ----“ 532171 532181-----M 532186 - 532188“mm<0-6 532189m 532197 40 66 85 532199 24 37 50 73 87 2.1 532222 12 41 67 84 94 1.8 Table 26 “M “M “M “M “M (HM) -532175mm --“ <96 532235 43 58 67 77 82 0.8 —————m -552254 -552500—m -552504“mm 532316 41 66 76 86 94 0.7 53239U} 32 U} 0\ 53240)—A 47 ©OO N4: HED) 532411 73 AA 532420 38 #0 \00 000 N-b 000 MN 0000 532436 37 L!) 00 \1 LI] Table 27 uM “M “M “M “M A "zEV 532410 66 83 92 94 97 <0.6 532468 45 . 532469 17 ---6 76 92 - 53247 10 34 ---62 84 53247 13 3 6 5 .NNNO M0000 532470\ 34 64 7 532480 28 54 6 532482 21 3 9 532490 42 60 68 84 93 532500 37 ---50 6 532506 13 "mm-1 ##9## l> 532507 47 59 7 1 86 89 532508 0 73 83 89 532526 31 56 78 79 A ’5:ZV -59 <0-6 53 75 85 91 97 /\00an 9 -M“/\ONo“ox --57 /\:0ex 532556 33 57 67 86 90 1.1 Table 29 0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 ”M ”M ”M ”M ”M 523421 32 57 81 82 -533121 533122 93 <0 6 533123 95 0 6 533125 91 0 6 —mm————m -533136 32 65 62 81 88 1 1 533139 13 51 72 90 94 ——————n —mm—”m —533156 ————m —momm —mm————m Table 30 mmmnnmmHM HM HM HM HM (11M) 533234---M <96 533237 1-9 533233---“ 533179 1-0 533178 ----I=9- <96 533187 5 15 53 79 86 2.7 533188 68 83 89 94 <0.6 ----EI 533134N1-6 533258 <96 533235 50 54 75 82 90 0.7 533262 54 78 91 96 1.2 533189---“ <96 533193 1-0 Table 31 -533291 533256“mu<36 533263 —————m 533265 67 78 91 95 97 <0.6 533318 45 77 87 95 1.5 533252mum- <36 533301 52 77 84 93 96 <0.6 533316 41 50 79 93 94 0.9 533270 71 88 94 97 533330 46 76 93 97 98 <0.6 533317 55 60 82 87 96 <0.6 533315 39 56 82 87 93 Table 32 0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 11M 11M 11M 11M 11M (11M) 533364 71 77 92 90 94 533925 533326 54 77 533916 62 69 83 533328-“““ 533932mm- 533352 42 82 88 93 533917 20 37 57 78 533333mm“ 533336 . 533323---m <36 533937 26 32 79 86 1.5 533908 66 81 88 94 533898 —539371 539382 18 58 74 91 34 59 79 94 -539398 -533333 —533466mum 539405 539412----m 539413 53 75 86 92 96 <0.6 539415 47 62 84 91 96 0.6 539416----“ 539430mm- 539431 14 40 71 89 95 1.7 539433 46 67 74 92 95 0.6 Example 3: Dose-dependent antisense inhibition of human GHR in Hep3B cells by MOE gapmers Gapmers from the studies described above exhibiting significant in vitro inhibition of GHR mRNA were selected and tested at various doses in Hep3B cells. The antisense oligonucleotides were tested in a series of ments that had similar e conditions. The results for each ment are presented in separate tables shown below. Cells were plated at a density of 20,000 cells per well and ected using electroporation with 0.3125 HM, 0.625 uM, 1.25 MM, 2.50 MM, 5.00 MM and 10.00 ”M concentrations of antisense oligonucleotide, as specified in the Tables below. After a ent period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were ed by quantitative real-time PCR. Human primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to untreated control cells.

The half maximal inhibitory concentration (ICSO) of each oligonucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense ucleotide treated cells.

Table 34 M M M M M M M -522214Emma -523805M“ -523822 “------ -523820um -523815 ------n 523828 12 19 32 51 64 74 2.7 -522224 -522724—————“ -522210 ————m-I— -222212Inn—“m Table 35 0.3125 0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 NM NM NM NM NM NM (NM) 539302 31 56 80 92 97 98 0.5 —539314m 539320 11 42 64 83 92 95 1.0 “um-m “um-mum ———————m Table 36 0.3125 0.625 1.250 2.50 5.00 10.00 lC50 ISIS N0 HM HM HM 11M 11M HM (MM) 14 26 38 74 92 98 539339 18 23 58 83 92 98 1.1 -539341 ----“ -539352m- 539356 24 46 62 83 9O 97 0.8 539361 37 42 73 88 96 98 0.6 539379 53 66 83 96 96 98 0.2 Table 37 0.3125 0.625 1.250 2.50 5.00 10.00 lC50 ISIS NO HM HM HM MM “M ”M (HM) 539360"mm 539362 21 36 72 90 98 99 0.8 539375 23 36 66 85 95 99 0.9 539376mm 539377 ---m-I- 539378----m 539389 539403 52 73 83 94 97 98 0.1 539404 22 55 74 88 94 96 0.6 539432“nun-n Example 4: Dose-dependent antisense inhibition of human GHR in Hep3B cells by MOE gapmers Gapmers from studies described above ting significant in vitro tion ofGHR mRNA were selected and tested at various doses in Hep3B cells. The antisense oligonucleotides were tested in a series of experiments that had similar e conditions. The results for each experiment are presented in separate tables shown below. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.625 “M, 1.25 “M, 2.50 MM, 5.00 MM and 10.00 uM concentrations of antisense oligonucleotide, as specified in the Tables below. After a ent period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Human primer probe set 7_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to untreated control cells.

The half maximal inhibitory concentration (ICSO) of each oligonucleotide is also ted. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

Table 38 NM NM NM NM NM (NM) -523271m“ -523274 -525555 -525504"m -525514mum Table 39 ISIS No 0.625 1.250 2.50 5.00 10.00 ICSO M M M M M M 523592 n----- 523595----M 523596 20 49 62 71 75 1.9 523607 63 66 74 76 523615mm- 523630m 523633 41 69 78 79 80 0.6 523665 16 45 56 71 80 2.1 523687 37 59 73 75 78 523711 33 63 78 91 93 0.9 523712 13 36 61 78 87 2.1 523714 63 85 91 96 96 <0.6 Table 40 MEEEMMMNM NM NM NM NM (NM) 523655 523656 43 53 74 88 523661 29 29 66 79 82 1.9 523713 523715 ----E <0-6 523723 ----E <0-6 523725m 523726mum-n 523736“mm 523747 ----“ <0-6 523766 523776 . 523789 63 75 76 83 83 <0.6 Table 41 ISIS No 0.625 1.250 2.50 5.00 10.00 1C50 “M “M “M “M “M (HM) 523719 18 40 56 73 83 2.1 -523720m -523724"m 523752 25 31 38 7O 84 2.5 523758m 523763 523764 22 49 45 73 75 2.1 523765 42 40 57 79 87 1.4 523767---M 523774m 523778 15 45 59 75 79 2.0 523783 5 3O 48 66 83 2.9 Table 42 0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 M M M M M M 552151 552155 552154 —————m 552155 552151mm 552155 552155 —————m 552225 —————m 552255————M 552241 ll————— 552245 5522 —————m 552515 —————m Table 43 -------ISISN0 ”M ”M ”M ”M ”M (uM) ---M 552555mum -532401 70 83 91 94 96 <0.6 532410 56 71 85 90 96 <0.6 -532420 -----“ 532436 49 77 90 97 532468 42 67 82 89 94 0.6 ---“ -532482 532490 18 47 55 69 86 2.0 “um-mm 532526 30 48 67 82 88 1.4 Table 44 MWflflflW“NM NM NM NM NM (NM) -----“ 533179 87 0 8 533 1 88 90 1 0 533189 0 4 533193---M 533233 39 60 59 84 1 0 533234 45 69 84 91 94 533235 28 49 69 82 90 1.4 Table 45 0.625 1.250 2.50 5.00 10.00 1C50 ISISNO “M (HM) 533256mm<0-6 533257 63 77 88 91 96 <0.6 533258 66 81 88 95 95 <0.6 533259---“ <0-6 533262 "mm-m 0-7 533265 74 85 93 96 <0.6 533269 25 55 74 86 87 1.2 533270 ----E 1-0 533271 <0-6 533291m18 533301 61 75 83 91 0.6 533315 22 39 73 76 91 1.7 533317---M 1-3 533318 1.9 Table 46 0.625 1.250 2.50 5.00 10.00 1C50 NM NM NM NM NM (NM) 533280 533316---M 333323"an“I“ 533328 533329 533330 533331-mmm 533352m 533364 533898 1 8 533908 35 533916 22 1 6 533932 62 533937 Example 5: Dose-dependent antisense tion of human GHR in Hep3B cells by MOE gapmers Gapmers from studies described above exhibiting significant in vitro inhibition ofGHR mRNA were selected and tested at various doses in Hep3B cells. The nse oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in te tables shown below. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.3125 uM, 0.625 “M, 1.25 MM, 2.50 MM, 5.00 MM and 10.00 uM concentrations of antisense oligonucleotide, as specified in the Tables below. After a treatment period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTSS437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted ing to total RNA content, as measured by EEN®. Results are presented as percent inhibition of GHR, relative to untreated control cells.

The half maximal tory concentration (ICSO) of each oligonucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells. wo 2015/002971 Table 47 0.3125 0.625 1.250 2.50 5.00 10.00 ICso ISIS No M M M M M M M 523577 0 16 33 59 72 94 2.2 523633 15 33 66 73 82 86 1.1 523764 11 33 50 68 78 83 1.5 523794 12 30 33 56 76 82 1.9 523805 21 48 66 78 85 92 0.8 523810 18 36 61 80 89 90 1.0 523814 13 35 52 67 81 88 1.3 523819 11 30 57 72 81 89 1.3 523820 0 15 43 61 84 92 1.8 523824 21 27 59 72 84 90 1.2 Table 48 0.3125 0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 11M 11M 11M 11M 11M 11M (11M) 539302 34 41 56 83 83 96 0 8 539321-m 2 22 36 57 72 78 94 539355 23 42 48 72 71 539359 21 38 48 73 78 539320 14 32 53 72 82 539341 3 19 -539356 -539358 ---m Table 50 0.3125 0.625 1.250 2.50 5.00 10.00 “M “M “M “M “M “M (HM) 539401 32 39 77 90 92 95 0.6 539404 22 59 77 87 93 95 0.6 539413 16 33 53 82 86 96 1.1 -----m Example 6: Antisense inhibition of human growth hormone receptor in Hep3B cells by deoxy, MOE and cEt s Additional antisense oligonucleotides were designed targeting a growth hormone receptor (GHR) nucleic acid and were tested for their effects on GHR mRNA in vitro. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are ted in separate tables shown below. Cultured Hep3B cells at a density of 20,000 cells per well were ected using electroporation with 5,000 nM antisense oligonucleotide. After a ent period of approximately 24 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3437_MGB was used to measure mRNA levels.

GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to ted control cells.

The newly designed chimeric antisense oligonucleotides in the Tables below were designed as deoxy, MOE, and cEt gapmers. The deoxy, MOE and cEt oligonucleotides are 16 sides in length wherein the side have either a MOE sugar modification, an cEt sugar modification, or a deoxy modification. The ‘Chemistry’ column describes the sugar modifications of each oligonucleotide. ‘k’ indicates a cEt sugar modification; ‘d’ indicates deoxyribose; and ‘e’ tes a MOE modification. The ucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout each gapmer are 5-methylcyt0sines. “Start site” indicates the 5 ’-most nucleoside to which the gapmer is targeted in the human gene sequence. “Stop site” indicates the 3’-most nucleoside to which the gapmer is ed human gene sequence. Each gapmer listed in the Tables below is targeted to either the human GHR mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_000163.4) or the human GHR genomic sequence, designated herein as SEQ ID NO: 2 NK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 42714000). ‘n/a’ indicates that the antisense oligonucleotide does not target that particular gene sequence with 100% complementarity. In case the sequence alignment for a target gene in a particular table is not shown, it is tood that none of the oligonucleotides ted in that table align with 100% complementarity with that target gene.

Table 51 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic and exonic regions of SEQ ID NO: 1 and 2 113138 Ni): Target Region Sequence Chemistry inhiOb/ition NO: 2 II Start Start N1 541262 Iva IntronZ 156891 13’ 541263 164 Intron 1 CCGAGCTTCGCCTCTG eekddddddddddkke 89 3040 13 ' 541264 167 Intronl 3043 13' Junction 541265 170 spanning two GGACCTCCGAGCTTCG eekddddddddddkke 89 n/a 13' exons 541266 176 spanning two CCTGTAGGACCTCCGA eekddddddddddkke 83 n/a 1 3' exons 541268 214 Exon 2 CCAGTGCCAAGGTCAA eekddddddddddkke 87 144998 13’ 541269 226 Exon 2 CACTTGATCCTGCCAG eekddddddddddkke 67 145010 13’ 541270 244 Exon 2 CACTTCCAGAAAAAGC eekddddddddddkke 34 145028 13’ 541278 365 Exon 4/Intron 3 GTCTCTCGCTCAGGTG eekddddddddddkke 77 268028 13' 541279 368 Exon 4/Intron 3 AAAGTCTCTCGCTCAG eekddddddddddkke 76 26803 1 13’ 541280 373 Exon 4/Intron 3 ATGAAAAAGTCTCTCG eekddddddddddkke 26803 6 131 541283 445 “331123311 3 TCCTTCTGGTATAGAA eekddddddddddkke n/a 13: 541288 554 Exon 5 CAATAAGGTATCCAGA eekddddddddddkke 274114 131 541289 561 Exon 5 CTTGATACAATAAGGT dddddddkke 66 274121 13: 541290 569 Exon 5 CTAGTTAGCTTGATAC eekddddddddddkke 61 274129 131 541293 628 332? 4 GATCTGGTTGCACTAT eekddddddddddkke 57 n/a 13: 541294 639 Exon 6 GGCAATGGGTGGATCT eekddddddddddkke 38 278933 13: 541295 648 Exon 6 CCAGTTGAGGGCAATG eekddddddddddkke 67 278942 131 541296 654 Exon 6 TAAAGTCCAGTTGAGG eekddddddddddkke 43 278948 131 541301 924 EXOH7 290422 13‘ 541302 927 Exon7 TGTTACATAGAGCACC dddddddkke 78 290425 13! 541303 930 Exon7 AAGTGTTACATAGAGC eekddddddddddkke 59 290428 13! 541304 958 Exon7 CTTCACATGTAAATTG eekddddddddddkke 26 290456 13! 541305 981 Exon8 GAGCCATGGAAAGTAG eekddddddddddkke 66 292535 13! 541310 1127 Exgflnl'teiEEM CCTTCCTTGAGGAGAT eekddddddddddkke 26 n/a 131 541320 1317 EXOHIO _97734 13’ 541321 1322 ExonlO CCATCCTTCACCCCTA eekddddddddddkke 81 297739 13! 541322 1326 Exonlo —97743 13’ 541323 1331 Exon 10 CCAGAGTCGCCATCCT eekddddddddddkke 64 297748 13! 541325 1420 EXOHIO _97837 13’ 541326 1434 Exonlo —97851 14‘ 541331 1492 Exon 10 CATCATGATAAGGTGA eekddddddddddkke 16 297909 141 541332 1526 Exon 10 TGGATAACACTGGGCT eekddddddddddkke 30 297943 141 541333 1532 Exon 10 TCTGCTTGGATAACAC eekddddddddddkke 63 297949 141 541335 1597 Exon 10 GAATATGGGCAGCTTG dddddddkke 33 298014 141 541336 1601 EXOH10 —98018 14‘ 541337 1607 Exon 10 TTGCTTAGCTGAATAT eekddddddddddkke 39 298024 141 541338 1611 EXOHIO 2_8028 14‘ 541339 1614 Exon 10 ACTTGGATTGCTTAGC eekddddddddddkke 73 298031 141 Example 7: Antisense inhibition of human growth hormone receptor in Hep3B cells by deoxy, MOE and cEt gapmers Additional antisense oligonucleotides were ed targeting a growth hormone receptor (GHR) nucleic acid and were tested for their effects on GHR mRNA in vitro. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below. Cultured Hep3B cells at a density of 20,000 cells per well were transfected using electroporation with 4,500 nM antisense ucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and GHR mRNA levels were ed by tative real-time PCR. Human primer probe set RTS3437_MGB was used to e mRNA levels.

GHR mRNA levels were ed according to total RNA content, as measured by RIBOGREEN® Results are presented as percent inhibition of GHR, relative to untreated control cells.

The newly designed chimeric nse oligonucleotides in the Tables below were designed as deoxy, MOE, and cEt gapmers. The deoxy, MOE and cEt oligonucleotides are 16 nucleosides in length wherein the nucleoside have either a MOE sugar modification, a cEt sugar modification, or a deoxy modification. The stry’ column describes the sugar modifications of each oligonucleotide. ‘k’ tes a cEt sugar modification; ‘d’ indicates deoxyribose; and ‘e’ indicates a MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. “Start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the human gene sequence. “Stop site” tes the 3’-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in the Tables below is targeted to either the human GHR mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_000163.4) or the human GHR genomic sequence, designated herein as SEQ ID NO: 2 (GENBANK Accession No. NT_006576.16 truncated from nucleotides 42411001 to 42714000). ‘n/a’ indicates that the antisense oligonucleotide does not target that particular gene sequence with 100% complementarity. In case the sequence alignment for a target gene in a particular table is not shown, it is understood that none of the oligonucleotides presented in that table align with 100% complementarity with that target gene. The oligonucleotides of Table 54 do not target SEQ ID NOs: 1 or 2, but instead target variant gene sequences SEQ ID NO: 4 (GENBANK Accession No.

DR006395.1) or SEQ ID NO: 7 (the complement of GENBANK Accession No. AA398260.1).

Table 52 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting ic and exonic regions of SEQ ID NO: 1 and 2 Sequence Chemistry inhibition 541262 Intron 2 TTGGTTTGTCAATCCT eekddddddddddkke 156891 541340 Exon 10 AGTGAACTTGGATTGC eekddddddddddkke 298036 541341 Exon 10 GGCATAAAAGTCGATG dddddddkke 298058 541342 CTGGGCATAAAAGTCG eekddddddddddkke 33 298061 541343 GGAAAGGACCACACTA eekddddddddddkke 34 298100 541344 GACCATTTCC eekddddddddddkke 65 298163 541345 GATGTGAGGAGCCACA dddddddkke 54 298244 541346 CTTGATGTGAGGAGCC eekddddddddddkke 70 298247 541347 TCAACCTTGATGTGAG eekddddddddddkke 38 298252 541348 TGATTCAACCTTGATG dddddddkke 39 298256 541349 GTGTGATTCAACCTTG eekddddddddddkke 74 298259 541350 TATGTGTGATTCAACC eekddddddddddkke 58 298262 541351 GGCATCTCAGAACCTG eekddddddddddkke 41 298366 541352 GGTATAGTCTGGGACA eekddddddddddkke 18 298382 541353 TGGAGGTATAGTCTGG eekddddddddddkke 17 298386 541354 AGGTATAGTC eekddddddddddkke 0 298389 541355 TATGAATGGAGGTATA dddddddkke 0 298392 541356 CTATATGAATGGAGGT eekddddddddddkke 30 298395 541357 TATGAATGGA eekddddddddddkke 298398 541358 GGGACTGTACTATATG eekddddddddddkke 298404 541369 TTACATTGCACAATAG eekddddddddddkke 298723 541375 2690 Exon 10 ACAGTGTGTAGTGTAA eekddddddddddkke 82 299107 541376 2697 Exon 10 GCAGTACACAGTGTGT eekddddddddddkke 46 299114 541377 2700 Exon 10 ACTGCAGTACACAGTG dddddddkke 32 541378 2740 Exon 10 TTAGACTGTAGTTGCT eekddddddddddkke 25 541379 2746 Exon 10 CCAGCTTTAGACTGTA eekddddddddddkke 69 299163 541380 2750 Exon 10 TAAACCAGCTTTAGAC eekddddddddddkke 20 299167 541381 2755 Exon 10 AACATTAAACCAGCTT eekddddddddddkke 64 299172 541382 2849 Exon 10 ATCATTTTAG eekddddddddddkke 0 299266 541383 2853 Exon 10 GATTACTACAATCATT dddddddkke 0 299270 541384 2859 Exon 10 AATGCAGATTACTACA eekddddddddddkke 46 299276 541385 2865 Exon 10 TCCAATAATGCAGATT eekddddddddddkke 52 541386 2941 Exon 10 GTTGATCTGTGCAAAC eekddddddddddkke 74 541395 3305 Exon 10 GGTTATAGGCTGTGAA eekddddddddddkke 0 541396 3308 Exon 10 TCTGGTTATAGGCTGT eekddddddddddkke 88 541398 3316 Exon 10 AGTATGTGTCTGGTTA eekddddddddddkke 76 299733 541399 3371 Exon 10 GGGACTGAAAACCTTG dddddddkke 50 299788 541402 4048 Exon 10 GTCTGCGATAAATGGG eekddddddddddkke 52 541403 4058 Exon 10 CCTAAAAAAGGTCTGC dddddddkke 51 541404 4072 Exon 10 CATTAAGCTTGCTTCC eekddddddddddkke 53 Table 53 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic and exonic regions of SEQ ID NO: 1 and2 Target Reglon. Sequence Chennstry. ID inhibition 541262 n/a Intr0n2 85 156891 1371 541421 4418 ExonlO 42 300835 145< 541422 4428 ExonIO 68 300845 145' 541423 4431 ExonIO 86 300848 145: 541424 4503 ExonIO 11 300920 1455 541425 4521 Exon 10 TTGATAACAGAAGCAC eekddddddddddkke 16 300938 146( 541426 Exon 10 TTGGTGTTTGATAACA dddddddkke 31 300945 146: 541427 Exon 10 ATGTTGGTGTTTGATA eekddddddddddkke 32 300948 146: 541429 Exon 1 CCGCCACTGTAGCAGC eekddddddddddkke 77 2906 146C 541430 Exon 1 CGCCACCGCCACTGTA eekddddddddddkke 88 2911 146‘ 541431 Exon 1 GCCGCCCGGGCTCAGC dddddddkke 86 2939 146i 541432 Exon 1 CGCCGCCGCCCGGGCT eekddddddddddkke 61 2943 146( 541433 Exon 1 GAGAGCGCGGGTTCGC eekddddddddddkke 57 3020 146' 541434 Exon l/Intron 1 CTACTGACCCCAGTTC eekddddddddddkke 80 3655 146? 541435 Exon 1/1ntr0n 1 TCACTCTACTGACCCC eekddddddddddkke 90 3660 1465 541436 Exon 1/111tr0n 1 TCATGCGGACTGGTGG eekddddddddddkke 56 3679 147( 541437 Exon 3/Intr0n 3 ATGTGAGCATGGACCC eekddddddddddkke 82 225438 147i 541438 Exon 3/Intron 3 TCTTGATATGTGAGCA eekddddddddddkke 93 225445 1472 541439 Exon 3/1ntron 3 TTCAAGTTGGTGAGCT eekddddddddddkke 72 226788 147: 541440 Enono/nnono no 226795 1474 541441 nnono o2 226809 1471 541442 Eno/nnono so 226876 147( 541443 Eno/nnons 77 226879 147' 541444 Eno/nnono oo 238331 147? 541445 Ens/Enono os 238338 1475 541446 nono 44 238341 148( 541447 Exon 3/1ntron 3 GGATTTCAGTTTGAAT dddddddkke 0 238363 148: 541448 Exon 3/1ntr0n 3 CTCAGAGCCTTGGTAG eekddddddddddkke 65 238428 1482 541449 Exon l/Intronl 1 3608 148: 541450 Exon on 1 11 3615 148; 541451 Exon l/Intronl 60 93190 1481 541452 Exon l/Intronl 85 93245 148< 541453 Exon onl 74 93248 148' 541454 Exon “Mom 71 93253 1485 541455 Exon l/Intronl 75 93256 1485 541456 Exon l/Intronl 15 93263 149( 541457 Exon l/Intronl 61 93302 149: 541458 Exon 1/Intron 1 TTGCAGAACAAATCTT eekddddddddddkke 1492 541459 Exon 1/Intron 1 AGATTTGCAG eekddddddddddkke 149: 541460 Exon 1/1ntr0n 1 GGTCATGGAAGATTTG eekddddddddddkke 1494 541461 Exon 1/1ntr0n 1 GACCTTGGTCATGGAA eekddddddddddkke 51 93352 149i 541462 Exon 1/Intron 1 TGCCAATCCAAAGAGG eekddddddddddkke 34 93369 149( 541463 Exon l/Intron 1 GGGTCTGCCAATCCAA eekddddddddddkke 67 93374 149' 541464 Exon 1/1ntr0n 1 TCCCTGGGTCTGCCAA eekddddddddddkke 82 93 3 79 1491 541465 Exon 1/1ntr0n 1 AAGTGTGAATTTATCT eekddddddddddkke 16 93408 1495 541466 Exon l/Intron 1 GGAGATCTCAACAAGG eekddddddddddkke 3 8 93428 150( 541468 Exon l/Intron 1 TCGCCCATCACTCTTC eekddddddddddkke 43 93989 150: 541469 Exon l/Intron 1 GCCCATCACT eekddddddddddkke 6 1 93993 1502 541470 Exon l/Intron 1 TCACCTGTCGCCCATC eekddddddddddkke 70 93996 150: 541471 n/ Exon 1/Intron 1 CCTGTCGCCC eekddddddddddkke 89 93 999 15 04 541472 Exon on 1 TCACCATCACCTGTCG eekddddddddddkke 72 94002 15 0: 541473 Exon 1/Intron 1 TAATAGTTGTCACCAT eekddddddddddkke 42 9401 1 15 0< 541474 Exon 1/Intron 1 TTCAGATCTTATTAAT eekddddddddddkke 0 94023 15 0' 541475 Exon 1/Intron 1 TTGCAAATTCAGTCTG eekddddddddddkke 32 94096 15 01 541477 Exon 2/Intron 2 CGTTCTCTTGGAAGTA eekddddddddddkke 78 198766 15 05 541478 Exon 2/Intron 2 TCTTGAATAAATTTCG eekddddddddddkke 25 198780 15 1( 541479 Exon 2/Intron 2 AAGCTCACTCTTCAAT eekddddddddddkke 60 198 810 15 1 j 541480 Exon 2/Intron 2 TCCAAGCTCACTCTTC eekddddddddddkke 49 198 813 15 1: 541481 Exon 2/Intron 2 GCTCCTGCCACTCTGT dddddddkke 75 198 8 3 7 15 1: 541482 Exon 2/Intron 2 ATGGGCAAAGGCATCT eekddddddddddkke 60 198 874 15 1 4 541483 5 ' UTR AGTCTTCCCGGCGAGG eekddddddddddkke 32 2571 15 1: figfiflplg 541484 CCGCCGCTCCCTAGCC eekddddddddddkke 73 2867 151< 541485 Intron 1 GCCCGCAACTCCCTGC eekddddddddddkke 37 3 3 41 15 1 ' 541486 Intron 1 CGCCTCCCCAGGCGCA eekddddddddddkke 34 4024 15 1 E 541487 Intron 1 GAGTGTCTTCCCAGGC eekddddddddddkke 86 4446 15 15 541488 n/ Intron 1 CTGAAGACTCCTTGAA dddddddkke 39 4721 152( 541489 Intron 1 GGCTAGCCAAGTTGGA eekddddddddddkke 54 53 92 152i 541490 n/a Intron 1 TGACTCCAGTCTTACC eekddddddddddkke 76 5802 152; 541491 n/a Intron 1 ATTCATTGTGGTCAGC eekddddddddddkke 91 6128 152: 541492 Intron 1 GAAGTGGGTTTTTCCC eekddddddddddkke 86 6543 152; 541493 Intron 1 GTTCAGGTGA eekddddddddddkke 79 6786 1521 Table 54 Inhibition of GHR mRNA by deoxy, MOE and cEt s targeting SEQ ID NO: 3 and 4 ISIS . % Sequence Chemistry ID NO inhibition 541428 CCACTGTAGCAGCCGC eekddddddddddkke 92 1526 541476 TAGGTATTTCAGAGCC eekddddddddddkke 80 1 527 Table 55 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic s of SEQ ID NO: 2 ISIS Target . % 541262 156891 541277 Intron 2 TTGGTTTGTCAATCCT eekddddddddddkke 80 13 70 541494 7231 541509 Intron 1 GTCCAGGCAGAGTTGT eekddddddddddkke 3 0 1528 541495 7570 541510 Intron 1 AGCCAAATGTTGGTCA eekddddddddddkke 19 1529 541496 8 3 95 54151 1 Intron 1 GAGTTTTTCC eekddddddddddkke 71 1 5 3 0 541497 9153 541512 GTGGCATTGGCAAGCC eekddddddddddkke 81 1531 541498 9554 541513 ACCCCACTGCACCAAG eekddddddddddkke 67 1532 541499 9931 541514 111110111 TCCAAGTACTTGCCAA 83 1533 541501 71 1535 541502 84 1536 541503 12214 541518 Intron 1 CCATCTTGCTCCAAGT eekddddddddddkke 93 153 7 541504 12474 541519 Intron 1 CTTACATCCTGTAGGC eekddddddddddkke 71 1 5 3 8 541505 12905 541520 Intron 1 CGCCTCCTGGTCCTCA eekddddddddddkke 97 1539 541506 13400 541521 Intron 1 GCACTACCTA eekddddddddddkke 49 1540 541507 13717 541522 111110111 GAGGGACTGTGGTGCT 65 1541 541509 90 1543 541510 67 1544 541511 68 1545 541512 49 1546 541513 85 1547 541514 89 1548 92 1549 541516 70 1550 541517 18636 541532 111110111 TTGGGCTTAAGCACTA 71 1551 541519 64 1553 541520 93 1554 541521 66 1555 541522 96 1556 541523 83 1557 541524 70 1558 541525 74 1559 541526 60 1560 541527 13 1561 541 528 541543 Intron 1 GGAGTAGCTA eekddddddddddkke 50 1 5 62 541529 541544 Intron 1 GCTGTTGTCAAGAGAC eekddddddddddkke 55 1563 541530 541545 Intron 1 CACCTAGACACTCAGT eekddddddddddkke 47 1564 541531 32366 541546 GTCAAGGGATCCCTGC eekddddddddddkke 34 1565 541532 32897 541547 111 TCCCCCTGGCACTCCA 79 1566 541533 33187 541548 eekddddddddddkke 56 1567 541534 39 1568 541535 37 1569 541536 10 mo 541537 79 1571 541538 75 1572 541539 93 1573 541540 37504 541555 CTAGCTTCCCAGCCCC eekddddddddddkke 46 1574 541541 38841 541556 TCAAGCCCAGCTAGCA eekddddddddddkke 39 1575 541542 39108 541557 1112122111 CCTCACAGGCCCTAAT eekddddddddddkke 4 1576 541544 52 1572 541545 27 1579 541546 40922 541561 Intron 1 GCTAGATGTTCAGGCC eekddddddddddkke 34 1 5 80 541547 41424 541562 Intron 1 CCTATGGCCATGCTGA eekddddddddddkke 32 15 81 541548 41999 541563 Intron 1 GTATGCTAGTTCCCAT eekddddddddddkke 83 15 82 541549 42481 541564 Intron 1 CCCTCATAATCTTGGG eekddddddddddkke 13 15 83 541550 42700 541565 l CCACTACCAC eekddddddddddkke 74 1584 241222 22 1222 241222 22 1222 22 1222 22 1222 241222 21 1222 241222 22 1221 241222 22 1222 12 2 1222 541561 48423 541576 IntI‘OIll TGCATGATCCACCCCA dddddddkke 65 1595 241222 22 1222 241222 21 1222 241224 21 1222 241222 22 1222 241222 11 1222 24222 22 1221 241222 22 1222 241222 42 1222 241222 22 1224 Table 56 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic regions of SEQ ID 1\O: 2 ISIS Target . % SEQ ID 541262 156891 156906 TTGGTTTGTCAATCCT eekddddddddddkke 88 1370 541571 54886 54901 GTCAAATGCTGTTGGG eekddddddddddkke 91 1605 541572 55900 55915 CATCCCCTATCAGGGT eekddddddddddkke 53 1606 541573 111116111 CTCGAATCCCTTGAGC eekddddddddddkke 73 1607 541574 111 GATTCCCTCCCCTAAC eekddddddddddkke 27 1608 541575 63173 63188 111116111 ATCCATCCATGTGCTG eekddddddddddkke 92 1609 541576 63751 63766 111116111 GAGCATGCCTCAGTGG eekddddddddddkke 81 1610 541577 111116111 CAGAAGGACTGCCTCT eekddddddddddkke 50 1611 541578 111116111 ACAATGCTCAACAGCC eekddddddddddkke 75 1612 541579 64576 64591 111116111 TCTGGCATGC dddddddkke 80 1613 541580 65027 65042 111116111 CGGCTGAGAGCAAGGG eekddddddddddkke 88 1614 541581 65363 65378 111116111 GAGAGGGTTCAGCCTG eekddddddddddkke 62 1615 541582 65600 65615 111116111 ACTTAGTTCCTAGCCA eekddddddddddkke 91 1616 541583 66087 66102 111 GTGAACCAGATGTGCT eekddddddddddkke 86 1617 541584 66566 66581 111116111 GGAGTGACAGCTAAGT eekddddddddddkke 98 1618 541585 111116111 AAGTGTTCAGAGCCAC eekddddddddddkke 97 1619 541586 111116111 AACCCTGCCAAGGTAC eekddddddddddkke 45 1620 541587 111116111 GATGGTGAGCACTACC eekddddddddddkke 78 1621 541588 111116111 GGCAGGATAGGACAGA eekddddddddddkke 11 1622 541589 111 GCAAAGTGATGAGCCT eekddddddddddkke 81 1623 541590 111116111 ACACCATTCC eekddddddddddkke 93 1624 541591 111116111 GGATCATGGGCCCCTA eekddddddddddkke 70 1625 541592 111116111 GTGAATTTGCTGGGCC eekddddddddddkke 94 1626 541593 70569 70584 111 GTGATGGGCCCAAGGC eekddddddddddkke 67 1627 541594 71056 71071 111116111 TCCTCAGTCGGCTTGC eekddddddddddkke 69 1628 541595 111116111 CAGCCTTTTGCCAGAT eekddddddddddkke 93 1629 541596 111116111 CCTCCCTAGGATTACC eekddddddddddkke 42 1630 541597 111116111 ACGCCCCAATCACTCA eekddddddddddkke 79 1631 541598 111116111 GCATGACCCATTATGT eekddddddddddkke 94 1632 541599 111116111 TCCCTCCAAGAGCTCA eekddddddddddkke 83 1633 541600 111116111 GATGCCTGTGGCTGAC eekddddddddddkke 84 1634 541601 111116111 GGCTAGCATGTTGCCT eekddddddddddkke 19 1635 541602 111116111 TAACCCACTAGGCTGG eekddddddddddkke 84 1636 541603 111116111 AAAACTAATC eekddddddddddkke 34 1637 541604 11111611 1 GGAGCAGTCTGGCACC eekddddddddddkke 85 1638 541605 11111611 1 TATTCTGTGGGACAAG eekddddddddddkke 51 1639 541606 11111611 1 AGTTCCAGCC eekddddddddddkke 86 1640 541607 111116111 TACTATCATGTAGCGC eekddddddddddkke 87 1641 541608 76701 76716 111116111 TGCCCTTGTAGTGAGA eekddddddddddkke 31 1642 541609 76980 76995 111116111 TCCCCAACCTACAAGC eekddddddddddkke 41 1643 541610 111 GCTCTAGGCATATGAA eekddddddddddkke 63 1644 541611 111116111 TACCTCCCTTGTAGGG eekddddddddddkke 27 1645 541612 111116111 CTTGCAGAGA eekddddddddddkke 62 1646 541613 111116111 TCTTCATGCC eekddddddddddkke 68 1647 541614 111116111 CCTGTGTGCAACTGGC eekddddddddddkke 85 1648 541615 111116111 CTGAGTCATTTGCCTG eekddddddddddkke 93 1649 541616 Intr0n1 AGTAGGCCAG eekddddddddddkke 0 1650 541617 80277 80292 Intronl GTCCTTGCAGTCAACC eekddddddddddkke 77 1651 541618 80575 80590 Intron] GCTGGGCCAAGTCCAT eekddddddddddkke 77 1652 541619 80895 80910 Intronl ACTTTTTGCC eekddddddddddkke 31 1653 541620 Intr0n1 GTCCCTCTCT eekddddddddddkke 34 1654 541621 IntI‘OII] CTTTGGTCCCATTGCC eekddddddddddkke 83 1655 541622 82233 82248 111116111 GGAACATGCCAAGGGC eekddddddddddkke 91 1656 541623 82738 82753 Intronl AGGTGGTCTCCCTTCA eekddddddddddkke 74 1657 541624 83056 83071 l TCCCAAAGCTCCCCTC eekddddddddddkke 53 1658 541625 83401 83416 Intronl CCTGGCCTAGCAAGCT eekddddddddddkke 47 1659 541626 84048 84063 Intron] TCTTAGCCCTGGGCTA eekddddddddddkke 12 1660 541627 84388 84403 Intronl GACTTGGACTGGGCTC eekddddddddddkke 81 1661 541628 Intr0n1 GGATCTAGGA eekddddddddddkke 0 1662 541629 Intr0n1 GTCAGGCTAGAGGGAC eekddddddddddkke 41 1663 541630 Intron] GGAAGTTCTCCCAGCC eekddddddddddkke 47 1664 541631 ] CCTGACTGATGTACAC eekddddddddddkke 35 1665 541632 Intronl CTCTGGCCTAGCCTAT eekddddddddddkke 54 1666 541633 Intronl GGCTGCTGTCAGATGC eekddddddddddkke 79 1667 541634 11111661 TCTCAGGTGTAGGCAG eekddddddddddkke 59 1668 541635 Intron] GGTCACTGAGACTGGG eekddddddddddkke 88 1669 541636 88952 88967 Intronl ACCCACTAGCAGCTAG eekddddddddddkke 61 1670 541637 89160 89175 Intronl CGGATGAGGCAGTTAG eekddddddddddkke 42 1671 541638 Intronl TGGTAGGCCCTCTGGC eekddddddddddkke 28 1672 541639 Intronl GTCACAAGGTGGGTGC eekddddddddddkke 28 1673 541640 Intronl GTCTTGCCCTCACGGA eekddddddddddkke 73 1674 541641 Intr0n1 GCAGTCTGTGGACTTA eekddddddddddkke 93 1675 541642 IntI‘OII] TGCTCTCTGGTCACAC eekddddddddddkke 75 1676 541643 11111661 TATCCCCCAGAGCCAT eekddddddddddkke 68 1677 541644 Intronl AGAGGGCACT eekddddddddddkke 75 1678 541645 Intr0n1 GTTTTAACCTCACCCT eekddddddddddkke 0 1679 541646 II] CCTTCCACTGACCTTC eekddddddddddkke 56 1680 541647 94374 94389 111116111 GACACTAGCCTAAGCC eekddddddddddkke 37 1681 Table 57 Inhibition of GHR mRNA by deoxy, MOE and cEt s targeting intronic regions of SEQ ID NO: 2 Target . % SEQ 541262 156891 156906 Intron 2 TGTCAATCCT eekddddddddddkke 13 70 541648 94638 94653 Intron 1 GGTTAGCCCTCAGCCT eekddddddddddkke 1682 541649 94839 94854 TATGAAGGTTGGACCA eekddddddddddkken 1683 541650 37 1684 541651 95829 95844 75 1685 541652 96158 96173 Intronl AGCTGTTACATGCCAA 93 1686 541653 96488 96503 l GGCCCAGAGGTTATAG eekddddddddddkke 30 1687 541654 70 1688 541655 39 1689 541656 98132 98147 Intronl CATCCAGCAGCTGGAC 35 1690 541657 98833 98848 Intronl GGTCATCACA dddddddkke 60 1691 541658 99258 99273 Intronl GGCCAGGCACATCATG 45 1692 541659 99843 99858 Intronl GGAGCTCATTGAGCCA eekddddddddddkke 36 1693 541660 100406 100421 Intronl GTGCCCATTGCTGTGT 70 1694 541661 100742 100757 Intronl CCAAGTGTGGCTTCAG eekddddddddddkke 54 1695 541662 87 1696 541663 12 1697 541664 9 1698 541665 9 1699 541666 20 1700 541667 51 1701 541668 62 1702 541669 35 1703 541670 106632 106647 Intronl GCTCTTGTGTTGGGTA 89 1704 541671 107084 107099 Intronl TGTGCAGGAGGTCTCA eekddddddddddkke 60 1705 541672 17 1706 541673 34 1707 541674 74 1708 541675 78 1709 541676 29 1710 541677 61 1711 541678 59 1712 541679 60 1713 541680 61 1714 541681 113896 113911 Intronl GGTGATCAGG eekddddddddddkke 29 1715 541682 117477 117492 Intronl CTGAGAGAATTGGCCC eekddddddddddkke 5 1716 541683 117740 117755 Intronl AGGCACATTGTTACCA eekddddddddddkke 26 1717 541684 13 1718 541685 119269 119284 Intronl TACAGTAACACATCCC 78 1719 541686 119688 119703 Intronl GAAGCTCAGCCTGATC eekddddddddddkke 45 1720 541687 53 1721 541688 10 1722 541689 7 1723 541690 23 1724 541691 40 1725 541692 0 1726 541693 35 1727 541694 80 1728 541695 123671 123686 hnron l 1rtrTcx3Ch4cx31‘ eekddddddddddkke 78 1729 541696 124040 124055 Intr0n1 ACATAGTACCCCTCCA 35 1730 541697 72 1731 541698 15 1732 541699 125032 125047 Intr0n1 ACATAAATGC 21 1733 541700 125533 125548 Intronl GAGCATCCCCTACACT eekddddddddddkke 12 1734 541701 126357 126372 Intronl GCTGGGCCTTTAGCTG 66 1735 541702 126736 126751 Innonl 'TTCK31C204TIIK3G(LAG» eekddddddddddkke 79 1736 541703 127179 127194 Intronl TGAGGCCTAT eekddddddddddkke 60 1737 541704 127454 127469 Intronl GGAGGTGGGATCCCAC 35 1738 541705 30 1739 541706 50 1740 541707 7 1741 541708 23 1742 541709 50 1743 541710 49 1744 541712 56 1746 541713 131676 131691 Intr0n1 AGGCCCCTAGAGTCTA 41 1747 541714 132292 132307 Intr0n1 TGGTGTGCCCAGACTT eekddddddddddkke 60 1748 541715 14 1749 541716 12 1750 541717 44 1751 541718 67 1752 541719 42 1753 541720 42 1754 541721 23 1755 541722 27 1756 541723 39 1757 541724 137000 137015 hnron l [XCKECHTFCI¥TCYFCHACK3T‘ eekddddddddddkke 86 1758 Table 58 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting introns 1 and 2 of SEQ ID NO: 2 ISIS Target . % SEQ NO inhibition ID NO 541262 156891 156906 Intron 2 TTGGTTTGTCAATCCT eekddddddddddkke 541725 137372 137387 Intron 1 TGTAAAAGGTCCTCCC eekddddddddddkke 53 541726 137750 137765 GACCTGTGCAGCAGGT eekddddddddddkke 1760 11106111 TCCTCTTGGAGATCCA eekddddddddddkke 44 1761 111116111 AGGTCATAGGACTGCT eekddddddddddkke 73 1762 541729 140343 140358 Intronl GAAGGTCAGACTAGGG dddddddkke 53 1763 140686 140701 TCTGTAGACTGCCCAG eekddddddddddkke 87 1764 GTCCCTCTATTCCCCT eekddddddddddkke 57 1765 AATTGCCATGCTCCCA eekddddddddddkke 56 1766 541733 142113 142128 11106111 GATGACCTTCCTCCAA eekddddddddddkke 15 1767 142327 142342 GTTTCCAGTAGCACCT dddddddkke 82 1768 541735 143118 143133 Intronl GGCCTTGAGCTGATGG eekddddddddddkke 11 1769 143836 143851 TATCCCTAATCAGGCT eekddddddddddkke 40 1770 541737 144094 144109 l GGTGTCCACATCCCGG eekddddddddddkke 58 1771 144558 144573 AGCTGGACAGGCCATA dddddddkke 27 1772 11106112 GGTAATCACCCAGAGA eekddddddddddkke 90 1773 11106112 GCGCTAAGTCTGCTGT eekddddddddddkke 92 1774 CCTCAAATCTTGCCCA eekddddddddddkke 96 1775 11106112 ATCCAGACCTGGCAGA eekddddddddddkke 84 1776 ATCCCTGCTCAAGTGC eekddddddddddkke 89 1777 CAGGCACTCCTTGGAA eekddddddddddkke 93 1778 AGCTGAGGTATCCCTC eekddddddddddkke 94 1779 GGGCCCAGCAAGTCTT eekddddddddddkke 33 1780 541748 149069 149084 11106112 GTTTTGTCAGTGTGCA dddddddkke 98 1781 149491 149506 GTGACCTGCTGAACTC eekddddddddddkke 95 1782 ACTGTGCACC eekddddddddddkke 95 1783 GGGTGGTCCCACTCCT dddddddkke 91 1784 11106112 GAGGAATCCTGGGCCC eekddddddddddkke 94 1785 11106112 ATGACAAGCTAGGTGC eekddddddddddkke 81 1786 111116112 TTGCCAGACAGGGCAC eekddddddddddkke 18 1787 11106112 AGACCCCTCCCACTAT eekddddddddddkke 43 1788 11106112 GGTGCTGGGTGACCGG eekddddddddddkke 91 1789 11106112 GGCCAAACGGTGCCCT eekddddddddddkke 23 1790 TGGGTGAATAGCAACC eekddddddddddkke 85 1791 541759 154171 154186 Intr0n2 GCCCCCAAGGAAGTGA eekddddddddddkke 76 1792 541760 154813 154828 IntronZ TCATGTGTGG eekddddddddddkke 92 1793 541761 155289 155304 11106112 GTGCTTTGGT eekddddddddddkke 52 1794 111116112 CCTGGCAGGT eekddddddddddkke 58 1795 541763 156847 156862 IntronZ TAGCTAGCACCTGGGT eekddddddddddkke 90 1796 157552 157567 GGCAAACCTTTGAGCC eekddddddddddkke 27 1797 11106112 GCTATCATTGGAGCAG eekddddddddddkke 94 1798 CCTCTGAGTACTCCCT eekddddddddddkke 96 1799 AGCTGAAGGCAACCAG dddddddkke 97 1800 11106112 GGGCAGTTTTCCATAG eekddddddddddkke 89 1801 11106112 GGTCCTACCTCTGACA eekddddddddddkke 82 1802 11106112 GGCTGCCTTAGGGTGG eekddddddddddkke 90 1803 541771 160812 160827 CGCACCTCCCCCACTA eekddddddddddkke 15 1804 IlZ GCTTATTGGTCCATGG eekddddddddddkke 93 1805 541773 161821 161836 1ntr0n2 AACCGCAGAGCCCCCA eekddddddddddkke 76 1806 162132 162147 1ntr0n2 GGGCTTGTTCTGCCAA eekddddddddddkke 33 1807 12 GGGACCTGCGCTGACT eekddddddddddkke 86 1808 CTTTCACCTGGTGACT eekddddddddddkke 83 1809 541777 163542 163557 1ntr0n2 AGCTTGAGGGAGTATA eekddddddddddkke 52 1810 164144 164159 GCCTGCTCAATTGAGG eekddddddddddkke 32 1811 541779 164570 164585 11166112 ATAGCAGCTGGCTGCC eekddddddddddkke 24 1812 165419 165434 111110112 AAAAGCTTGGCACCCC eekddddddddddkke 91 1813 541781 165859 165874 1ntr0n2 CCTGGCAAGAAGGGCC eekddddddddddkke 65 1814 166435 166450 CATCTATCCC eekddddddddddkke 82 1815 11106112 GTGGTCTCCCTGTGCC eekddddddddddkke 90 1816 11106112 AGCCCTCTCTGGCAAA eekddddddddddkke 38 1817 541785 168004 168019 TTACTGTGGCCCGAGT eekddddddddddkke 94 1818 541786 169062 169077 GTAGACTCCTAGGGTC eekddddddddddkke 90 1819 541787 169696 169711 CCTCCAGTTAGTGTGC eekddddddddddkke 91 1820 11106112 GTGGGTGGCCAACAGG eekddddddddddkke 91 1821 111116112 GGGATTCCCTGGTAGC eekddddddddddkke 77 1822 1ntr0n2 GTGAGACCGGCCTTTG dddddddkke 23 1823 541791 171530 171545 1ntr0n2 ACTGGCACCCACTTGG eekddddddddddkke 54 1824 172447 172462 ATTGGCCTAATGCCCC eekddddddddddkke 76 1825 IntI‘OIlZ AGGCTATACATTCCAG eekddddddddddkke 94 1826 1ntr0n2 AGCTAGGTGG eekddddddddddkke 80 1827 1ntr0n2 TCCACAGTTGGCACTG eekddddddddddkke 77 1828 TTAGATTGTA eekddddddddddkke 69 1829 IntI‘OIlZ TGTCTTCCTGGTGGCC dddddddkke 97 1830 CCCGCCTCTCCAGCAA eekddddddddddkke 89 1831 1ntr0n2 GCAGCAGCCAATAAGT dddddddkke 76 1832 TTGTATCCTGGCCCCT eekddddddddddkke 80 1833 111110112 GCCTCATGGGCCTTAC eekddddddddddkke 66 1834 Table 59 tion of GHR mRNA by deoxy, MOE and cEt gapmers targeting introns 2 and 3 of SEQ ID NO: 2 Target . % 541802 176619 176634 Intr0n2 GGATGCCAGTCTTGGC eekddddddddddkke 541803 176835 176850 Intr0n2 CTGCTCTCAGTACCTC 73 1838 541806 178066 178081 81 1839 541807 178361 178376 Intron2 GGTCCACATGGCCCTA 90 1840 541808 178895 178910 Intron2 CAGGATTGTC eekddddddddddkke 81 1841 541809 179444 179459 81 1842 541810 179863 179878 87 1843 541811 180524 180539 Intron2 CTGGGTAACAGTCCTC 98 1844 541812 181528 181543 Intr0n2 ACTGTATGGTTTCCAC eekddddddddddkke 83 1845 541813 182103 182118 Intr0n2 GCCAAAGATAGCTCTT 94 1846 541814 182978 182993 IntronZ GGCATTGGAAGTTGGT eekddddddddddkke 87 1847 541815 183193 183208 Intron2 CCCTTCCTGACCTTAC 55 1848 541816 183658 183673 Intron2 TTACCCTCTATTCACC eekddddddddddkke 65 1849 541818 184501 184516 25 1850 541819 185080 185095 96 1851 75 1852 1853 98 1854 541823 186570 186585 44 1855 484 488844 488888 88 4888 541825 187176 187191 96 1857 541826 187629 187644 Intr0n2 GCCTTTGTGTGTCACT 99 1858 541827 187857 187872 Intron2 TATGTGGTAGCATGTC eekddddddddddkke 96 1859 68 1860 90 1861 541830 189534 189549 20 1862 541831 189889 189904 74 1863 541832 190172 190187 68 1864 541833 190961 190976 95 1865 541834 191404 191419 79 1866 95 1867 91 1868 541837 192860 192875 2 ACCCAGTGGA eekddddddddddkke 71 1869 541838 193460 193475 Intron2 GGTGGTTTTCCTCCCT eekddddddddddkke 95 1870 541839 194144 194159 Intr0n2 GAGCCTGCCCAACTTT eekddddddddddkke 90 1871 85 1872 541841 194953 194968 Intron2 TTCCCTCTGCGAACAT 96 1873 541842 195428 195443 Intr0n2 TCTCAATCCA eekddddddddddkke 94 1874 44 1875 541844 197326 197341 90 1876 84848 487848 487884 47 4877 541846 198366 198381 26 1878 541847 198715 198730 83 1879 541848 198939 198954 Intron2 CATGTCAGAGGTGTCC eekddddddddddkke 93 1880 87 1881 541850 199816 199831 90 1882 541851 200249 200264 Intr0n2 GCCCAGCTAGCCACCC eekddddddddddkke 68 1883 541852 201258 201273 Intr0n2 CCTTAGCAGCCAGGCC 86 1884 541853 202079 202094 94 1885 541854 202382 202397 53 1886 541855 202702 202717 Intr0n2 TGACTCCTTGAGACAG 83 1887 541856 203098 203113 2 TGCGCTGGCTTAGCAA eekddddddddddkke 59 1888 541857 203464 203479 Intr0n2 GGCCTAACATCAGCAG 88 1889 541858 204212 204227 12 ACTCCTCCCAGTTAGC eekddddddddddkke 70 1890 541859 205630 205645 Intr0n2 ACCAGTGGCCAATGTC eekddddddddddkke 92 1891 541861 206422 206437 Intr0n2 ACACAGTAGG 70 1892 541862 206749 206764 42 1893 210196 210211 1895 541867 209999 210014 58 1896 211033 211048 541869 210502 210517 80 1898 541870 210920 210935 Intr0n3 GTCAGTTCTGGCTAGG 97 1899 541871 211269 211284 3 GCCTGAACTTACAAGC eekddddddddddkke 68 1900 92 1901 97 1902 541874 213099 213114 7 1903 541875 213425 213440 96 1904 541876 213846 213861 37 1905 541877 214483 214498 94 1906 541878 214884 214899 72 1907 Table 60 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting introns 2 and 3 of SEQ ID NO: 2 ISIS 5158:? ID NO: Target % SEQ ID Sequence Chemistry NO . . . 2 Stop Reglon 1nh1b1t10n NO Start S1te 541262 156891 156906 Intron 2 TTGGTTTGTCAATCCT eekddddddddddkke 91 13 70 541879 215493 215508 TTCACCACCCATTGGG eekddddddddddkke 63 1908 541880 216192 216207 ATCTGGTCTGAGGGCC eekddddddddddkke 92 1909 5418 81 21645 8 216473 Intron 3 GACATGCAATTGACCC eekddddddddddkke 98 1910 541882 217580 217595 GTGTGCAGCAGACTGT eekddddddddddkke 92 1911 541883 218233 218248 GACAGTCCAGCTGCAA eekddddddddddkke 84 1912 CCTGCGGCAGTGAAGA eekddddddddddkke 85 1913 541885 218734 218749 CTCTGAGGATAACCCT eekddddddddddkke 76 1914 541886 219342 219357 11106113 GTTCCCAGCTCCCCAA eekddddddddddkke 68 1915 541887 219618 219633 TAGGGTCAGTGTCCCA eekddddddddddkke 79 1916 541888 220039 220054 GGCGAGCCTCTCAGCC dddddddkke 52 1917 541889 220393 220408 GACTCATCCAGGCAGT eekddddddddddkke 91 1918 541890 220665 220680 11166113 TCCCTCCCTTAGGCAC eekddddddddddkke 71 1919 541891 221044 221059 GAGGAGCCAGGCATAT eekddddddddddkke 80 1920 541892 221562 221577 Intr0n3 CACCAACGAAGTCCCC eekddddddddddkke 89 1921 541893 221947 221962 GCTGGCAGTCACCAAA eekddddddddddkke 90 1922 541894 222569 222584 111116113 GCCCACACCATTGAGC eekddddddddddkke 70 1923 541895 222983 222998 AGTGAGATGCCCTGGT eekddddddddddkke 92 1924 541896 223436 223451 CACTGGCAGTTAGACC eekddddddddddkke 88 1925 541897 224107 224122 ACTCTGGCCACTAGTA eekddddddddddkke 80 1926 GGTAGGGTGGCCACAT eekddddddddddkke 78 1927 GAGCCATGTCTAGGCA eekddddddddddkke 18 1928 CAGACTGAAACCCACC eekddddddddddkke 86 1929 541901 225671 225686 TATGGTCCAGCCACCA dddddddkke 76 1930 541902 226110 226125 TACCTCCTCTGTTGGT dddddddkke 36 1931 541903 227025 227040 ACACCTCAGTCATGAT eekddddddddddkke 92 1932 541904 227236 227251 11166113 AACAGGCTTCAAGAGG eekddddddddddkke 91 1933 541905 227485 227500 GTACTACTGGCCATGT eekddddddddddkke 73 1934 CTGCAGGCGGTTGCTA eekddddddddddkke 60 1935 GTCTGTTGCCAAGAGC eekddddddddddkke 95 1936 541908 229174 229189 CCCTGGGTCACTTAAG eekddddddddddkke 44 1937 541909 229423 229438 CCTGTCCTTGCTTGCA eekddddddddddkke 96 1938 541910 230042 230057 GCCCAGCTTATCCTAA eekddddddddddkke 78 1939 541911 230313 230328 AGTAGAGCCTTTGCCT eekddddddddddkke 75 1940 541912 230580 230595 CTGTCTCTTGGCCCAT dddddddkke 80 1941 541913 231330 231345 AATCTTGAGT dddddddkke 67 1942 541914 231817 231832 13 GCTTGTTACAGCACTA eekddddddddddkke 92 1943 541915 232088 232103 11166113 ACTTTGGCCCAGAGAT eekddddddddddkke 51 1944 541916 232884 232899 Intr0n3 GCAGTCAGGTCAGCTG eekddddddddddkke 75 1945 541917 233210 233225 3 GCCTTGTCCTACTACC eekddddddddddkke 65 1946 541918 233657 233672 Intron3 GGCTCTGCTATTGGCC eekddddddddddkke 59 1947 541919 233998 234013 111116113 CTTATAGAGCCTTGCC eekddddddddddkke 59 1948 541920 234296 234311 GGAAGGGCCCAAATAT eekddddddddddkke 15 1949 GATCTACTCCTACTGC eekddddddddddkke 65 1950 541922 235313 235328 GTCAGCCTGTGTCTGA eekddddddddddkke 45 1951 541923 235770 235785 AGCTTCCTCCTTACAC eekddddddddddkke 54 1952 541924 236198 236213 CTGCTAAGCCCCTACC eekddddddddddkke 59 1953 541925 236684 236699 AGAGGTCAGGTGCATA eekddddddddddkke 77 1954 541926 237055 237070 TTCAGCCTGGTTGGGA eekddddddddddkke 71 1955 WO 02971 PCT/USZOl4/045088 GATTGATTGAGCTCCT eekddddddddddkke 86 1956 541928 237949 237964 ATGGACTCCCTAGGCT eekddddddddddkke 61 1957 541929 238542 238557 3 AGGGCCCCTC eekddddddddddkke 67 1958 541930 245319 245334 GGCATATGTAGCTTGC eekddddddddddkke 91 1959 541931 245765 245780 GAGCTTAGATCTGTGC eekddddddddddkke 73 1960 541932 246251 246266 ACGGCTGTGT dddddddkke 81 1961 541933 246500 246515 Intr0n3 AGGCCCATCA eekddddddddddkke 45 1962 541934 246936 246951 CAACCCAGTTTGCCGG eekddddddddddkke 71 1963 541935 247225 247240 CAGCTATTCCCTGTTT eekddddddddddkke 53 1964 541936 247644 247659 11106113 GCTGTGTCACACTTCC eekddddddddddkke 98 1965 541937 248223 248238 Intr0n3 GTCCAAGGATCACAGC eekddddddddddkke 86 1966 541938 248695 248710 GCTACCACTAGAGCCT eekddddddddddkke 81 1967 541939 249494 249509 GTTTCAGGGCTTATGT eekddddddddddkke 63 1968 541940 250693 250708 TCCCACACCTATTGAA eekddddddddddkke 51 1969 ACTGACTAGAGAGTCC eekddddddddddkke 81 1970 541942 251950 251965 TCCAAGGCTGATGTCC eekddddddddddkke 85 1971 541943 252665 252680 TCCCATGGTGGACATG eekddddddddddkke 39 1972 541944 253140 253155 Intr0n3 AGTAGCTGGCAGAAGG eekddddddddddkke 85 1973 541945 253594 253609 GTGACTACTA eekddddddddddkke 77 1974 541946 254036 254051 TGGTATAGCTACTGGG eekddddddddddkke 84 1975 541947 254905 254920 CTGTGGTTTGGCAGGT eekddddddddddkke 90 1976 541948 255407 255422 11100113 GTTCTCACCTGAACTA eekddddddddddkke 65 1977 ATAGGCTACTGGCAGG eekddddddddddkke 89 1978 CCCAGCTAGCTGGAGT eekddddddddddkke 50 1979 541951 256428 256443 GGCTGGCTCTCAAAGG eekddddddddddkke 61 1980 541952 256689 256704 TGGTGATACTGTGGCA eekddddddddddkke 94 1981 541953 257317 257332 GCTGATTTTGGTGCCA eekddddddddddkke 92 1982 541954 257826 257841 GCTAATCTTGCCTCGA eekddddddddddkke 52 1983 541955 258407 258422 CACTGGTGGCTTTCAA eekddddddddddkke 31 1984 Table 61 Inhibition of GHR mRNA by deoxy, MOE and cEt s targeting intronic and exonic regions of SEQ ID NOS: 1 and 2 Sequence Chemistry . . . . 1D 1nh1b1t10n 541262 Intron 2 TTGGTTTGTCAATCCT eekddddddddddkke 93 156891 1370 541956 Intron 3 GTCCCCTTCTTAAGCA eekddddddddddkke 56 258980 1985 541957 Intron 3 GCCAGGCCAACTGTGG eekddddddddddkke 5 3 259290 1986 541958 Intron 3 GGCCCGTTATGGTGGA eekddddddddddkke 72 259500 1987 541959 Intron 3 CCTAAAGTCCAACTCC eekddddddddddkke 76 261641 1988 1 3 8 541960 02 1000031989 541961 02 1000031990 541962 n/a Intr0n3 TACCCTGCACCCTCCT dddddddkke 262764 1991 541963 n/a Intr0n3 eekddddddddddkke 263342 1992 541964 122 100003 1993 541965 02 100003 1994 541966 n/a Intr0n3 GGGAGGCTCTCAATCT eekddddddddddkke 266861 1995 541967 n/a Intr0n3 eekddddddddddkke 87 267116 1996 541968 n/a 111116113 eekddddddddddkke 33 267380 1997 541969 n/a 111t1‘0113 TCCGTGTCTAGGAGGT eekddddddddddkke 84 267865 1998 541970 n/a Intron4 GTCTCCCTGCATTGGA eekddddddddddkke 31 268366 1999 541972 120 100004 2001 541973 02 100004 2002 541974 02 109004 2003 541975 02 100004 2004 541976 02 100004 2005 541977 02 100004 2006 040220 00 2002 541979 02 100004 2008 541980 n/a 4 eekddddddddddkke 273257 2009 541981 n/a 111116114 TACAGAGAATCACCCC dddddddkke 273651 2010 541982 02 1000004 2011 541983 02 Introns 2012 541984 02 100005 2013 541985 02 100005 2014 541986 00 100005 2015 541987 ma IntronS 2016 541988 02 100005 2017 541989 02 100005 2018 541990 02 100005 2019 541991 IntronS GCTCTTGTGTGCACCC eekddddddddddkke 277730 2020 541992 IntronS TCACCGCCTGCACCAC eekddddddddddkke 278342 2021 541993 S GGTTGCACTGTGCAAT eekddddddddddkke 278917 2022 541994 02 100006 2023 541995 n/a Intron6 GCTGAGTTCCATATGC eekddddddddddkke 279679 2024 541996 n/a Intron6 eekddddddddddkke 280157 2025 541997 02 100006 2026 541998 022 100006 2027 040222 00 00000 2020 542000 02 Intron6 2029 542001 02 100006 2030 542002 n/a Intron 6 TGGGTAACTGGCTAGT eekddddddddddkke 47 28571 1 2031 1 3 9 042000 00000 2002 042004 000000 2000 542005 IntI‘OIl 6 GGCTCCTATCATACCT :ekddddddddddkke 288943 2034 042000 000000 000000000000000 200000 2002 042002 00000 2000 042000 00000 2002 542009 Intron 7 TTGACTACCT eekddddddddddkke 290924 2038 542010 Intron 7 GTACCTGCCAGCTACT eekddddddddddkke 291 807 203 9 Exon 8- 54201 1 intron 8 CCTACCTTTGCTGTTT eekddddddddddkke 29261 1 2040 'unction 542012 Intron 8 CAGCCTAAGC eekddddddddddkke 292860 2041 542013 Intron 8 CCTGGGAGTG eekddddddddddkke 293 377 2042 542014 Intron 8 TCACAATGGC eekddddddddddkke 294052 2043 542015 Intron 8 GGTGAAGTGGGTTGGA eekddddddddddkke 294536 2044 042000 00000 2040 042007 00000 2040 042000 000000 2040 042000 00000 2040 042020 00000 2040 042022 00040 2000 042020 00040 2000 042020 2000 542026 Exon 2 CCAAGGTCAACAGCAG eekddddddddddkke 144992 2054 542027 Exon 2 GCCAAGGTCAACAGCA eekddddddddddkke 84 144993 2055 Table 62 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic and exonic regions of SEQ ID NOS: 1 and 2 SEQ Sf? ISIS ID NO: Target . % SEQ sequence Chemlstry NO 1 Start Region inhibition 1:21:. ID NO 541262 n/a 10000102 TTGGTTTGTCAATCCT eekddddddddddkke“ 156891 1370 542034 870 Exon 7 TCTCACACGCACTTCA eekddddddddddkke 290368 542035 871 Exon 7 ATCTCACACGCACTTC eekddddddddddkke 290369 542036 872 Exon 7 GATCTCACACGCACTT eekddddddddddkke 290370 542049 000 100001——_0— 542050 000 100001——_— 542051 000 1000001———“ 542052 000 100001——_- 542053 Na l 542054 Ma Intronl 542055 n/a Intronl TGATGGTCTTTCATGA eekddddddddddkke 83 17935 2065 542057 Na Intronl 542055 525 555555 542059 n/a Intronl TAGCAATAGT eekddddddddddkke 22519 2069 542062 n/a 11100111 CTCCATTAGGGTTCTG eekddddddddddkke 91 50948 2072 542063 n/a Intronl TCTCCATTAGGGTTCT eekddddddddddkke 88 50949 2073 542065 Na Intronl 542066 Na Intronl 542067 ma Intronl 542068 ma Intronl 542069 ma Intronl 542070 Na Intronl———“ 542072 Na Intronl 542074 n/a Intronl CTCTTCCACTCACATC eekddddddddddkke 79 65992 2084 542075 Ma Intronl———“ 542076 ma Intronl 542077 ma Intron1———-3. 542078 Na Intronl 542079 Ma l———E 542080 ma Intronl 542081 ma Intronl———E 542082 Na Intronl———E 542083 Iva l——_— 542084 n/a Intr0n2 GAATTCTGAGCTCTGG eekddddddddddkke 145430 542085 n/a Intr0n2 TGAATTCTGAGCTCTG eekddddddddddkke 145431 542086 n/a Intr0n2 CTGAATTCTGAGCTCT eekddddddddddkke 145432 542087 Ma Intronz——_— 542088 n/a IntronZ GCCTGAATTCTGAGCT-_ 145434 2098 542089 n/a Z eekddddddddddkke 145435 2099 542090 Na Intronz——_— 542091 Ma Intronz 542022 525 ———n 542093 Na Intronz 542094 Na Intronz 542095 n/a Intr0n2 GCCTGATATTGTAATT eekddddddddddkke 148065 2105 542096 1011 111110112———E 542097 170 11111012———“ 542098 n/a 111110112 AATTATGTGCTTTGCC eekddddddddddkke 75 148908 2108 542100 1011 111110112 542101 1011 11111012 542102 n/a 111110112 ACCAAACACC 150973 2112 542103 100 111110112 eekddddddddddkke 90 150974 2113 542104 100 111110112 150975 2114 542105 n/a 111110112 TGGTGACTCTGCCTGA eekddddddddddkke 98 151388 2115 542106 n/a 111110112 CTGGTGACTCTGCCTG eekddddddddddkke 96 151389 2116 542108 1011 112 542109 1011 111110112 Table 63 Inhibition of GHR mRVA by deoxy, MOE and cEt s targeting introns 2 and 3 of SEQ ID NO: 2 ISIS 1; Target % SEQ NO 1:: sequence Chem‘Stry Stop Region 11111011 ID NO 541262 156891 156906 111110112 TTGGTTTGTCAATCCT eekddddddddddkke 95 1370 153002 153017 111110112 AGTAGTCAATATTATT eekddddddddddkke 74 2120 97 2122 90 2123 153923 153938 112 ACCTTTGGGTGAATAG eekddddddddddkke 71 2124 153924 153939 111110112 CACCTTTGGGTGAATA eekddddddddddkke 78 2125 155595 155610 111110112 CAACTTGAGGACAATA eekddddddddddkke 89 2126 155597 155612 111110112 CTCAACTTGAGGACAA eekddddddddddkke 98 2127 95 2128 156396 156411 111110112 CCAGGAAGAAAGGAAC eekddddddddddkke 83 2129 542121 156397 156412 111110112 ACCAGGAAGAAAGGAA eekddddddddddkke 90 2130 156595 156610 111110112 TGCAGTCATGTACACA eekddddddddddkke 97 2131 156596 156611 111110112 CTGCAGTCATGTACAC eekddddddddddkke 90 2132 156597 156612 111110112 TCTGCAGTCATGTACA dddddddkke 81 2133 542125 156890 156905 111110112 TGGTTTGTCAATCCTT eekddddddddddkke 97 2134 156892 156907 111110112 CTTGGTTTGTCAATCC eekddddddddddkke 99 2135 98 2136 157205 157220 111110112 TGCTACAATGCACAGG eekddddddddddkke 98 2137 158008 158023 111110112 GATATTTATTGCTGTA eekddddddddddkke 61 2138 41 2139 158010 158025 Intron2 CTGATATTTATTGCTG eekddddddddddkke 86 2140 542132 162752 162767 Intr0n2 AGGGTCTTTACAAAGT dddddddkke 69 2141 162753 162768 Intron2 CAGGGTCTTTACAAAG eekddddddddddkke 71 2142 162754 162769 Intron2 CCAGGGTCTTTACAAA eekddddddddddkke 93 2143 166353 166368 IntronZ TTCTGCAGTATCCTAG eekddddddddddkke 84 2144 542136 166354 166369 2 TTTCTGCAGTATCCTA eekddddddddddkke 88 2145 166355 166370 Intron2 GTTTCTGCAGTATCCT eekddddddddddkke 95 2146 542138 166356 166371 Intron2 TGCAGTATCC eekddddddddddkke 92 2147 166357 166372 Intron2 CAGTTTCTGCAGTATC eekddddddddddkke 93 2148 542140 172747 172762 Intron2 CCAGTCCTAG eekddddddddddkke 73 2149 172748 172763 Intron2 CCAAATTCCAGTCCTA eekddddddddddkke 91 2150 172749 172764 Intron2 TCCAAATTCCAGTCCT eekddddddddddkke 90 2151 175372 175387 Intron2 ACCCATTTCATCCATT eekddddddddddkke 94 2152 175373 175388 Intron2 AACCCATTTCATCCAT eekddddddddddkke 93 2153 97 2154 175375 175390 2 GGAACCCATTTCATCC eekddddddddddkke 96 2155 175376 175391 Intron2 CCATTTCATC eekddddddddddkke 68 2156 189121 189136 IntronZ TGCTTCATGTCTTTCT eekddddddddddkke 96 2158 542150 189122 189137 Intron2 GTGCTTCATGTCTTTC eekddddddddddkke 97 2159 189485 189500 Intron2 TAGCAGTCAC eekddddddddddkke 92 2160 189486 189501 Intron2 ATGAGCTTAGCAGTCA eekddddddddddkke 95 2161 95 2162 191143 191158 Intron2 TACAGACATAGCTCTA dddddddkke 91 2163 191144 191159 Intron2 ATACAGACATAGCTCT eekddddddddddkke 74 2164 191145 191160 Intron2 GATACAGACATAGCTC eekddddddddddkke 91 2165 191146 191161 Intr0n2 GGATACAGACATAGCT eekddddddddddkke 94 2166 71 2167 198150 198165 Intron2 ATGTGGCTTTAATTCA eekddddddddddkke 81 2168 198151 198166 Intron2 TATGTGGCTTTAATTC eekddddddddddkke 78 2169 542161 199817 199832 Intr0n2 TGTTCAGTTGCATCAC eekddddddddddkke 91 2170 542162 199818 199833 Intron2 GTGTTCAGTTGCATCA eekddddddddddkke 89 2171 542163 199819 199834 Intron2 TGTGTTCAGTTGCATC eekddddddddddkke 90 2172 90 2173 542165 210563 210578 Intron3 ACATCTGGATGTGAGG eekddddddddddkke 78 2174 210564 210579 Intron3 CACATCTGGATGTGAG dddddddkke 55 2175 219020 219035 Intron3 TCAGGTAATTTCTGGA eekddddddddddkke 82 2176 219021 219036 Intr0n3 CTCAGGTAATTTCTGG eekddddddddddkke 73 2177 40 2178 225568 225583 Intron3 TGCTTATTTACCTGGG eekddddddddddkke 90 2179 225569 225584 Intron3 TTGCTTATTTACCTGG dddddddkke 90 2180 225570 225585 Intron3 TTTGCTTATTTACCTG eekddddddddddkke 79 2181 225571 225586 Intron3 TTTTGCTTATTTACCT eekddddddddddkke 32 2182 229619 229634 Intron3 ATGATGTTACTACTAC eekddddddddddkke 63 2183 542175 229620 229635 Intron3 GTTACTACTA eekddddddddddkke 53 2184 229621 229636 Intron3 CAATGATGTTACTACT eekddddddddddkke 12 2185 232827 232842 Intron3 CCCCTAGAGCAATGGT eekddddddddddkke 76 2186 232828 232843 Intron3 CCCCCTAGAGCAATGG eekddddddddddkke 83 2187 232829 232844 Intron3 TAGAGCAATG eekddddddddddkke 49 2188 542180 237676 237691 Intron3 TCAATTGCAGATGCTC eekddddddddddkke 88 2189 237677 237692 Intron3 CTCAATTGCAGATGCT eekddddddddddkke 90 2190 542182 237678 237693 Intron3 GCTCAATTGCAGATGC eekddddddddddkke 81 2191 542183 237679 237694 Intron3 AGCTCAATTGCAGATG eekddddddddddkke 85 2192 248232 248247 Intron3 GTATATTCAGTCCAAG dddddddkke 90 2193 248233 248248 Intron3 AGTATATTCAGTCCAA eekddddddddddkke 94 2194 248234 248249 Intron 3 CAGTATATTCAGTCCA eekddddddddddkke 97 2195 Table 64 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic and exonic s of SEQ ID NOS: 1 and 2 0 SEQ ID 113% NO: 1 Target Region Sequence try inhilfition NO: 2 SEN( Start Start Site 541262 n/a Intron 2 TTGGTTTGTCAATCCT eekddddddddddkke 93 156891 13 545316 168 “0314;635:011 1 GAGCTTCGCC dddddddkke 80 3044 21 545317 173 ”13:52:“ GTAGGACCTCCGAGCT eekddddddddddkke 74 n/a 21 545318 177 631$? ACCTGTAGGACCTCCG dddddddkke 70 n/a 21 545321 213 Exon 2 CAGTGCCAAGGTCAAC eekddddddddddkke 77 144997 21 545322 225 Exon 2 ACTTGATCCTGCCAGT eekddddddddddkke 36 145009 22 545332 361 Exon 4/ Intron 3 CTCGCTCAGGTGAACG eekddddddddddkke 57 268024 22 545333 366 Exon 4/ Intron 3 AGTCTCTCGCTCAGGT eekddddddddddkke 88 268029 22 545337 444 Emilfifiiqon 4 CCTTCTGGTATAGAAC eekddddddddddkke 21 268107 22 545340 570 Exon 5 GCTAGTTAGCTTGATA eekddddddddddkke 39 274130 22 545343 626 ”0;;$211 4 TCTGGTTGCACTATTT eekddddddddddkke 34 n/a 22 545344 629 ”0.131131;3:11 4 GGATCTGGTTGCACTA eekddddddddddkke 30 n/a 22 545345 632 Exon 6 GGTGGATCTGGTTGCA eekddddddddddkke 18 278926 22 545346 638 Exon 6 GCAATGGGTGGATCTG eekddddddddddkke 50 278932 22 545347 647 Exon 6 CAGTTGAGGGCAATGG eekddddddddddkke 71 278941 22 545348 651 278945 22 545349 655 278949 22 545350 660 EXOn6 GTTCAGTAAAGTCCAG eekddddddddddkke 52 278954 22 545351 685 Exon6 CTGCATGAATCCCAGT 278979 22 545355 923 290421 22 545356 926 290424 22 545357 929 EXOn7 AGTGTTACATAGAGCA eekddddddddddkke 70 290427 22 545362 1124 Ex‘gflgétfg‘gng TCCTTGAGGAGATCTG eekddddddddddkke 3 n/a 22 545363 1170 297587 22 545364 1180 297597 22 545369 1320 297737 22 545370 1328 297745 22 545371 1332 297749 22 545373 1418 Ex0n10 GCAACCTCTG 297835 22 545374 1422 Exon 10 CTGTGGCTGAGCAACC eekddddddddddkke 63 297839 22 545380 1524 297941 22 545381 1530 297947 22 545382 1533 297950 22 545386 1600 298017 22 545387 1613 298030 22 545388 1645 298062 22 945292 1922 299249 22 Table 65 Inhibition of GHR mRNA by deoxy, MOE and cEt gapmers targeting intronic and exonic regions of SEQ ID NOS: 1 and2 Sequence try.

NO: 2 SEQ ID N1 inhibition Start 541262 Intr0n2 TTGGTTTGTCAATCCT dddddddkke 89 156891 1370 545393 Exon 10 GATTCAACCTTGATGT eekddddddddddkke 40 298255 2232 545394 Exon 10 ATGTGTGATTCAACCT eekddddddddddkke 80 298261 2233 545395 TGGGACAGGCATCTCA eekddddddddddkke 29 298373 2234 545396 TAGTCTGGGACAGGCA eekddddddddddkke 48 298378 2235 545397 GGAGGTATAGTCTGGG eekddddddddddkke 61 298385 2236 298403 2237 298494 2238 545402 2095 Exon 10 GCTAAGGCATGATTTT eekddddddddddkke 53 298512 2239 545406 2665 Exon 10 GCCATGCTTGAAGTCT eekddddddddddkke 87 299082 2240 545407 2668 Exon 10 ATAGCCATGCTTGAAG eekddddddddddkke 70 299085 2241 545408 2692 Exon 10 ACACAGTGTGTAGTGT eekddddddddddkke 60 299109 2242 545409 2699 Exon 10 CTGCAGTACACAGTGT eekddddddddddkke 31 299116 2243 545410 2704 Exon 10 TGCAGTACAC eekddddddddddkke 57 299121 2244 545411 2739 Exon 10 TAGACTGTAGTTGCTA dddddddkke 53 299156 2245 545412 2747 Exon 10 ACCAGCTTTAGACTGT eekddddddddddkke 56 299164 2246 545413 2945 Exon 10 GTAAGTTGATCTGTGC eekddddddddddkke 79 299362 2247 545414 2963 Exon 10 TACTTCTTTTGGTGCC eekddddddddddkke 82 299380 2248 545416 3212 Exon 10 TCTTGTACCTTATTCC eekddddddddddkke 73 299629 2249 545417 3306 Exon 10 TGGTTATAGGCTGTGA eekddddddddddkke 90 299723 2250 545418 3309 Exon 10 GTCTGGTTATAGGCTG eekddddddddddkke 88 299726 2251 545419 3313 Exon 10 ATGTGTCTGGTTATAG eekddddddddddkke 68 299730 2252 545420 3317 Exon 10 GAGTATGTGTCTGGTT eekddddddddddkke 84 299734 2253 545421 4049 Exon 10 CGATAAATGG dddddddkke 69 300466 2254 545429 4424 Exon 10 GCCAGACACAACTAGT eekddddddddddkke 59 300841 2255 545430 31 Exonl ACCGCCACTGTAGCAG eekddddddddddkke 76 2907 2256 545431 36 Exonl CCGCCACCGCCACTGT eekddddddddddkke 94 2912 2257 545432 103 Exonl GGGCCTCCGGCCCGCG eekddddddddddkke 22 2979 2258 545433 143 Exonl AGAGCGCGGGTTCGCG eekddddddddddkke 61 3019 2259 545434 n/a $351131 TACTGACCCCAGTTCC eekddddddddddkke 68 3654 2260 545435 n/a JESSE] ACTCTACTGACCCCAG eekddddddddddkke 70 3658 2261 545436 n/a #3331131 GTCACTCTACTGACCC eekddddddddddkke 83 3661 2262 545437 n/a $23531 TTCATGCGGACTGGTG eekddddddddddkke 68 3680 2263 545438 n/a 523311113 GTGAGCATGGACCCCA eekddddddddddkke 94 225436 2264 545439 JESS; TGATATGTGAGCATGG eekddddddddddkke 225442 2265 545440 #23:; AAGTTGGTGAGCTTCT eekddddddddddkke 226785 2266 545441 33 CCTTCAAGTTGGTGAG eekddddddddddkke 226790 2267 545442 #2351112 GTAAGATCCTTTTGCC eekddddddddddkke 226883 2268 545443 n/a 3123:1133 CAGCTGTGCAACTTGC eekddddddddddkke 50 238345 2269 545444 n/a 3}];13333 GCCTTGGTAGGTAGGG eekddddddddddkke 68 238422 2270 545445 n/a 523:; AGAGCCTTGGTAGGTA eekddddddddddkke 85 238425 2271 545446 31 CCCGCACAAACGCGCA eekddddddddddkke 3614 2272 545447 JESS; AAGGTCAGTT eekddddddddddkke 93208 2273 545448 n/a JESSE] GCCCAGTGAATTCAGC dddddddkke 76 93246 2274 545449 JESS; AGATGCGCCCAGTGAA eekddddddddddkke 93252 2275 545450 1 GTAAGATGCGCCCAGT eekddddddddddkke 93255 2276 545451 n/a JESSE] CCAGAAGGCACTTGTA eekddddddddddkke 42 93301 2277 545452 n/a $351131 GGAAGATTTGCAGAAC eekddddddddddkke 15 93340 2278 545453 n/a 523311111 CCTTGGTCATGGAAGA eekddddddddddkke 35 93350 2279 545454 n/a $3331 TGACCTTGGTCATGGA eekddddddddddkke 55 93353 2280 545455 n/a $300113] GAGGTGACCTTGGTCA eekddddddddddkke 70 93357 2281 545456 n/a JESSE] ATCCAAAGAGGTGACC eekddddddddddkke 41 93364 2282 545457 n/a $30031 GCCAATCCAAAGAGGT dddddddkke 56 93368 2283 545458 n/a $331131 GGTCTGCCAATCCAAA eekddddddddddkke 79 93373 2284 545459 $331131 CCCTGGGTCTGCCAAT dddddddkke 93378 2285 545460 $300113] GAGATCTCAACAAGGG eekddddddddddkke 93427 2286 545461 JESSE] CGCCCATCACTCTTCC eekddddddddddkke 93988 2287 545462 n/a $30031 CACCTGTCGCCCATCA eekddddddddddkke 67 93995 2288 545463 n/a JESSE] CATCACCTGTCGCCCA eekddddddddddkke 78 93998 2289 545464 523311111 CACCATCACCTGTCGC eekddddddddddkke 94001 2290 545465 JESS; AATAGTTGTCACCATC eekddddddddddkke 94010 2291 545466 n/a 123311111 GCCACCTTTCATGAGA eekddddddddddkke 58 94048 2292 545467 n/a 511313311112 CTCTTGGAAGTAGGTA eekddddddddddkke 89 198762 2293 545468 n/a 523511112 GTTCTCTTGGAAGTAG eekddddddddddkke 80 198765 2294 545469 n/a ”12:31:12 GGTTGGTCTG dddddddkke 68 198854 2295 Example 8: Dose-dependent antisense inhibition of human GHR in Hep3B cells by deoxy, MOE and cEt gapmers Gapmers from studies bed above exhibiting significant in vitro inhibition ofGHR mRNA were selected and tested at various doses in Hep3B cells. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.625 “M, 1.25 “M, 2.50 “M, 5.00 MM and 10.00 uM concentrations of antisense oligonucleotide. After a treatment period of approximately 16 hours, RNA was ed from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Human primer probe set 7_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by EEN®. s are presented as percent inhibition of GHR, relative to ted control cells.

The half maximal inhibitory concentration (ICSO) of each oligonucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

Table 66 -0625 1250 250 500 1000 1C50 ISIS No HM HM HM HM HM (HM) 541396 541262 541393 30 38 52 66 2.1 541375 41 45 54 64 1.6 541438“um-m 541428 541491 13 46 67 55 541435 46 55 72 541471 541430 541492 541431 Table 67 0.625 1.250 2.50 5.00 10.00 NM NM NM NM NM (NM) -541487m --M ---M ---M -541539m 541503 54 65 80 93 97 0.5 541520 - 541564 541554 541585 70 0.625 1:130 2.50 5.00 10. 00 500 N100 1818110 ”B4 “B4 541748 98 98 541767 96 98 541797 97 99 541766 97 99 541742 95 99 541750 96 99 541262 97 97 541749 95 98 541793 97 98 541785 93 98 541746 94 97 WO 02971 541752 49 72 88 93 93 <06 —«IlliilllllliilllllllllllIIIIIIII IIEIIEIIIIllliillllllliilllIllliillllllliilllIllllllllliilfill Table 70 ISIS No 541822 541870 541262 541873 541819 541841 541825 541863 541827 541875 541835 541838 541833 . 541813 47 75 86 95 97 <06 Table 71 0625 1250 250 500 1000 1C5C I$SNO uMi uMi uMi uMi uMi (MM) 541853 74 79 88 93 91 <06 541842 69 85 91 97 99 <06 541877 79 91 93 98 97 <06 541848 58 90 96 98 98 07 541804 23 81 89 95 95 08 541881 87 94 98 98 99 <06 541936 91 96 98 99 98 <06 541909 56 80 89 95 97 <06 541907 75 91 95 97 98 <06 541952 68 81 93 97 98 <06 541953 68 80 94 97 98 <06 541914 60 78 94 97 97 <06 541880 56 74 89 94 95 <06 541903 37 74 87 96 98 (16 W0 02971 PCT/USZOl4/045088 Table 72 0.625 1.250 2.50 5.00 10.00 1C50 ISIS N0 11M 11M 11M 11M 11M (11M) 541895 47 72 85 93 94 <06 541882 60 67 89 93 97 <06 541889 63 80 87 94 97 <06 541904 26 78 23 89 93 1.4 545418 0 81 91 94 95 1.7 541930 58 71 82 88 92 <06 545439 67 87 93 96 98 <06 542024 15 58 78 87 90 1.4 541985 59 81 88 93 97 <06 541972 47 58 83 90 92 0.6 541991 57 64 88 92 83 <06 541980 33 50 76 72 93 1.2 Table 73 0.625 1.250 2.50 5.00 10.00 ISIS No 11M 11M 11M 11M 1.1M 541264 26 ——79 m 541265 29 32 62 79 91 541263 25 40 62 78 93 541268 57 73 541266 15 33 542107 93 97 542052 93 96 542105 80 92 542102 94 96 542108 90 92 542080 87 93 Table 74 -----0.625 1.250 2.50 5.00 10.00 IC50 ISIS N0 542101 90 97 97 97 95 <0.6 542051 89 96 95 98 97 <0.6 542106 83 93 96 96 98 <0.6 542071 84 91 94 97 97 <0.6 --85 mm 542069 89 94 97 95 98 <06 542086mm 542085----M 542053 64 83 94 98 97 <0.6 542087 69 84 99 95 98 <0.6 542162—mmm 542126 “mumm— 542127 94 96 97 98 542128 90 96 98 98 Table 75 0.625 1.250 2.50 5.00 10.00 ISIS N0 ”M ”M ”M ”M ”M 542118 542186 -542156—mmm 542122“—M -542125 88 <0.6 542145 90 <0.6 -542112m-“mm -54216———m -25mm 542112 —————m -542137 76 91 97 97 98 <0.6 542152 94 96 96 97 mmm Table 76 0.625 1.250 2.50 5.00 10.00 IC50 ISIS NO NM NM NM NM NM (NM) 542185 82 93 96 96 94 <0.6 542143 81 91 96 98 98 <0.6 542144 77 93 95 96 99 <0.6 542139 87 93 98 98 98 <0.6 542134 83 90 90 95 96 <0.6 545333 68 85 91 96 98 <0.6 545373 57 73 86 92 97 <0.6 545438 84 96 98 97 99 <0.6 545431 77 91 93 97 98 <0.6 545447 70 85 96 96 97 <0.6 545417 62 82 90 93 95 <0.6 545467 77 88 91 94 95 <0.6 WO 02971 Example 9: Dose-dependent antisense inhibition of human GHR in Hep3B cells by deoxy, MOE and cEt gapmers Gapmers from studies described above exhibiting significant in vitro inhibition ofGHR mRNA were selected and tested at various doses in Hep3B cells. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are ted in separate tables shown below. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.04 MM, 0.11 “M, 0.33 “M, 1.00 MM, and 3.00 “M concentrations of antisense oligonucleotide. After a treatment period of approximately 16 hours, RNA was ed from the cells and GHR mRNA levels were measured by tative real-time PCR. Human primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to untreated control cells.

The half maximal inhibitory concentration (IC50) of each oligonucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in nse oligonucleotide treated cells.

Table 77 0.04 0.11 0.33 1.00 3.00 1C50 “M “M “M “M “M (HM) 539380---“ 541724n”.- 541748 28 40 71 90 97 0 1 541767 38 54 87 98 541797 544555 —————m 544545 544555“mm 541826 541811 541822 wo 2015/002971 Table 78 0.04 1.00 3.00 1C ISIS N0 0.11 ”M 0.33 11M 11M MM MM ) 539380 0 16 47 82 98 0.4 541819 3 12 50 76 94 0.3 541841 0 19 47 80 95 0.3 541825 0 6 40 74 96 0.4 541827 5 26 48 76 95 0.3 541835 7 11 33 74 93 0.4 541838 21 26 61 90 97 0.2 541833 0 9 41 63 89 0.5 541813 0 17 28 65 92 0.5 541842 5 15 30 72 90 0.4 541804 0 12 3 49 79 1.1 542024 0 0 26 54 76 1.0 542107 15 45 78 92 99 0.1 542105 2 14 55 88 98 0.3 542102 10 16 73 88 98 0.2 Table 79 539380 542108 542101 542106 542094 542086 n--mm ----m-- ----M“ mun-mm Table 80 -u(1:\)/I 0 11 033 100 300 1c HM HM HM (HM) 539380 38 61 37 63 34 Table 81 0.33 1.00 3.00 IC50 M M M M 539380 64 541870 48 8O 92 0.3 541262 O\] 63 90 98 0.2 I541863 40 541875 71 84 91 0.2 541853 000 39 541877 41 541881 54 541936 [\J00 73 93 98 0.1 541909 34 64 90 0.5 541907 00 59 541952 0 O 50 541953 CO 50 80 92 0.4 541914 46 76 93 0.4 541880 O 48 Table 82 ISIS No u-M HM uM HM HM (HM) 12 “- 27 "m- 541889 12 12 47 68 87 0.4 -541930 -541985 542031 541972 -541991 542080 542051 542071 542069 Table 83 0.04 0.11 0.33 1.00 3.00 1C50 ISIS N0 “M “M “M “M “M (HM) 539380 11 20 54 89 92 0.3 542053“nu-m 542186mm“2 542185 Inn-an“3 545333“mmm 545336 15 24 43 79 0.9 545373 2 9 42 86 1.0 545438n---- 545431 0-4 545447n---4 545417 nun-m5 545467 4 545441----m_m 545439 3 Example 10: Dose-dependent antisense inhibition of rhesus monkey GHR in LLC-MKZ cells Gapmers from studies described above exhibiting significant in vitro inhibition ofGHR mRNA were selected and tested for their potency for rhesus GHR mRNA in LLC-MK2 cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.12 MM, 0.37 MM, 1.11 11M, 3.33 MM, and 10.00 uM concentrations of antisense oligonucleotide. After a treatment period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real—time PCR. Primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as ed by RIBOGREEN®. s are presented as percent tion of GHR, relative to untreated control cells.

The half maximal inhibitory concentration (ICSO) of each ucleotide is also presented. GHR mRNA levels were significantly reduced in a ependent manner in antisense oligonucleotide treated cells.

Table 84 ISIS . 0.12 0.37 1.11 3. 33 1000 ICCC Chem” No M M M MS—Mml Deoxy’ “OE and 541262 9 25 42 541742 136°“;ng and 0 24 19 58 77 3.2 541767 DCOXY’CEPE and 6 10 30 68 541875 136°“;ng and 7 19 64 84 n" 541881 Deoxy’sE/[PE and 6 24 59 79 542112 136°“;ng and 5 17 33 67 542125 138°“;ng and 0 12 57 83 Deoxy’ VICE and 542127 1 84 2.4 Deoxy’ “OE and 542128 12 83 2.7 Deoxy’ “OE and 542153 4 59 6.6 542186 139°“;ng and 15 23 51 73 “- Deoxy’ VICE and 542051 5 19 40 81 94 1 2 Table 85 CW ChCmCC 9M0 523723 5105 MOE 532254 5—10—5 MOE 532401 55 MOE 533932 55 MOE 539376 3104 MOE 21 8 8 35 81 4.3 539399 34 MOE 2 10 14 18 57 8.3 539404 34 MOE 539416 34 MOE 539432 34 MOE Deoxy, MOE 541262 and cEt Deoxy, MOE 541742 and cEt Deoxy, MOE 541767 and cEt Deoxy, MOE 545439 and cEt Deoxy’ MOE 545447 25 34 58 80 90 0.6 and cEt Example 11: Dose-dependent antisense inhibition of GHR in cynomolgus primary hepatocytes Gapmers from studies described above exhibiting significant in vitro inhibition ofGHR mRNA were ed and tested for their potency for GHR mRNA in cynomolgus monkey primary hepatocytes. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.12 MM, 0.37 MM, 1.11 MM, 3.33 ”M, and 10.00 uM concentrations of antisense oligonucleotide. After a treatment period of approximately 16 hours, RNA was ed from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are ted as percent inhibition of GHR, ve to ted control cells.

The half maximal inhibitory concentration (ICSO) of each oligonucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense ucleotide treated cells.

Table 86 . 0.12 0.37 111 1000 ISIS No Chemlst 1M 1M 1M 1M (1M) Dew/MOE 541262 40 52 0.3 and cEt 541742 40 57 51 91 96 0.2 541767 36 59 6O 78 91 0.4 541881 53 75 85 98 98 <0.1 542101 38 55 78 89 0.2 542112 Deoxy, VIOE 28 50 74 89 96 0.4 Deoxy, VIOE 542118 20 ancht Deoxy,\/[OE 542125 33 and CE: 542127 542128 542153 542185 542186 542051 Table87 . 0.12 0.37 1.11 3.33 10.00 ICSO ISIS N0 Chemlstry M M M M M 55 523435 35 47 74 85 0.5 523723 4 16 40 66 86 1.8 532254 14 15 24 16 9 >10 55 532401 37 54 88 94 0.3 533932 23 40 69 78 86 0.6 539376 3 0 44 65 91 2.0 34 34 34 539416 8 29 89 93 0.7 539432 0 24 55 85 93 0.9 541262 23 52 73 92 96 0.4 Deoxy, 541742 MOE and 15 51 73 86 97 0.5 Deoxy, 541767 MOE and 19 20 39 68 81 1.8 WO 02971 Deoxy, 545439 MOE and 30 61 2.4 Deoxy, 545447 MOE and 17 17 19 27 >10 Example 12: Dose-dependent antisense inhibition of GHR in Hep3B cells Gapmers from studies described above exhibiting significant in vitro inhibition ofGHR mRNA were selected and tested for their y for GHR mRNA at various doses in Hep3B cells. Cells were plated at a density of 20,000 cells per well and transfected using oporation with 0.12 MM, 0.37 MM, 1.11 uM, 3.33 MM, and 10.00 uM concentrations of antisense oligonucleotide. After a ent period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were ed by quantitative real-time PCR. Human primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to untreated control cells.

The half maximal inhibitory concentration (ICSO) of each ucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

Table 88 012 037 111 333 1000 1C 412°) 88 97 ----541767 29 56 83 97 --“-541875 38 00 4: 0 U) 94 ----541881 32 U] \1 oo ._. O4; 97 --n-542051 34 00 U) 0 kl] ----542101 25 U] £11 00 U] 0 £11 ----542112 18 U] 0\ 00 U) G Ll] ----542118 42 95 ----542125 30 O\ U) 00 \l 0 kl] ----542127 50 \]O O)—| O._i ----542128 38 O\ U) 00 00 ----542153 37 m0 00 an O4; ----542185 44 Ell 4—1 \1 O\ ----542186 46 U]0 oo 4; 0 UI 9.093399999999990 HNNNHNH$WNWHWUJM Table 89 01Mz . 1.11 3.31; 1000 ISISN 1M (1M) 523723 39 1.4 539376 54 73 86 0.8 539399 72 89 94 0.5 541767 22 74 85 92 0.4 545439 88 95 96 0.1 545447 63 74 82 Example 13: ependent antisense inhibition of GHR in cynomolgus primary hepatocytes Gapmers from studies described above ting significant in vitro inhibition ofGHR mRNA were ed and tested at s doses in lgous monkey primary hepatocytes. Cells were plated at a density of 35,000 cells per well and transfected using electroporation with 0.04 MM, 0.12 MM, 0.37 11M, 1.11 MM, 3.33 MM, and 10.00 11M concentrations of antisense oligonucleotide. After a treatment period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of GHR, relative to ted control cells.

The half maximal inhibitory concentration (ICSO) of each oligonucleotide is also presented. GHR mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

Table 90 -0.04uM 0.12uM 0.37uM 1.11uM 3.33 uM 10310 ------n 541875 ———m—— --—---m- ———————m ———————n Example 14: Comparative analysis of dose-dependent antisense inhibition of GHR in Hep3B cells ISIS 532401 was compared with specific antisense oligonucleotides disclosed in US 2006/0178325 by testing at various doses in Hep3B cells. The oligonucleotides were selected based on the potency trated in studies described in the application. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 0.11 MM, 0.33 MM, 1.00 MM, 1.11 MM, 3.00 MM, and 9.00 MM trations of antisense oligonucleotide. After a ent period of approximately 16 hours, RNA was isolated from the cells and GHR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3437_MGB was used to measure mRNA levels. GHR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are ted as percent inhibition of GHR, relative to untreated control cells.

The half l inhibitory concentration (ICSO) of each oligonucleotide is also presented. The results indicate that ISIS 532401 was markedly more potent than the most potent oligonucleotides of US 2006/0178325.

Table 91 . . 1.00 3. 00 9. 00 ISIS No HM (HM) 227452 46 73 92 227488 39 272309 39 1. 6 ——fi272322 13 2O 44 Example 15: bility of 55 MOE gapmers targeting human GHR in CD1 mice CD1® mice (Charles River, MA) are a multipurpose mice model, frequently utilized for safety and efficacy testing. The mice were treated with ISIS antisense oligonucleotides ed from studies described above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment Groups of eight— to ten-week old male CD1 mice were injected subcutaneously twice a week for 6 weeks with 50 mg/kg of ISIS oligonucleotides (100 mg/kg/week dose). One group of male CD1 mice was ed subcutaneously twice a week for 6 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were ted for further analysis.

Plasma chemistry markers To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, creatinine, and BUN were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, le, NY). The results are presented in Table 92. ISIS oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 92 Plasma chemistry markers in CD1 mice plasma at week 6 ALT AST bin Creatinine BUN (IU/L) (IU/L) (mg/dL) (mg/dL) (mg/dL) PBS 31 50 0.28 0.15 28 ISIS 523604 2106 1157 0.41 0.06 48 logy assays Blood obtained from all mice groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as measurements of the various blood cells, such as WBC, RBC, and platelets, and total hemoglobin content. The results are presented in Table 93. ISIS oligonucleotides that caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 93 Hematology markers in CD1 mice plasma at week 6 HCT Hemoglobin RBC WBC ets (%) (g/dL) (106mm (103mm (103mm PBS 45 13 ISIS 523271 42 12 ISIS 523324 39 11 ISIS 523604 33 10 ISIS 532254 35 10 ISIS 533121 39 12 ISIS 533161 49 14 9 3 9.0 607 ISIS 533178 44 13 8.5 6.9 765 ISIS 533234 42 12 Example 16: Tolerability of 55 MOE gapmers targeting human GHR in CD1 mice CD1® mice were treated with ISIS antisense oligonucleotides selected from studies described above and evaluated for changes in the levels of s plasma chemistry markers.

Treatment Groups of eight— to ten-week old male CD1 mice were ed subcutaneously twice a week for 6 weeks with 50 mg/kg of ISIS oligonucleotide (100 mg/kg/week dose). One group of male CD1 mice was injected subcutaneously twice a week for 6 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further analysis.

Plasma chemistry markers To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, creatinine, and BUN were measured using an automated clinical chemistry er (Hitachi s , Melville, NY). The results are presented in Table 94. ISIS oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 94 Plasma chemistry markers in CD1 mice plasma at week 6 (TU/L) (IU/L) (mg/dL) (mg/dL) (mg/dL) PBS 30 59 ISIS 523715 636 505 ISIS 523723 57 80 ISIS 523726 165 167 ISIS 523736 140 177 ISIS 523747 96 108 ISIS 523789 45 74 ISIS 532395 64 111 ISIS 532401 47 88 ISIS 532411 225 426 ISIS 532420 60 99 ISIS 532468 319 273 0.15 0.14 21 ISIS 533932 62 81 0.18 0.14 21 Hematology assays Blood obtained from all mice groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as ements of the various blood cells, such as WB), RBC, and platelets, and total hemoglobin content. The results are presented in Table 95. ISIS oligonucleotides that caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 95 logy markers in CD1 mice plasma at week 6 HCT RBC WBC ets (%) (g/dL) (10mm) (103/uL) (103mm PBS 43 3.3 1047 ISIS 523715 40 4.2 1153 ISIS 523723 35 11 2.9 1154 ISIS 523726 32 10 6.8 5.8 1056 ISIS 523736 35 3.6 1019 ISIS 523747 37 11 7.7 2.8 1146 ISIS 523789 37 2.5 1033 ISIS 532395 37 11 7.4 4.5 890 ISIS 532401 36 3.7 1175 ISIS 532411 27 8 5.3 3.2 641 ISIS 533932 36 1 1 7.2 3 .8 981 Example 17: Tolerability of 34 MOE gapmers targeting human GHR in CD1 mice CD1® mice were treated with ISIS antisense ucleotides selected from studies described above and ted for changes in the levels of various plasma chemistry markers.

Groups of eight— to ten-week old male CD1 mice were injected subcutaneously twice a week for 6 weeks with 50 mg/kg of ISIS oligonucleotide (100 mg/kg/week dose). One group of male CD1 mice was injected subcutaneously twice a week for 6 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further analysis.

Plasma chemistry markers To te the effect of ISIS ucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, creatinine, and BUN were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, NY). The results are presented in Table 96. ISIS oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 96 Plasma chemistry markers in CD1 mice plasma at week 6 ALT AST Bilirubin Creatinine BUN (IU/L) (IU/L) (mg/dL) (mg/dL) ) 63 0.20 0.13 28 192 0.15 0.15 24 455 0.17 0.12 27 3287 2495 0.58 0.13 22 226 0.17 0.11 21 75 0.14 0.12 27 136 0.16 0.13 24 188 0.14 0.12 23 _m-81 0.15 0.12 25 127 0.13 0.12 24 1172 0.24 0.11 24 1818539403 1543 883 0.18 0.12 26 109 0.16 0.13 23 ——_——- ISIS 539433 0.12 0.13 Hematology assays Blood obtained from all mice groups were sent to Antech stics for hematocrit (HCT) measurements and analysis, as well as measurements of the various blood cells, such as WBC, RBC, and platelets, and total hemoglobin content. The results are presented in Table 97. ISIS ucleotides that caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 97 Hematology markers in CD1 mice plasma at week 6 HCT Hemoglobin RBC WBC Platelets % ; dL 106/ L 103/ L 103/ L PBS 46 13 8.5 6 954 ISIS 539302 40 11 8.1 13 830 ISIS 539321 39 11 7.8 16 723 ISIS 539360 49 14 9.0 14 671 ISIS 539361 45 13 8.5 9 893 ISIS 539376 42 12 7.7 6 988 ISIS 539379 42 12 8.1 7 795 ISIS 539380 38 10 7.7 8 950 ISIS 539383 45 12 8.4 8 795 ISIS 539399 41 12 8.0 10 895 ISIS 539401 41 11 8.2 9 897 ISIS 539403 33 9 6.2 13 1104 ISIS 539404 42 12 8.4 7 641 ISIS 539416 41 11 7.5 5 686 ISIS 539432 44 12 8.0 6 920 ISIS 539433 40 11 7.4 6 987 e 18: Tolerability of deoxy, MOE and cEt gapmers targeting human GHR in CD1 mice CD1® mice were treated with ISIS antisense oligonucleotides selected from studies described above and evaluated for changes in the levels of s plasma chemistry markers.

Treatment WO 02971 Groups of eight— to ten-week old male CD1 mice were injected subcutaneously twice a week for 6 weeks with 25 mg/kg of ISIS ucleotide (50 mg/kg/week dose). One group of male CD1 mice was injected subcutaneously twice a week for 6 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further analysis.

Plasma chemistry markers To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of minases, bilirubin, creatinine, and BUN were measured using an automated clinical chemistry er (Hitachi Olympus AU400e, le, NY). The results are presented in Table 98. ISIS ucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 98 Plasma chemistry markers in CD1 mice plasma at week 6 ALT AST Bilirubin Creatinine BUN (IU/L) (IU/L) (mg/dL) (mg/dL) (mg/dL) PBS 36 71 ISIS 541748 269 582 ISIS 541749 626 491 ISIS 541750 1531 670 ISIS 541766 2107 1139 ISIS 541767 42 62 ISIS 541822 493 202 ISIS 541838 266 172 272 ISIS 541875 1 03 114 ISIS 541907 940 725 ISIS 541991 1690 1733 Hematology assays Blood obtained from all mice groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as measurements of the various blood cells, such as WBC, RBC, and platelets, and total hemoglobin content. The results are presented in Table 99. ISIS oligonucleotides that WO 02971 caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in further s.

Table 99 Hematology markers in CD1 mice plasma at week 6 HCT RBC WBC Platelets (%) (g/dL) (106mm (103mm (103mm PBS 37 3 1083 ISIS 541262 38 6 1010 ISIS 541724 52 9 940 ISIS 541742 47 _n 6 1134 ISIS 541748 41 _.- 7 941 ISIS 541749 41 _“ 5 1142 ISIS 541750 42 _“ 4 1409 ISIS 541766 39 7 989 ISIS 541767 46 _n 2 994 ISIS 541822 42 12 3 1190 ISIS 541826 41 12 8 10 1069 ISIS 541838 44 _“ 6 1005 ISIS 541870 38 8 1020 ISIS 541875 44 13 6 1104 ISIS 541907 40 11 8 9 1271 ISIS 541991 34 _n 6 1274 e 19: bility 0f deoxy, MOE and cEt gapmers targeting human GHR in CD1 mice CD1® mice were treated with ISIS antisense oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma chemistry markers. The 34 MOE gapmer ISIS 539376 was also included in the study.

Treatment Groups of eight— to ten-week old male CD1 mice were injected subcutaneously twice a week for 6 weeks with 25 mg/kg of ISIS oligonucleotide (50 mg/kg/week dose). One group of male CD1 mice was injected subcutaneously twice a week for 6 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further is.

Plasma chemistry markers To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, creatinine, and BUN were measured using an automated clinical chemistry analyzer (Hitachi s AU400e, Melville, NY). The results are presented in Table 100. ISIS oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 100 Plasma try markers in CD1 mice plasma at week 6 (IUL/L) (IU/L) (mg/dL) (mg/dL) (mg/dL) —___- _———- ISIS 542086 137 133 0.24 0.10 23 _———- ISIS 539376 0.27 008 Hematology assays Blood obtained from all mice groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as measurements of the various blood cells, such as WBC, RBC, and total hemoglobin content. The s are presented in Table 101. ISIS oligonucleotides that caused changes in the levels of any of the hematology markers e the expected range for antisense oligonucleotides were excluded in further studies.

Table 101 Hematology s in CD1 mice plasma at week 6 HCT Hemoglobin RBC WBC (%) (g/dL) (10mm) (103mm PBS 46 13 8 6 ISIS 541881 53 15 10 7 ISIS 541936 41 11 8 18 ISIS 542051 49 14 9 8 ISIS 542052 46 13 9 9 ISIS 542069 43 13 8 7 ISIS 542085 38 11 7 5 ISIS 542086 49 14 9 9 ISIS 542094 36 10 6 5 ISIS 542101 44 13 9 5 ISIS 542102 27 7 5 25 ISIS 542105 42 12 8 7 ISIS 542106 37 10 7 14 ISIS 542107 41 12 7 17 ISIS 542108 51 14 8 10 ISIS 539376 49 14 10 5 e 20: Tolerability 0f deoxy, MOE and cEt gapmers targeting human GHR in CD1 mice CD1® mice were treated with ISIS antisense oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma try markers.

Treatment Groups of eight— to ten—week old male CD1 mice were injected subcutaneously twice a week for 6 weeks with 25 mg/kg of ISIS oligonucleotide (50 mg/kg/week dose). One group of male CD1 mice was injected subcutaneously twice a week for 6 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further analysis.

Plasma chemistry s To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, creatinine, and BUN were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, NY). The results are presented in Table 102. ISIS oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 102 Plasma try markers in CD1 mice plasma at week 6 (IU/L) (IU/L) (mg/dL) ) (mg/dL) ISIS 542109 —“-é-&—-ISIS 542112 WO 02971 2014/045088 ISIS 542122 350 0.3 0.16 27 ISIS 542125 92 0.2 0.13 26 ISIS 542126 381 398 0.5 0.14 23 ISIS 542127 54 85 0.3 0.16 26 ISIS 542128 89 0.2 0.12 24 ISIS 542145 671 0.3 0.11 24 ISIS 542146 163 107 0.2 0.14 30 ISIS 542149 974 752 0.3 0.12 26 ISIS 542150 2840 2126 2.4 0.17 23 ISIS 542153 53 75 0.2 0.14 28 ISIS 542157 137 122 0.3 0.13 25 ISIS 542185 57 72 0.2 0.11 23 ISIS 542186 84 0.2 0.12 24 ISIS 545431 1375 3.0 0.15 28 ISIS 545438 1000 0.3 0.14 26 ISIS 545439 117 0.2 0.12 28 ISIS 545447 141 108 0.3 0.13 26 Hematology assays Blood obtained from all mice groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as measurements of the various blood cells, such as WBC, RBC, and total hemoglobin content. The results are presented in Table 103. ISIS oligonucleotides that caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 103 Hematology markers in CD1 mice plasma at week 6 HCT obin RBC WBC Platelets (%) (g/dL) (106/0L) (103/uh) (103/0L) PBS mm1210 ISIS 542109mm 1244 ISIS 542112mm 1065 ms 542118 -_---I mo ISIS 542122 1064 ISIS 542125mm 1063 ISIS 542126 -__n 1477 1515542127 1144 1818542128mm 1196 ISIS 542145 -_-_-_ 1305 ISIS 542146 45 13 8 7 1310 —-—-.-903 1515542153 46 13 n- 1130 —-_--1031 —-—nl-985 ISIS 545431 28 7 13 2609 ISIS 545447 45 13 9 964 Example 21: Tolerability of MOE gapmers targeting human GHR in Sprague-Dawley rats Sprague-Dawley rats are a multipurpose model used for safety and efficacy evaluations. The rats were treated with ISIS antisense oligonucleotides from the studies described in the Examples above and evaluated for changes in the levels of various plasma chemistry s.

Male Sprague-Dawley rats were maintained on a 12-hour light/dark cycle and fed ad libitum with Purina normal rat chow, diet 5001. Groups of 4 Sprague—Dawley rats each were injected subcutaneously twice a week for 6 weeks with 50 mg/kg of ISIS oligonucleotide (100 mg/kg weekly dose). Forty eight hours after the last dose, rats were euthanized and organs and plasma were ted for r analysis.

Liverfunction To evaluate the effect of ISIS oligonucleotides on hepatic function, plasma levels of transaminases were measured using an automated al chemistry analyzer (Hitachi Olympus AU400e, Melville, NY).

Plasma levels of ALT (alanine transaminase) and AST tate transaminase) were measured and the results are presented in Table 104 expressed in IU/L. Plasma levels of bilirubin were also measured using the same clinical chemistry er and the results are also presented in Table 104 expressed in mg/dL. ISIS oligonucleotides that caused changes in the levels of any markers of liver function outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 104 Liver function markers in Sprague-Dawley rats AST Bilirubin (IU/L) (mg/dL) 90 0.15 ISIS 523723 123 0.12 ISIS 523789 105 0.15 ISIS 532254 97 0.14 ISIS 532401 77 0.12 ISIS 532420 127 0.17 ISIS 533178 219 0.34 ISIS 533234 90 0.11 ISIS 533932 81 0.12 ISIS 539376 101 0.14 ISIS 539380 128 0.16 ISIS 539383 94 0.14 ISIS 539399 95 0.14 ISIS 539404 118 0.13 ISIS 539416 104 0.14 ISIS 539432 90 0.13 ISIS 539433 92 0.13 Kidneyfunction To evaluate the effect of ISIS oligonucleotides on kidney function, plasma levels of blood urea nitrogen (BUN) and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, le, NY). s are presented in Table 105, expressed in mg/dL. ISIS oligonucleotides that caused changes in the levels of any of the kidney function markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 105 Kidney on markers (mg/dL) in Sprague-Dawley rats Creatinine PBS 0.32 ISIS 523723 20 0.39 ISIS 523789 19 0.37 ISIS 532254 0.43 ISIS 532401 0.36 ISIS 532420 20 0.31 ISIS 533178 20 0.43 ISIS 533234 0.41 ISIS 533932 0.43 ISIS 539376 19 0.36 ISIS 539380 18 0.35 ISIS 539383 0.35 ISIS 539399 0.39 ISIS 539404 0.39 ISIS 539416 _0.39 ISIS 539432 ISIS 539433 20 0.34 Hematology assays Blood obtained from all rat groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as measurements of the s blood cells, such as WBC, RBC, and total hemoglobin t. The results are presented in Table 106. ISIS oligonucleotides that caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in r studies.

Table 106 logy markers in Sprague-Dawley rats HCT Hemoglobin RBC WBC Platelets % dL 106/ L 103/ L 103/ L PBS 46 15 8 11 1078 ISIS 523723 38 12 7 19 626 ISIS 523789 38 12 8 12 702 ISIS 532254 36 12 7 11 547 ISIS 532401 42 14 8 12 858 ISIS 532420 37 12 7 17 542 ISIS 533178 37 12 7 15 1117 ISIS 533234 38 12 7 8 657 ISIS 533932 40 13 7 9 999 ISIS 539376 43 14 9 8 910 ISIS 539380 33 11 5 6 330 ISIS 539383 39 13 7 10 832 ISIS 539399 37 11 7 4 603 ISIS 539404 37 12 7 6 639 ISIS 539416 33 11 6 9 601 ISIS 539432 44 14 9 10 810 ISIS 539433 38 12 7 9 742 Organ weights Liver, heart, spleen and kidney weights were measured at the end of the study, and are presented in Table 107. ISIS oligonucleotides that caused any changes in organ weights outside the expected range for antisense oligonucleotides were excluded from filrther studies.

Table 107 Organ weights (g) Heart Liver Spleen Kidney ISIS 523723 ISIS 523789 “in 1s1ss324m msssmo 1.0 ISIS 533178 0.34 5.2 0.7 0.9 ISIS 533234 0.30 4.4 0.6 1.0 ISIS 533932 ISIS 539376 ISIS 539380 ISIS 539383 0.31 4.5 0.6 ISIS 539399 ISIS 539404 --m 1515539432 ISIS 539433 0.28 4.1 0.7 1.0 Example 22: bility 0f deoxy, MOE, and cEt gapmers targeting human GHR in Sprague-Dawley e-Dawley rats were treated with ISIS antisense oligonucleotides from the studies described in the Examples above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment Male Sprague-Dawley rats were maintained on a 12-hour light/dark cycle and fed ad libitum with Purina normal rat chow, diet 5001. Groups of 4 Sprague-Dawley rats each were injected subcutaneously once a week for 6 weeks with 50 mg/kg of ISIS oligonucleotide (50 mg/kg weekly dose). Two groups of rats were injected aneously once a week for 6 weeks with PBS. Forty eight hours after the last dose, rats were euthanized and organs and plasma were harvested for further analysis.

Liverfunction To evaluate the effect of ISIS ucleotides on c function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, NY).

Plasma levels of ALT and AST were measured and the results are presented in Table 108 sed in IU/L.

Plasma levels of bilirubin were also measured using the same clinical chemistry analyzer and the results are also presented in Table 108 expressed in mg/dL. ISIS ucleotides that caused changes in the levels of any markers of liver function outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 108 Liver function markers in Sprague-Dawley rats ALT AST Bilirubin (IU/L) (IU/L) ) ISIS 542101 64 214 0.10 ISIS 542125 39 67 0.10 ISIS 542185 44 93 0.09 ISIS 541262 106 133 0.12 ISIS 541742 56 102 0.11 ISIS 541767 53 69 0.09 Kidneyfunction To evaluate the effect of ISIS oligonucleotides on kidney function, plasma levels of blood urea nitrogen (BUN) and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, NY). Results are presented in Table 109, expressed in mg/dL. ISIS oligonucleotides that caused changes in the levels of any of the kidney function markers outside the expected range for antisense ucleotides were excluded in further studies.

Table 109 Kidney function markers (mg/dL) in Sprague-Dawley rats BUN Creatinine PBS group 1 16 0.2 PBS group 2 15 0.2 ISIS 541881 22 0.3 ISIS 542051 18 0.2 ISIS 542101 22 0.3 ISIS 542112 18 0.2 ISIS 542118 18 0.3 ISIS 542125 18 0.3 ISIS 542127 19 0.3 ISIS 542128 18 0.3 ISIS 542153 17 0.3 ISIS 542185 19 0.3 ISIS 542186 19 0.3 ISIS 545439 16 0.2 ISIS 545447 16 0.2 ISIS 541262 21 0.4 ISIS 541742 19 0.2 ISIS 541767 15 0.2 ISIS 541875 16 0.2 Hematology assays Blood obtained from all rat groups were sent to Antech Diagnostics for hematocrit (HCT) measurements and analysis, as well as measurements of the various blood cells, such as WBC, RBC, and total hemoglobin content. The results are ted in Table 110. ISIS ucleotides that caused changes in the levels of any of the hematology markers outside the expected range for antisense oligonucleotides were excluded in further studies.

Table 110 Hematology markers in Sprague-Dawley rats HCT Hemoglobin RBC WBC Platelets (%) (g/dL) (106/uL) (103/uL) (103/uL) PBS group 1 43 14 7 7 775 PBS group 2 49 15 8 8 1065 ISIS 541881 41 13 8 6 553 1s1s 542051 39 13 7 9 564 ISIS 542101 37 12 7 15 603 ISIS 542112 45 14 8 10 587 ISIS 542118 47 15 8 7 817 ISIS 542125 41 13 7 7 909 ISIS 542127 44 14 8 10 872 ISIS 542128 44 14 8 7 679 ISIS 542153 48 15 8 7 519 ISIS 542185 44 14 8 9 453 ISIS 542186 44 14 8 12 433 ISIS 545439 40 12 7 11 733 ISIS 545447 43 13 8 9 843 ISIS 541262 46 14 8 17 881 ISIS 541742 47 15 8 10 813 ISIS 541767 53 16 9 9 860 ISIS 541875 42 13 7 9 840 Organ weights Liver, heart, Spleen and kidney weights were ed at the end of the study, and are presented in Table 111. ISIS oligonucleotideS that caused any changes in organ weights e the expected range for antisense oligonucleotideS were excluded from further studies.

Table 1 1 1 Organ weights (g) PBS group 1 PBS group 2 ISIS 541881 ISIS 542051 ISIS 542101 ISIS 542112 m ISIS 542118 . It.

ISIS 542125 . -1.1 ISIS 542127M ISIS 542128--m ISIS 542153 m ISIS 542185 m ISIS 542186“Em ISIS 545439 m ISIS 545447 -1.1 ISIS 541262 0.3 3.4 0.3 2.0 4747744742 ———m ISIS 541875 Example 23: Effect of ISIS antisense oligonucleotides targeting human GHR in cynomolgus monkeys Cynomolgus s were treated with ISIS antisense oligonucleotides selected from studies described in the Examples above. Antisense oligonucleotide efficacy and tolerability, as well as their pharmacokinetic profile in the liver and kidney, were evaluated.

At the time this study was undertaken, the cynomolgus monkey genomic sequence was not available in the al Center for Biotechnology Information (NCBI) database; therefore, cross-reactivity with the cynomolgus monkey gene sequence could not be confirmed. Instead, the sequences of the ISIS antisense ucleotides used in the cynomolgus monkeys was compared to a rhesus monkey sequence for gy. It is expected that ISIS oligonucleotides with homology to the rhesus monkey sequence are fully cross-reactive with the cynomolgus monkey sequence as well. The human antisense oligonucleotides tested are cross-reactive with the rhesus genomic sequence NK Accession No. NW_001 120958.1 truncated from nucleotides 4410000 to 4720000, designated herein as SEQ ID NO: 2296). The greater the mentarity n the human oligonucleotide and the rhesus monkey sequence, the more likely the human oligonucleotide can cross-react with the rhesus monkey sequence. The start and stop sites of each oligonucleotide to SEQ ID NO: 2296 is presented in Table 112. “Start site” indicates the 5 ’-m0st nucleotide to which the gapmer is targeted in the rhesus monkey gene sequence.

Table 112 Antisense ucleotides complementary to the rhesus GHR genomic sequence (SEQ ID NO: 2296) Target Target SEQ ID ISIS No Start Stop Chemistry . . NO S1te S1te 523723 149071 149090 55 MOE 918 532254 64701 64720 55 MOE 479 532401 147560 147579 55 MOE 703 DCOXY’MOE 541767 152700 152715 1800 ancht DCOXY’MOE 541875 210099 210114 1904 ancht DCOXY’MOE 542112 146650 146665 2122 ancht DCOXY’MOE 542118 149074 149089 2127 ancht De°xy7MOE 542185 245782 245797 2194 ancht WO 02971 Study 1 Prior to the study, the monkeys were kept in quarantine during which the animals were observed daily for general health. The s were 2-4 years old and weighed between 2 and 4 kg. Nine groups of 5 randomly assigned male cynomolgus monkeys each were ed subcutaneously with ISIS oligonucleotide or PBS using a stainless steel dosing needle and e of appropriate size into the intracapsular region and outer thigh ofthe monkeys. The monkeys were dosed three times (days 1, 4, and 7) for the first week, and then subsequently once a week for 12 weeks with 40 mg/kg of ISIS oligonucleotide. A control group of 5 cynomolgus monkeys was ed with PBS in a similar manner and served as the control group.

During the study period, the s were observed twice daily for signs of illness or distress. Any animal experiencing more than momentary or slight pain or ss due to the treatment, injury or illness was treated by the veterinary staff with approved analgesics or agents to relieve the pain after consultation with the Study Director. Any animal in poor health or in a possible moribund condition was identified for further monitoring and le euthanasia. Scheduled euthanasia of the animals was conducted on day 86 by exsanguination after ketamine/xylazine-induced anesthesia and administration of sodium arbital. The protocols bed in the Example were approved by the Institutional Animal Care and Use Committee (IACUC).

Target Reduction RNA analysis On day 86, RNA was extracted from liver, white adipose tissue (WAT) and kidney for real-time PCR analysis of measurement ofmRNA expression of GHR. Results are presented as percent tion of mRNA, relative to PBS control, normalized with RIBOGREEN®. ‘n.d.’ indicates that the data for that particular oligonucleotide was not measured. As shown in Table 113, treatment with ISIS antisense oligonucleotides resulted in significant reduction of GHR mRNA in comparison to the PBS control.

Specifically, treatment with ISIS 532401 ed in significant reduction ofmRNA expression in all tissues.

The expression of the growth hormone-responsive gene, ALS was also measured in liver, kidney and adipose tissue. Treatment with ISIS 532401 resulted in ALS RNA expression reduction in liver by 44 i 9 %, correlating with GHR levels. There was no reduction observed in e tissue. The expression of IGF1 in the liver was also measured. Treatment with ISIS 532401 resulted in IGF1 RNA expression reduction in liver by 71 i 10 %, correlating with GHR levels.

Table 113 Percent inhibition of GHR mRNA in the cynomolgus monkey liver relative to the PBS control ISIS No Liver WAT 532401 60 47 59 —-_n-d- 542112 61 60 36 542185 66 n.d. 541767 0 14 n.d.

Protein is Approximately 1 mL of blood was collected from all available animals at day 85 and placed in tubes containing the potassium salt of EDTA. The tubes were centrifuged (3000 rpm for 10 min at room ature) to obtain plasma. Plasma levels of IGF-1 and GH were measured in the plasma. The results are presented in Table 114. The s indicate that treatment with ISIS oligonucleotides ed in reduced IGF-1 protein levels.

Plasma levels of IGFl after treatment with ISIS 532401 are also presented in Table 115 and demonstrate the effect of antisense inhibition of GHR in reducing IGFl levels at day 7 and day 85.

Table 114 Plasma protein levels in the cynomolgus monkey IGF-1 (% GH baseline) (ng/mL) PBS 121 19 532401 57 39 532254 51 26 523723 77 16 542112 46 48 542118 97 6 542185 59 32 541767 101 22 541875 45 47 Table 115 Plasma IGFl levels in the cynomolgus monkey ISIS 532401 Tolerability studies Body and organ weight measurements To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body and organ weights were measured. Body weights were measured on day 84 and are presented in Table 115. Organ weights were measured on day 86 and the data is also presented in Table 115. The results indicate that effect of ent with antisense oligonucleotides on body and organ s was within the expected range for antisense oligonucleotides. Specifically, treatment with ISIS 532401 was well tolerated in terms of the body and organ weights of the s.

Table 115 Final body and organ weights in cynomolgus monkey Wt (kg) (g) (g) (g) PBS 2.7 2.8 12.3 56.7 523723 2.8 3.1 14.8 69.4 542112 2.6 3.5 13.6 60.0 542185 541767 541875 2.8 5.5 13.2 55.0 Liverfunction To te the effect of ISIS oligonucleotides on hepatic function, blood samples were collected from all the study groups. The blood samples were collected via femoral venipuncture, 48 hrs post-dosing.

The monkeys were fasted overnight prior to blood collection. Blood was collected in tubes ning K2- EDTA anticoagulant, which were centrifuged to obtain plasma. Levels of various liver function markers were measured using a Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Japan). Plasma levels ofALT and AST and bilirubin were measured. The Tables below t the results for ALT and AST levels at various time points. The results te that antisense oligonucleotides had no effect on liver function outside the expected range for antisense oligonucleotides. Specifically, treatment with ISIS 532401 was well tolerated in terms ofthe liver function in monkeys.

Table 116 ALT levels (IU/L) in lgus monkey ISIS 532401 ISIS 532254 ISIS 523723 ISIS 542112 ISIS 542118 ISIS 542185 ISIS 541767 ISIS 541875 70 54 71 Table 117 AST levels (IU/L) in cynomolgus monkey ISIS 532401 ISIS 532254 ISIS 523723 ISIS 542112 ISIS 542118 ISIS 542185 ISIS 541767 ISIS 541875 70 50 70 Kidneyfunction To evaluate the effect of ISIS oligonucleotides on kidney function, blood samples were collected from all the study groups. The blood samples were collected via femoral venipuncture, 48 hrs post-dosing.

The monkeys were fasted overnight prior to blood collection. Blood was collected in tubes containing K2- EDTA anticoagulant, which were centrifuged to obtain plasma. Levels of BUN and creatinine were measured using a Toshiba 200FR NEO chemistry er (Toshiba Co., . The Tables below present the results for BUN and creatinine levels at various time points.

The plasma chemistry data indicate that most of the ISIS oligonucleotides did not have any effect on the kidney function outside the expected range for antisense oligonucleotides. Specifically, treatment with ISIS 532401 was well ted in terms of the kidney fianction of the monkeys.

Table 118 BUN levels (mg/dL) in cynomolgus monkey Day 16 Day 44 Day 86 PBS 29 26 26 ISIS 532401 27 ISIS 532254 21 ISIS 523723 25 ISIS 542112 26 ISIS 542118 29 ISIS 542185 22 ISIS 541767 29 ISIS 541875 29 Table 119 Creatinine levels (mg/dL) in cynomolgus monkey PBS 0-9 mm ISIS 532401 1.1 ISIS 532254 1.0 ISIS 523723 1.0 ISIS 542112 1. 0 0.9 1.0 ISIS 542118 0.9 0.9 0.9 ISIS 542185 1-0 mm ISIS 541767 - mm ISIS 541875 .

Hematology To evaluate any effect of ISIS oligonucleotides in cynomolgus monkeys on hematologic parameters, blood samples of approximately 1.3 mL of blood was collected from each of the ble study animals in tubes containing Kz-EDTA. Samples were analyzed for red blood cell (RBC) count, white blood cells (WBC) count, individual white blood cell counts, such as that of monocytes, neutrophils, lymphocytes, as well as for platelet count, hemoglobin content and hematocrit, using an ADVIA120 hematology analyzer (Bayer, USA).

The Table below presents the results for platelet count at various time . ‘n/a’ indicates that the data for that time point is not available.

The data te the oligonucleotides did not cause any changes in hematologic parameters outside the expected range for nse oligonucleotides at this dose. Specifically, treatment with ISIS 532401 was well tolerated in terms of the hematologic parameters of the monkeys.

Table 120 Platelet count (x 103/uL) in cynomolgus monkey Day 30 Day 58 Day 86 PBS 538 464 403 151s 532401 493 ISIS532254 334 ISIS 523723 352 304 ISIS 542112 ISIS 542118 ISIS 542185 ISIS 541767 ISIS 541875 C—reactiveprolein and complement C3 level analysis To evaluate any inflammatory effect of ISIS oligonucleotides in cynomolgus monkeys, blood samples were taken for is. The monkeys were fasted overnight prior to blood tion.

Approximately 1.5 mL of blood was collected from each animal and put into tubes without anticoagulant for serum separation. The tubes were kept at room temperature for a minimum of 90 min and then centrifuged at 3,000 rpm for 10 min at room temperature to obtain serum. C-reactive protein (CRP), which is synthesized in the liver and which serves as a marker of ation, was measured using a Toshiba 200FR NEO chemistry analyzer ba Co., Japan). The Tables below present the results for CRP and C3 levels at various time points. The results indicate that treatment with ISIS 532401 did not cause inflammation in monkeys.

Table 121 CRP (mg/L) in cynomolgus monkey Day 16 Day 44 Day 86 PBS 3.8 2.0 2.0 ISIS 541767 9 ISIS 541875 4.9 3.5 8.4 Table 122 C3 (mg/dL) on day 85 (24 hours after dosing) in cynomolgus monkey ISIS 532401 ISIS 532254 100 ISIS 523723 ISIS 542112 100 ISIS 542118 ISIS 542185 m ISIS 541767 m ISIS 541875 Measurement ofOligonucleotide concentration The concentration of the full-length Oligonucleotide in the liver and the kidney of the monkeys was measured. The method used is a modification of previously published methods (Leeds et al., 1996; Geary et al., 1999) which consist of a phenol-chloroform (liquid-liquid) extraction followed by a solid phase extraction. An internal standard (ISIS , a 27-mer ethoxyethyl modified phosphorothioate Oligonucleotide, GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 2300) was added prior to tion. Tissue sample trations were calculated using calibration curves, with a lower limit of quantitation (LLOQ) of approximately 1.14 ug/g. Half-lives were then calculated using WinNonlin software (PHARSIGHT).

The results are presented in Table 123, expressed as ug/g of tissue, as well as the ratio of concentration in kidney versus liver.

Table 123 Oligonucleotide concentration in the liver and kidney of cynomolgus monkeys Chem1stry. L1ver. Kldney. 1:30 ISIS 532401 55 MOE 725 2154 3.0 ISIS 532254 55 MOE 911 4467 4.9 ISIS 523723 55 MOE 657 3093 4.7 ISIS 542112 33 cEt/MOE 491 2863 5.8 ISIS 542118 33 cEt/MOE 429 1222 2.8 1818542185 3--103cEt/MOE _ 3126 ————— ISIS 541875 33 cEt/MOE 3892 5.1 Study 2 One group of 5 randomly assigned male cynomolgus monkeys was injected subcutaneously with ISIS 532401 or PBS using a stainless steel dosing needle and syringe of riate size into the intracapsular region and outer thigh of the monkeys. The monkeys were dosed a loading dose per week (days 1, 3, 5, and 7) for the first week, and then subsequently once a week (days 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, and 91) with 40 mg/kg of ISIS 532401. A control group of 5 cynomolgus monkeys was injected with PBS in a similar manner and served as the control group.

Target Reduction RNA analysis On day 93, RNA was extracted from liver, white adipose tissue (WAT) and muscle for real-time PCR analysis of measurement ofmRNA expression of GHR. Treatment with ISIS 532401 resulted in cant reduction of GHR mRNA in liver and white adipose tissue.

The expression of the growth hormone-responsive gene, ALS was also measured in the liver.

Treatment with ISIS 532401 resulted in ALS RNA expression reduction in liver by 38%, correlating with GHR levels. ‘n.d.’ indicates that the levels were not checked in that particular . The sion of IGFl in the liver, muscle and fat tissues was also measured. Treatment with ISIS 532401 resulted in IGFl RNA expression reduction in liver and in the WAT, correlating with GHR levels.

Table 124 Effect of treatment with ISIS 532401 on mRNA levels (% tion compared to the PBS control) in the lgus monkey Muscle . . n.d.

IGFl 73 56 35 Protein analysis Plasma levels of IGF-1 and GH were ed in the plasma. The results are presented in the Table below. The results indicate that treatment with ISIS 532401 resulted in d IGF-l protein levels. There was no increase in plasma growth hormone levels.

Table 125 Plasma IGFl levels (ng/mL) in the cynomolgus monkey PBS 625 776 850 ISIS 532401 Table 126 Plasma growth hormone levels ) in the cynomolgus monkey ISIS 532401 _5_7— Example 24: Measurement of viscosity of ISIS antisense oligonucleotides targeting human GHR The viscosity of select antisense oligonucleotides from the study bed in the Examples above was measured with the aim of screening out antisense oligonucleotides which have a viscosity more than 40 GP. Oligonucleotides having a viscosity greater than 40 cP would be too s to be administered to any subject.

ISIS oligonucleotides (32-35 mg) were weighed into a glass vial, 120 uL of water was added and the antisense oligonucleotide was dissolved into solution by heating the vial at 500C. Part of (75 ML) the pre- heated sample was pipetted to a micro-viscometer (Cambridge). The temperature of the micro-viscometer was set to 250C and the viscosity of the sample was measured. Another part (20 uL) of the pre-heated sample was pipetted into 10 mL of water for UV reading at 260 nM at 850C (Cary UV instrument). The results are presented in Table 127 and indicate that all the antisense oligonucleotides solutions are optimal in their viscosity under the criterion stated above.

Table 127 Viscosity of ISIS antisense ucleotides ing human GHR ISIS . Viscosity Chemistry No. (CP) 523723 55 MOE 8 532254 55 MOE 22 532401 55 MOE 12 Deoxy, MOE 541767 13 and cEt Deoxy, MOE 541875 33 and cEt WO 02971 Deoxy, MOE Deoxy, MOE 5421 1 8 and cEt Deoxy, MOE 542185 and cEt Example 25: Effect of antisense inhibition of GHR in mice In order to confirm the effect of antisense inhibition of GHR in the primate model, an ISIS oligonucleotide targeting murine GHR was employed to replicate the result in a mouse model.

ISIS 563223 (GAGACTTTTCCTTGTACACA, designated herein as SEQ ID NO: 2301) is a 55 MOE gapmer murine antisense oligonucleotide targeting murine GHR (GENBANK Accession No; NM_010284.2, designated herein as SEQ ID NO: 2302) at target start site 3230. A group of male and female CD1 mice were injected with a loading dose (on days 1, 3, 5, and 7) on the first week and subsequently with a once weekly dose (on days 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, and 91) with 40 mg/kg of ISIS 563223.

One group of CD1 mice was injected in a r manner with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further is. mRNA expression Liver mRNA expression of GHR, GHBP, IGF1, and ALS were measured. The results are presented in Table 128. Antisense inhibition of GHR resulted in inhibition of GHBP, IGF1 and ALS gene expression levels.

Table 128 mRNA expression (% Inhibition) in CD1 mice liver % (in male mice) % (in female mice) 98 96 74 66 60 48 Protein expression Plasma levels of IGF1 and growth hormone were measured. The results are presented in Table 129.

Antisense tion of GHR resulted in decrease in IGF1 levels, and had no effect on growth e levels.

Table 129 IGFl n levels (ng/mL) in CD1 mice liver PBS 949 1002 ISIS 563223 439 740 Table 130 Growth hormone protein levels (ng/mL) in CD1 mice liver 3.3 :22 2.2: 1.3 ISIS 563223 56 : 6.7 2.9 : 1.7

Claims (26)

CLAIMS :

1. A compound sing a modified oligonucleotide consisting of 18 to 30 linked nucleosides in length, wherein the modified oligonucleotide has a nucleobase sequence comprising a portion of at least 18 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 153921-153940 of a growth hormone receptor nucleic acid having the nucleobase sequence of SEQ ID NO: 2, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 2, n the compound reduces the amount or activity of the growth e receptor nucleic acid.

2. The compound of claim 1, wherein the modified oligonucleotide is 100% complementary to SEQ ID NO: 2.

3. The compound of any one of claims 1-2, wherein the modified oligonucleotide has a nucleobase sequence comprising the sequence recited in SEQ ID NO: 703.

4. The compound of claim 3, wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 703.

5. The compound of any one of claims 1-4, wherein the ed oligonucleotide comprises at least one modified sugar.

6. The compound of claim 5, n the at least one modified sugar comprises a 2’-O-methoxyethyl group or is a bicyclic sugar.

7. The compound of claim 6, wherein the at least one modified sugar is a bicyclic sugar that comprises a 4’-CH(CH3)-O-2’ group or a bicyclic sugar that comprises a 4’-CH2- O-2’ or 4’-(CH2)2-O-2’group.

8. The compound of any one of claims 1-7, wherein the modified ucleotide comprises at least one modified internucleoside e.

9. The compound of claim 8, n the modified internucleoside linkage is a phosphorothioate ucleoside linkage.

10. The compound of any one of claims 1-9, wherein the modified oligonucleotide comprises at least one modified nucleobase.

11. The compound of claim 10, wherein the ed nucleobase is ylcytosine.

12. The nd of any one of claims 1-11, wherein the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5’ wing segment consisting of linked nucleosides; and a 3’ wing segment consisting of linked nucleosides; wherein the gap t is positioned between the 5’ wing segment and the 3’ wing segment and wherein each nucleoside of each wing t comprises a modified sugar.

13. The compound of any one of claims 1-12, wherein the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 703, and wherein the modified oligonucleotide ses: a gap segment consisting of ten linked deoxynucleosides; a 5’ wing segment consisting of five linked nucleosides; and a 3’ wing segment consisting of five linked nucleosides; wherein the gap segment is oned between the 5’ wing segment and the 3’ wing t; wherein each nucleoside of each wing t comprises a 2’-O-methoxyethyl sugar; n at least one internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

14. The compound of any one of claims 1-13, wherein the compound is singlestranded.

15. A composition comprising the compound of any one of claims 1-14 or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent.

16. The compound of any one of claims 1-14, or the composition of claim 15, for use in therapy.

17. The compound or composition for use of claim 16, for use in treating or preventing a disease associated with excess growth hormone in a human.

18. The compound or composition for use of claim 17, wherein the disease associated with excess growth hormone is acromegaly.

19. The compound or composition for use according to claim 18, wherein ng the acromegaly reduces IGF-1 levels.

20. The compound of any one of claims 1-14, or the composition of claim 15, for use in a method of reducing growth hormone receptor (GHR) levels in a human, said method comprising administering to the human a eutically effective amount of the compound or ition, y reducing GHR levels in the human.

21. The compound or composition for use of claim 20, wherein the human has a disease associated with excess growth hormone.

22. The compound or composition for use of claim 21, wherein the disease is acromegaly.

23. Use of the compound of any one of claims 1-14, or the composition of claim 15, in the manufacture of a medicament for treating or preventing a disease associated with excess growth hormone in a human.

24. The use of claim 23, wherein the disease associated with excess growth hormone is acromegaly.

25. The use of any one of claims 23 or 24, wherein the medicament is formulated to treat acromegaly by reducing IGF-1 levels.

26. Use of the compound of any one of claims 1-14, or the ition of claim 15, in the manufacture of a ment for reducing growth hormone receptor (GHR) levels in a human.